Mechanisms underlying progressive nephron injury in chronic kidney disease by Taal, Maarten Willem
(0 
Mechanisms underlying progressive nephron 
injury in chronic kidney disease 
Maarten W. Taal MB.ChB(UCT), M.Med(UCT), FCP(SA) 
Supervisor: Associate Professor Roal van Zyl-Smit 
MB.BCh(Wits), FCP(SA), FRCP(UK), MD(UCT) 
! 
.Thbsis presented for the Degree of Doctor of Medicine (MD) 
in the Department of Medicine of the Faculty of Health Sciences 
University of-Cape Town 
August 2003 
1 
  
 
 
 
 
 
 
 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
 
Un
ive
rsi
ty 
f C
ap
e T
ow
n
Table of Contents: 
Declaration ................................................................................................................................................... 6 
Acknowledgements ...................................................................................................................................... 7 
Abstract. ..................................................................................................................................................... to 
1. Literature Review .................................................................................................................................. 12 
1.1. Introduction ........................................................................................................................................ 12 
1.2. Structural and functional adaptation of the kidney to nephron loss ................................................... 13 
1.2.1. Alterations in Glomerular Physiology .......................................................................................... 13 
1.2.2. Mediators of the glomerular haemodynamic responses to nephron loss .................................... 15 
1.2.2.1. Renin-Angiotensin System ................................................................................................... 15 
1.2.2.2. Endothelins ........................................................................................................................... 17 
1.2.2.3. Natriuretic peptides ............................................................................................................... 17 
1.2.2.4. Eicosanoids ................................................................................. , ........................................ 17 
1.2.2.5. Nitric oxide ............................................................................................................................ 18 
1.2.2.6. Adjustments in renal autoregulatory mechanisms ................................................................ 19 
1.2.3. Renal Hypertrophic Responses to Nephron Loss ....................................................................... 20 
1.2.3.1. Whole - Kidney Hypertrophic Responses ............................................................................. 20 
1.2.3.2. Glomerular Enlargement ...................................................................................................... 21 
1.2.3.3. Mechanisms of Renal Hypertrophy ...................................................................................... 22 
1.3. Adverse long-term consequences of adaptations to nephron loss .................................................... 23 
1.3.1. Haemodynamic Factors ............................................................................................................... 24 
1.3.2. Mechanisms of haemodynamically - induced injury ................................................................... 28 
1.3.2.1. Mechanical Stress ................................................................................................................ 28 
1.3.2.2. Endothelial Cells ................................................................................................................... 28 
1.3.2.3. Mesangial Cells .................................................................................................................... 30 
1.3.2.4. Podocytes ............................................................................................................................. 31 
1.3.2.5. Inflammatory cell infiltration .................................................................................................. 31 
1.3.3. Non-haemodynamic factors in the development of nephron injury following extensive renal mass 
ablation ................................................................................................................................................... 33 
2 
1.3.3.1. Hypertrophy .......................................................................................................................... 33 
1.3.3.2. Transforming Growth Factor-p ............................................................................................. 36 
1.3.3.3. Angiotensin II ........................................................................................................................ 36 
1.3.3.4. Aldosterone ................................................. ' ......................................................................... 38 
1.3.3.5. Hepatocyte Growth Factor .................................................................................................... 39 
1.3.3.6. Altered glomerular permselectivity to proteins ...................................................................... 40 
1.4. Strategies for Achieving Renal Protection ........................................................................................ .44 
1.4.1. Control of Systemic Hypertension ............................................................................................... 44 
1.4.2. Pharmacological inhibition of the Renin-Angiotensin System ..................................................... 47 
1.4.2.1. Angiotensin-Converting Enzyme Inhibitors ........................................................................... 47 
1.4.2.1.1. Diabetic Nephropathy ..................................................................................................... 47 
1.4.2.1.2. Non-Diabetic CKD .......................................................................................................... 48 
1.4.2.2. Angiotensin Receptor Antagonists ....................................................................................... 50 
1.4.3. Dietary Protein Restriction ........................................................................................................... 53 
1.4.4. Treatment of Hyperlipidaemia ..................................................................................................... 55 
1.4.5. Smoking Cessation .............................................................................................. : ...................... 55 
1.5. Unanswered Questions ..................................................................................................................... 56 
1.5.1. In vivo expression of pro-inflammatory and fibrotic growth factors ............................................. 56 
1.5.2. Pharmacological inhibition of the Renin-Angiotensin System ..................................................... 57 
1.5.3. Extent of Blood Pressure and Proteinuria Reduction .................................................................. 60 
1.5.4. New Pharmacological Agents for lowering Glomerular Capillary Pressure ................................ 60 
2. Proinflammatory gene expression and macrophage infiltration in the rat remnant kidney ................... 61 
2.1. Introduction ..................................................................................................................................... 61 
2.2. Methods .......................................................................................................................................... 62 
2.2.1. Animals .................................................................................................................................... 62 
2.2.2. Competitive reverse transcription polymerase chain reaction (RT-PCR) ................................ 63 
2.2.3. Immunohistochemistry ............................................................................................................ 65 
2.2.4. Morphology .............................................................................................................................. 66 
2.2.5. Statistical Analysis ................................................................................................................... 66 
3 
2.3. Results ........................................................................................................................................... 66 
2.3.1. General Data ........................................................................................................................... 66 
2.3.2. Competitive RT-PCR ............................................................................................................... 67 
2.3.3. Immunohistochemistry ............................................................................................................ 68 
2.3.4. Macrophage infiltration ............................................................................................................ 68 
2.5. Discussion ...................................................................................................................................... 78 
3. Renal Protection in the Setting of Established Renallnjury .................................................................. 83 
3.1. Introduction ..................................................................................................................................... 83 
3.2. Methods .......................................................................................................................................... 84 
3.2.1. Animals .................................................................................................................................... 84 
3.2.2. Morphology .............................................................................................................................. 85 
3.2.3. Chemical Analysis ........ : .......................................................................................................... 86 
3.2.4. Competitive reverse transcription polymerase chain reaction (RT-PCR) ................................ 86 
3.2.5. Immunohistochemistry ............................................................................................................ 86 
3.2.6. Statistical Analysis ................................................................................................................... 87 
3.3. Results ........................................................................................................................................... 88 
3.3.1. Chronic Studies ....................................................................................................................... 88 
3.3.2. Morphology .......... ; ................................................................................................................... 89 
3.3.3. Multivariable Analysis .............................................................................................................. 90 
3.3.4. Competitive RT PCR ............................................................................................................... 90 
3.3.5. Immunohistology ..................................................................................................................... 91 
3.3.6. Macrophage Infiltration ............................................................................................................ 92 
3.4. Discussion .................................................................................................................................... 107 
4. Glomerular Capillary Hydraulic Pressure Lowering Revisited with Novel Therapeutic Agents ........... 112 
4.1. Introduction ................................................................................................................................... 112 
4.2. Methods ........................................................................................................................................ 113 
4.2.1. Short-term treatment protocol ............................................................................................... 113 
4.2.2. Micropuncture studies ........................................................................................................... 114 
4.2.3. Long-term treatment protocol ................................................................................................ 115 
4 
4.2.4. Morphology ............................................................................................................................ 115 
4.2.5. Statistical Analysis ................................................................................................................. 116 
4.3. Results ......................................................................................................................................... 116 
4.3.1. Short-term treatment protocol ............................................................................................... 116 
4.3.2. Micropuncture studies ........................................................................................................... 116 
4.3.3. Long-term treatment protocol ................................................................................................ 117 
4.4. Discussion .................................................................................................................................... 127 
4.4.1. Short-term treatment protocol ............................................................................................... 127 
4.4.2. Micropuncture Studies ........................................................................................................... 127 
4.4.3. Long-term treatment protocol ................................................................................................ 128 
5. Discussion and Conclusions ............................................................................................................... 131 
5.1. ACEI versus AT1RA in renal protection ........................................................................................ 131 
5.2. Proinflammatory and fibrotic cytokines in CKD progression ........................................................ 132 
5.3. Hypertension and CKD progression ............................................................................................. 134 
5.4. Proteinuria and CKD progression ................................................................................................ 135 
5.5. Glomerular capillary hypertension in CKD progression ................................................................ 135 
5.6. Vasopeptidase inhibitors in renal protection ................................................................................. 136 
5.7. Conclusion .................................................................................................................................... 137 
References .............................................................................................................................................. 138 
5 
Declaration 
i, Maarten Willem Taal, hereby declare that the research described herein was performed by me with 
assistance as indicated in the acknowledgements. The dissertation was written by me and reviewed by 
my supervisor. Neither the whole thesis nor any part of it has been, is being or will be submitted by me for 
any other degree at this or any other University. 
I give permission to the University to reproduce the whole or any part of this manuscript for research 
purposes. 
. ......... ~ .. I.8.l.~3 
Date 
6 
Acknowledgements 
The data presented in this dissertation represent work done during my time as a Research Fellow in the 
Laboratory of Kidney and Electrolyte Physiology (LKEP) in the Renal Division, Brigham and Women's 
Hospital and Harvard Medical School. There are many people who have contributed to this effort whose 
assistance I acknowledge and who deserve my sincere thanks: 
Kambiz Zandi-Nejad (Research Fellow) performed all of the surgery for the experiments in Chapter 2 and 
was responsible for most of the chronic care of the animals, including the regular blood pressure and 
proteinuria measurements. Under my supervision he performed the RNA extraction and reverse 
transcription to cDNA. He also performed the initial competitive RT-PCR experiments for this study. 
Berber Weening (Research Assistant) provided valuable assistance that enabled me to complete the large 
amount of RT -PCR work required for the studies in Chapter 2. 
Aliakbar Shahsafaei (Laboratory Technician) contributed expert technical assistance and performed the 
histology and immunohistology preparations for all the studies presented. 
Jiang Tang (Research Fellow) assisted with the ED-1 staining and macrophage counting in the study 
presented in Chapter 3. 
Helmut Rennke (Professor in Pathology) performed the histological assessment of renal injury for the 
study in Chapter 3 and trained me in the necessary techniques, enabling me to score the specimens for 
the other studies presented. 
Glenn Chertow (Associate Professor in Medicine) generously assisted with the linear regression analysis 
presented in Chapter 3. 
7 
Shinichiro Kato (Post-doctoral Research Fellow) was a patient instructor who taught me most of what I 
know about molecular biology techniques. He was largely responsible for establishing the RT-PCR 
technique in the laboratory and designed many of the primers employed. 
Julia Troy (Chief Laboratory Technician) provided invaluable technical and moral support throughout all of 
the studies. Specifically, she performed most of the proteinuria assays for the studies in Chapter 3, 
prepared the rats for the micropuncture studies presented in Chapter 4 and performed the tubule fluid 
inulin and PAH assays for those studies. 
Vessel in Nenov (Research Fellow) performed most of the animal surgery as well as blood pressure and 
proteinuria measurements for the chronic studies in Chapter 4. 
Harald Mackenzie (Assistant Professor in Medicine) taught me the basic techniques for animal research 
and provided essential support and supervision for the studies in Chapters 2 and 3. He also assisted with 
meticulous editing of some of the material presented in Chapters 1-3. 
To Barry Brenner (Samuel A. Levine Professor in Medicine and Director, Renal Division and LKEP) lowe 
a special debt of thanks. He offered me the opportunity to join his prestigious laboratory and provided 
thoughtful and stimulating supervision throughout these projects. In addition he assisted with the 
micropuncture studies and taught me the required techniques. It was truly a great privilege to have been 
nurtured and supervised by a pioneer in this field and one of the major contributors to our understanding 
of renal pathophysiology. 
I also gratefully acknowledge the support of the International Society of Nephrology who awarded me a 
Research Fellowship that partially funded my first year in the laboratory. The work in Chapters 2 and 3 
was supported by a grant from Takeda Chemical Industries and that in Chapter 4 was supported by a 
grant from Bristol-Myers Squibb Company. 
8 
lowe a special debt of gratitude to my supervisor, Roal van Zyl~Smit, who first stimulated my interest in 
research and encouraged me to pursue the opportunity I had to join Prof Brenner's laboratory. Though 
not directly involved in the research, he has remained a source of support and a valued mentor throughout 
this period. He also provided invaluable assistance in reviewing this manuscript. 
Finally my deepest thanks to Diane, who supported me through difficult circumstances and made 
enormous sacrifices to enable me to take up this opportunity, and to God, who sustained me throughout. 
The data presented in this dissertation have previously been published in the following journals: 
1. Taal MW and Brenner BM. Renoprotective effects of RAS inhibition: From ACEI to Angiotensin II 
Antagonists. Kidney Int 57:1803-1817,2000. 
2. Taal MW, Zandi-Nejad K, Weening B, Shahsafaei A, Kato S, Lee K-W, Ziai F, Jiang T, Brenner 
BM and Mackenzie HS. Proinfiammatory gene expression and macrophage recruitment in the rat 
remnant kidney. Kidney Int 58:1664-1676,2000. 
3. Taal MW, Chertow GM, Rennke HG, Gurnani A, Jiang T, Shahsafaei A, Troy JL, Brenner BM and 
Mackenzie HS. Mechanisms underlying renoprotection during renin-angiotensin system 
blockade. Am J Physio/280: F343-F355, 2001. 
4. Taal MW, Nenov VD, Satyal SR, Wong W, Sakharova 0, Choi Jeong Hoon, Troy JL and Brenner 
BM. Vasopeptidase inhibition affords greater renoprotection than ACE inhibition alone. J Am Soc 
Nephro/12:2051-2059,2001. 
/ 
9 
Abstract 
It has been appreciated for several decades that when renal disease of diverse aetiology results in 
substantial renal injury, a common clinicopathological syndrome ensues characterised by hypertension, 
proteinuria and a progressive decline in renal function due to focal and segmental glomerulosclerosis. 
These observations suggest that common mechanisms may contribute to progressive renal injury and that 
therapeutic interventions that inhibit these common pathways may result in renal protection. 
Early studies of glomerular haemodynamic adaptations to nephron loss identified increased glomerular 
capillary hydraulic pressure (PGd as a critical factor. Subsequent experiments showed that treatment with 
angiotensin-converting enzyme inhibitors (ACEI) normalized PGC and afforded substantial renal protection. 
Angiotensin II (Ang II) also appears to exert non-haemodynamic effects that may contribute to progressive 
renal injury. In addition proteinuria, recognized as a marker of glomerular injury, has recently been 
proposed to contribute directly to renal damage. Finally, a major role for proinflammatory cytokines and 
profibrotic growth factors in renal scarring has been proposed. The importance of ACEI in renal protective 
strategies has been confirmed in several experimental and clinical studies, indicating a central role for 
angiotensin II in the pathogenesis of chronic kidney disease (CKO). The development of the angiotensin 
subtype 1 receptor antagonists (AT1RA), a new class of drug that inhibits the renin-angiotensin system by 
blocking the AT 1 receptor has made it possible to compare the effects on renal protection of inhibiting the 
renin-angiotensin system by two different means. 
The first two studies presented in this dissertation examined the relative effects of ACEI and AT1RA 
treatment in the 5/6 nephrectomy rodent model of CKD. In the first experiment drug treatment was started 
immediately after 5/6 nephrectomy. ACEI and AT 1 RA treatment were equally effective in controlling 
hypertension and proteinuria as well as preventing renal injury over a period of 12 weeks. Reverse 
transcriptase PCR and immunohistology showed an increase in expression of several proinflammatory 
genes including TGF-p1, MCP-1, ICAM-1, VCAM-1, IL-1P and TNF-a. as well as mesangial and interstitial 
infiltration by macrophages in untreated rats. Both drugs abrogated the proinflammatory gene expression 
and macrophage infiltration observed in untreated rats. In the second study treatment with either an ACEI 
or AT1RA was delayed for 5 weeks after 5/6 nephrectomy, when evidence of renal injury was already 
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present. This strategy would potentially allow detection of more subtle differences in renal protective 
efficacy of ACEI vs. AT1RA as both drugs reduced but did not prevent renal injury. Treatment with either 
ACEI or AT1RA did not suppress remnant kidney expression of TGF-~1 or MCP-1 to normal levels at 12 
or 24 weeks. Strong correlation was shown between TGF-~1, MCP-1 or IL-1 ~ mRNA levels and the 
extent of renal injury at 24 weeks. In addition linear regression analysis showed that blood pressure and 
the level of proteinuria were major determinants of renal injury at 24 weeks. There was no difference in 
the extent of renal injury between rats receiving ACEI or AT1RA treatment nor was there a difference in 
the relationship between renal injury, blood pressure and proteinuria between the groups. We conclude 
that in this model, ACEI and AT1RA treatment afforded equivalent renal protection and exerted their 
beneficial effects predominantly by inhibiting the actions of Ang II mediated by AT1 receptors. In addition 
our results lend support to the notion that coordinated upregulation of proinflammatory molecules and 
associated macrophage infiltration play an important role in CKO progression. 
A third set of experiments revisited the concept of lowering PGC with vasopeptidase inhibitors (VPI), a 
novel class of antihypertensive agents that inhibit neutral endopeptidase in addition to angiotensin-
converting enzyme. A preliminary study showed that ACEI and VPI treatment both abrogated renal injury 
when started shortly after 5/6 nephrectomy. A subsequent study utilizing the delayed treatment model 
described above showed that VPI treatment delayed the progression of renal injury significantly more than 
ACEI treatment. In addition micropuncture studies revealed that VPI treatment reduced PGC to 
significantly lower levels than ACE I treatment. We suggest that this greater lowering of PGC may be one of 
the mechanisms whereby VPI treatment affords more effective renal protection. 
Together these data shed new light on some of the many mechanisms implicated in the progression of 
CKO. This improved understanding should lead to more effective strategies for limiting renal injury in a 
wide variety of kidney diseases. 
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1. Literature Review 
1.1. Introduction 
Despite substantial advances in our understanding of the pathogenesis and pathophysiology of many 
renal disorders over the past 50 years there are as yet few effective treatments for specific renal diseases 
and many cases progress towards chronic renal failure. Moreover the rapid rise in the prevalence of type 
2 diabetes mellitus in many parts of the world can be predicted to result in a large. increase in the number 
of patients with diabetic nephropathy, the single most common cause of end-sta~e/enal disease (ESRD) 
.. 
in many parts of the world. Consequently the worldwide population of patients req"uiring renal replacement 
therapy is projected to grow rapidly. In the U.S. alone approximately 300,000 people currently require 
chronic dialysis and 80,000 are living with renal transplants [1]. This "epidemic' of chronic kidney disease 
(CKD) has serious implications for health care providers and patients alike. Whereas first-world countries 
are struggling to come to terms with the high cost of c;jialysis, many third-world countries are simply unable 
to fund adequate dialysis provision. From a patient's perspective chronic dialysi.s is associated with an 
annual mortality rate of 20-25% and substantial morbidity. Whereas renal transplantation represents 
optimal renal replacement therapy there is a worldwide shortage of donor organs. Transplanted kidneys 
also tend to suffer a progressive decline in function over time. The development of more effective 
treatment for slowing the rate of progression of CKD therefore represents one of the most urgent priorities 
facing Renal Physicians today. 
In an attempt to address this problem, much attention has been focused on mechanisms whereby CKD 
progresses to end-stage renal failure (ESRF). It has been appreciated for several decades that when 
diverse renal diseases result in substantial loss of functioning nephrons a common clinicopathological 
syndrome ensues, characterized by systemic hypertension, proteinuria and a progressive decline in 
glomerular filtration rate (GFR). The rate of decline in renal function seems to depend more upon 
individual patient characteristics than specific disease aetiology [2, 3]. These observations suggest that 
CKD progresses via a common pathway of mechanisms and that therapeutic interventions inhibiting these 
mechanisms may be successful in slowing the rate of progression of CKD irrespective of the initiating 
cause. Central to this hypothesis is the notion that the loss of functioning nephrons provokes adaptive 
changes in remaining nephrons ultimately resulting in injury to those nephrons and establishing a vicious 
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cycle of progressive nephron loss. Considerable progress has been made in understanding the central 
role of glomerular haemodynamic adaptations and the renin-angiotensin system in CKD progression. In 
this dissertation we review previously published work in this field describing the adaptive changes 
observed after nephron loss and discuss how these may contribute to progressive renal injury. We then 
present a series of experiments designed to define the role of selected factors and the impact of different 
treatment strategies in CKD progression. 
1.2. Structural and functional adaptation of the kidney to nephron loss 
1.2.1. Alterations in Glomerular Physiology 
Glomerular haemodynamic responses to nephron loss have largely been studied in animals subjected to 
surgical ablation of renal mass. As early as 1947 it was recognized that unilateral nephrectomy in rats 
resulted in a rapid increase in function of the remaining kidney such that the GFR eventually achieved 70-
85% of the previous 2-kidney value [4]. An increase in GFR is detectable 3 days after nephrectomy and is 
maximal 2-3 weeks later [5]. As no new nephrons are formed in mature rodents [6-11] this rise in GFR 
represents an increase in the filtration rate of remaining nephrons. 
Detailed investigation of glomerular haemodynamics was made possible by the study of Munich-Wistar 
rats that are unique in bearing glomeruli on the kidney surface. Surface glomeruli are accessible for 
micropuncture studies that allow direct measurement of intraglomerular pressures as well as sampling of 
blood from afferent and efferent arterioles. These techniques made it possible to study the mechanisms 
underlying observed compensatory increases in GFR after renal mass ablation. Early studies found that 
increases in whole kidney GFR at 2-4 weeks after unilateral nephrectomy resulted from an in increase in 
single nephron GFR (SNGFR) averaging 83%, an effect achieved in large part by an augmented 
glomerular plasma flow rate (ON that in turn resulted from dilation of both afferent and efferent arterioles. 
Although systemic blood pressure was not elevated, glomerular capillary hydraulic pressure (PGd and the 
glomerular transcapillary pressure difference (ilP) were increased Significantly post uninephrectomy, 
accounting for an estimated 25% of the rise in SNGFR [12]. The glomerular ultrafiltration coefficient Kf 
(the product of glomerular hydraulic permeability and surface area available for filtration) was unaltered at 
this stage but may become elevated later [13]. 
13 
With more extensive nephron loss, even greater compensatory increases in SNGFR were observed [14]. 
In Munich-Wistar rats studied 7 days after unilateral nephrectomy and infarction of 5/6 of the contralateral 
kidney, SNGFR in the remnant was more than double that of 2-kidney controls. This increment was again 
attributable to large increases in QA, and a substantial rise in PGc. Efferent and afferent arteriolar 
resistances were reduced to half or less of control values [15]. Changes in Kf after extensive renal mass 
ablation appear to be time-dependent, with a decrease reported at 2 weeks after surgery [16], and an 
increase at 4 weeks [17]. Further studies indicated that glomerular haemodynamic responses to nephron 
loss seem to be similar between the superficial cortical and juxtamedullary nephrons [18]. The rise in 
SNGFR associated with renal mass ablation is generally referred to as glomerular hyperfiltration and the 
elevated PGC is termed glomerular hypertension. Together these terms summarise the central concepts 
underlying haemodynamic adaptations in the remnant kidney. 
Glomerular haemodynamic adaptations to nephron loss may show interspecies variation. In dogs, 
increases in SNGFR observed 4 weeks after 3/4 or 7/8 nephrectomy were attributable largely to increases 
in QA and Kt. In contrast to the findings in rodents, AP was only modestly elevated. After ablation of 7/8 of 
their renal mass, dogs developed a significant rise in PGC independent of arterial pressure, as a result of 
relatively greater relaxation of afferent versus efferent arterioles [19]. 
In humans, the effects of nephron loss on the physiology of the remnant kidney have been studied mainly 
in healthy individuals undergoing donor nephrectomy for kidney transplantation. Inulin clearance studies 
of the earliest kidney donors revealed that GFR in the donor's remaining kidney had increased to 65-70% 
of the previous 2-kidney value by 1 week post nephrectomy [20, 21]. A meta-analysis of data from 48 
studies that included 2,988 living kidney donors estimated that GFR decreased on average by only 
17mllmin after uninephrectomy [22]. These observations imply that single kidney GFR (and therefore also 
the average SNGFR) increases by 30%-40% after uninephrectomy in humans. There is currently no non-
invasive method for estimating SNGFR or PGC in humans and more detailed assessments of glomerular 
haemodynamics have thus not yet been possible. 
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1.2.2. Mediators of the glomerular haemodynamic responses to nephron loss 
The factors that serve as signals to initiate the changes in glomerular haemodynamics after renal mass 
ablation remain ill defined. Nevertheless, the effector mechanisms have been studied extensively and 
haemodynamic changes can be attributed to the net effects of complex interactions of multiple factors 
each having specific and sometimes opposing actions on the various determinants of glomerular 
ultrafiltration. Several vasoactive substances, including angiotensin II (Ang II), natriuretic peptides (NP), 
endothelins (ET) and prostaglandins (PG) have been implicated in this process. Moreover, sustained 
increases in SNGFR also require resetting of the autoregulatory mechanisms that normally govern GFR 
and renal plasma flow (RPF). 
1.2.2.1. Renin-Angiotensin System 
Angiotensin (Ang) II appears to playa central role in the development of glomerular capillary hypertension 
following renal ablation and may also contribute to changes in Kt- Acute infusion of Ang II in normal rats 
results in a rise in PGC, due to a greater increase in efferent than afferent arteriolar resistance, and 
reductions in QA and Kf [23-25]. Chronic administration of Ang II for 8 weeks resulted in systemic 
hypertension, lowered single kidney GFR and with the exception of Kt, elicited similar glomerular 
haemodynamic changes to those observed after acute infusion in both normal and uninephrectomized 
rats [13]. The importance of the influence of endogenous Ang II on glomerular haemodynamics in 
remnant kidneys was further revealed by studies with pharmacological inhibitors of the renin-angiotensin 
system (RAS). Chronic treatment of 5/6 nephrectomized rats with either angiotensin-converting enzyme 
inhibitors (ACEI) [26, 27] or angiotensin II (subtype 1) receptor antagonists (AT,RA) [28, 29] resulted in 
normalization of PGC through reduction in systemic blood pressure and dilatation of both afferent and 
efferent arterioles. SNGFR, however, remained elevated due to an increase in Kf. Furthermore, acute 
infusion of an ACEI or saralasin, a peptide analogue receptor antagonist of Ang II, was found to normalize 
PGC in 5/6 nephrectomized rats through efferent arteriolar dilatation, without affecting mean arterial 
pressure (MAP) [16,30]. For reasons that are not clear these changes were not duplicated by infusion of 
the AT,RA, losartan, [31]. 
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These effects of RAS inhibition imply that there is increased local activity of endogenous Ang II even 
though plasma renin levels are reduced following 5/6 nephrectomy [26, 32]. This suggests a differential 
regulation of the systemic versus intrarenal RAS and implies that Ang II is formed locally. Renin mRNA 
and protein levels are both increased in glomeruli adjacent to the infarction scar in 5/6 nephrectomized 
rats [33-35]. These findings suggest that ablating renal mass by infarction activates the RAS by creating a 
margin of ischaemic tissue around the organizing infarct, explaining the greater severity of hypertension 
and glomerulosclerosis obtained than that observed when renal mass is excised surgically [36]. Detailed 
studies of intrarenal Ang II levels following 5/6 nephrectomy achieved by infarction have confirmed these 
findings by showing higher Ang " levels in the peri-infarct portion of the kidney than the intact portion at all 
time points [32]. By contrast the rise in intra renal Ang II following 5/6 nephrectomy was transient. 
Whereas Ang II levels in the peri-infarct portion were elevated compared to sham-operated controls 2 
weeks after surgery, they were not statistically different at 5 or 7 weeks. In the intact portion of the 
remnant kidney Ang II levels were similar to controls at 2 and 5 weeks and were lower at 7 weeks [32]. 
Sustained increases in intrarenal Ang II levels are therefor~ not required to maintain the hypertension and 
progressive renal injury characteristic of this model. 
Subsequent studies have shown that the renal protective effects of ACEI and AT1RA treatment are 
associated with a reduction in intrarenal Ang II levels in both the peri-infarct and intact portions of the 
remnant kidney [37]. By contrast, treatment with the dihydropyridine calcium antagonist, nifedipine, did not 
reduce proteinuria despite lowering blood pressure to the same levels as the RAS antagonists and was 
associated with an increase in intra renal Ang II [37). Thus intrarenal Ang II appears to playa central role 
in the pathogeneSiS of hypertension and renal injury in this model even in the absence of sustained 
increases in Ang II levels. Further research is required to fully explain these findings. It is possible that 
apparently normal intrarenal Ang II levels are inappropriately high in the context of hypertension and ECF 
volume expansion in these animals or alternatively average intrarenal Ang " levels measured may have 
failed to detect important local elevations of Ang II. 
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1.2.2.2. .Endothelins 
Renal production of endothelins is increased after 5/6 nephrectomy, raising the possibility that these 
potent vasoconstrictor peptides may also contribute to the characteristic adjustments in glomerular 
haemodynamics described above [38, 39]. Acute infusion of endothelin consistently elicits dose 
dependent reductions in RPF and GFR in normal rats and dogs [40-43]. Chronic infusion of endothelin-3 
in normal rats resulted in sustained reductions in RPF and GFR, likely due to constriction of both afferent 
and efferent arterioles, with resultant reductions in QA and SNGFR [44]. Inconsistencies in the observed 
effects of endothelins on PGC may reflect differences in experimental conditions that influenced the relative 
effects on afferent and efferent arterioles [43, 45-47]. Most studies have however reported a reduction in 
Kf after endothelin infusion [43, 45-47]. 
1.2.2.3. Natriuretic peptides 
Atrial natriuretic peptide (ANP) and other structurally related natriuretic peptides (NP) mediate to a large 
extent the functional adaptations in tubular sodium reabsorption that maintain sodium excretion in 5/6 
nephrectomized rats [48, 49]. NPs also appear to be important mediators of observed increases in GFR 
and RPF. Circulating ANP levels are elevated in 5/6 nephrectomized rats [49, 50] and acute 
administration of a NP antagonist elicited profound decreases in GFR and RPF in rats on high salt diet but 
not in those subjected to sodium restriction [51]. When pharmacological doses of exogenous ANP were 
administered to normal rats, increases in baseline GFR were observed that were attributable to a rise in 
PGC resulting from significant afferent arteriolar dilatation [52]. Nevertheless, baseline remnant kidney 
GFR was not decreased when the NP system was suppressed by sodium restriction suggesting that 
factors other than NPs contribute to the afferent arteriolar vasodilatation associated with glomerular 
hyperfiltration in this model [51]. 
1.2.2.4. Eicosanoids 
Renal prostaglandins, another family of potent vasoactive molecules present in abundance in the kidney, 
may also playa role in mediating glomerular hyperfiltration. Infusion of PGE2• PGI2 or 6-keto PGE1 into 
the renal artery elicits significant renal vasodilatation in normal kidneys [53]. After renal mass ablation 
urinary excretion per nephron of both vasodilator and vasoconstrictor prostaglandins is increased in rats 
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and rabbits [54-57] and acute inhibition of prostaglandin synthesis by infusion of indomethacin after 3/4 or 
5/6 nephrectomy lowers both SNGFR and QA [55, 56]. The relative effects of prostaglandin synthesis 
inhibitors on afferent and efferent arterioles may vary with time post nephrectomy. Afferent arteriolar 
constriction was the predominant finding reported at 24 hours post surgery, whereas constriction of both 
afferent and efferent arterioles was observed at 3-4 weeks [55, 56]. Some contribution of thromboxanes 
to glomerular haemodynamic adjustments in 5/6 nephrectomized rats is suggested by the increase in 
GFR seen after acute infusion of a selective thromboxane synthesis inhibitor [57]. Nevertheless the 
general impression, although not entirely uniform [58], is that the combined effects of vasodilator 
prostaglandins outweigh those of the vasoconstrictors. 
1.2.2.5. Nitric oxide 
Intravenous infusion of nitric oxide synthase (NOS) inhibitors results in systemic and renal 
vasoconstriction in rats [59, 60], dogs [61, 62] and rabbits [63], and a reduction in GFR in rats and dogs. 
Chronic NOS inhibition in 5/6 nephrectomized rats produced elevations in systemic blood pressure and 
PGC without affecting GFR [64). Thus NO appears to exert a tonic effect on the physiological maintenance 
of systemic blood pressure and renal perfusion under resting conditions. It is unclear, however, whether 
NO plays a specific role in the adaptive haemodynamic changes that follow renal mass ablation. MAP, 
renal vascular resistance, RBF and GFR all changed to a similar extent after acute infusion of a NOS 
inhibitor irrespective of whether given to normal, uninephrectomized or 5/6 nephrectomized rats. It 
therefore appears that NO retains a tonic influence on systemic and renal haemodynamics in the context 
of renal mass ablation but is not a specific determinant of the adaptive changes in glomerular 
haemodynamics [60]. This view is further supported by a recent study, which found that renal expression 
of all three isoforms of NOS is decreased after 5/6 nephrectomy. Furthermore, inhibition of the inducible 
isoform of NOS with aminoguanidine had no effect on renal haemodynamic variables including PGc. 
Interestingly, aminoguanidine treatment did attenuate the extent of glomerular and interstitial fibrosis, 
possibly through anti-inflammatory mechanisms [65]. 
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Table 1.1. Haemodynamic effects of vasoactive molecules mediating glomerular haemodynamic 
adaptations after partial renal mass ablation 
RA RI; PGC QA Kf SNGFR RPF GFR 
angiotensin II t tt t ..j, ..j,B ..j,B ..j, B 
[26-29] 
endothelins tB t tB ..j, ..j,B ..j,B ..j, ..j,B 
[40-471 
natriuretic peptides ..j, t (?) t B B t tB t 
[51,52] 
prostaglandins ..j, ..j, B t t t t t 
[55,56,58] 
observed changes after partial ..j,..j, ..j, t t t..j, t ..j, 
renal ablation 
[14-18] 
1.2.2.6. Adjustments in renal autoregulatory mechanisms 
There is a marked readjustment of the autoregulatory mechanisms that control RPF and GFR after 
extensive renal mass ~blation [66, 67]. The tubuloglomerular feedback system is reset to permit and 
sustain the elevations in SNGFR and PGC described above [68, 69]. Resetting appears to occur as early 
as 20 minutes after unilateral nephrectomy [70] and the magnitude of the change is in proportion to the 
extent of renal ablation [68]. 
The adjustments in glomerular haemodynamics seen after renal mass ablation represent the net effect of 
several of the endogenous vasoactive factors discussed above (Table 1.1.). Ang II, vasoconstrictor 
prostaglandins and possibly endothelins constrict both afferent and efferent arterioles whereas NPs and 
vasodilator prostaglandins dilate predominantly the preglomerular vessels. A net fall in preglomerular 
vascular resistance may therefore be expected, whereas efferent arteriolar resistance may decrease to a 
lesser degree. The role of bradykinin, a potent vasodilator that is elevated in the remnant kidney [32], 
remains to be defined. Together with transmission of a greater proportion of the raised systemic blood 
pressure to the glomerular capillary network, these alterations in microvascular resistances account for 
the observed elevations in QA, PGC, AP and SNGFR. 
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1.2.3. Renal Hypertrophic Responses to Nephron Loss 
The notion that a single kidney enlarges to compensate for the loss of its partner has been entertained 
since antiquity. Aristotle (384-322 BC) noted the sufficiency of a single kidney to sustain life in animals 
and that such kidneys were enlarged [71, 72]. In preparation for the first human nephrectomy in 1869 a 
German surgeon, Gustav Simon, uninephrectomized dogs and noted a 1.5 fold increase in the size of the 
remaining kidney at 20 days [71, 72]. Compensatory renal hypertrophy has been studied in a variety of 
species including rats, mice, guinea pigs, rabbits, cats, dogs, pigs, baboons and toads [73]. In recent 
years the majority of experimental work has been conducted on rodents subjected to uninephrectomy. 
Hypertrophic responses have also been studied in response to unilateral ureteric obstruction [74-78] or 
after nephrotoxin administration [79], presumably reflecting hypertrophy of the least injured nephrons. 
1.2.3.1. Whole - Kidney Hypertrophic Responses 
Among the earliest responses to unilateral nephrectomy are biochemical changes that precede cell 
growth. Increased incorporation of choline, a precursor of cell membrane phospholipid, has been 
detected as early as 5 minutes [80,81] and increased choline kinase activity at 2 hours after nephrectomy 
[82]. Activity of ornithine decarboxylase, the enzyme catalyzing the first step of polyamine synthesis, is 
elevated at 45-120 minutes and polyamine levels peak 1-2 days post nephrectomy [83-85]. Early 
alterations in mRNA metabolism have also been observed. Although there is no change in the half-life or 
cytoplasmic distribution of mRNA, a near 25% increase in the fraction of newly-synthesized poly (A)-
deficient mRNA occurs within 1 hour of uninephrectomy and total RNA synthesis in the kidney increases 
by 25%-100% relative to that in the liver [86-88J. Ribosomal RNA synthesis is increased by 40%-50% at 6 
hours [891. The rate of protein syntheSis is increased at 2 hours and is nearly doubled at 3 hours [90]. 
Data on cyclic nucleotide levels, which are thought to affect cell growth and proliferation, are conflicting. 
Some stUdies report elevated levels of cGMP in the remaining kidney as early as 10 minutes after surgery 
[91-93] whereas others have found no consistent changes in cAMP or cGMP levels [94J. 
Early biochemical changes are followed by a period of rapid growth. DNA synthesis is increased at 24 
hours and increased numbers of mitotic figures are evident at 28-36 hours. Both reach a maximum 
increase of 5-10 fold at 40-72 hours [73, 95-98J. Kidney weight is increased at 48-72 hours and on 
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average achieves a 35% gain at 2-3 weeks [73, 99]. As nephron number is fixed shortly after birth in most 
species, this gain in kidney weight is attributable to increased nephron size. Growth is thought to occur 
largely through cell hypertrophy. accounting for 80% of the increase in renal mass seen in adult animals 
and, to a lesser extent, through hyperplasia [90]. Renal mass continues to rise for 1-2 months until a 40-
50% increase is achieved [73]. The degree of compensatory growth is related to the extent of renal 
ablation. Uninephrectomy has been shown to provoke an 81 % increase of residual renal mass at 4 weeks 
compared to an increase of 168% after 70% renal ablation. Controls gained 31% in kidney weight during 
normal growth over the same period [100]. Hypertrophic responses in the kidney appear to diminish with 
age. After uninephrectomy, greater increases in kidney weight and more extensive hyperplasia were 
observed in 5-day vs. 55-dayold rats [73, 101] and aging rats exhibited gains in kidney weight of only 1/3 
to 3/4 of those seen in younger controls [73, 102-104]. 
In humans, radiological studies estimating gain in renal size after uninephrectomy based on tomography 
or intravenous urograms reported average increases of 3.3%-9% in renal length [105-108], 18%-23% in 
renal size "index" (product of length and width) [105, 109], or 20% in renal cross sectional area, as 
assessed by planimetry [110]. One study, however, was unable to detect any increase in average renal 
length [111]. Ultrasound estimates report inceases of 19%-100% in kidney volume [112-114] and CT 
studies show an increase of 30%-53% in renal cross-sectional area [115, 116]. Interpretation of these 
data is complicated by the small numbers of subjects, wide variation in the time intervals between 
nephrectomy and assessment of renal size as well as differing indications for nephrectomy. 
1.2.3.2. Glomerular Enlargement 
The principal morphometric change observed in glomeruli after uninephrectomy is an increase in volume 
[117-121]. Glomerular enlargement appears to parallel whole-kidney growth and has been detected as 
early as 4 days after surgery [120]. The degree of enlargement of superficial and juxtamedullary glomeruli 
is similar. Proportionally similar increases in number and size of all cell types occur with preservation of 
the relative volumes of different glomerular components [118. 119]. There is consensus that glomerular 
capillaries increase in length and number (i.e. more branching) but most studies report that the diameter 
or cross sectional surface a~~a of the glomerular capillaries remains constant or increases only minimally 
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[118, 119, 122, 123]. Transplantation of hypertrophied kidneys into uninephrectomized recipients has 
demonstrated regression of glomerular hypertrophy within 3 weeks, yet the increase in capillary length 
was maintained [1231. 
Glomerular hypertrophy, as evidenced by elevated RNA/DNA and protein/DNA ratios and by increased 
glomerular volume (VG) on electron microscopy. has been detected at 2 days after 5/6 nephrectomy [124]. 
The initial increase in VG was almost entirely due to increases in visceral epithelial cell volume. whereas at 
14 days the increase in VG was largely accounted for by mesangial matrix expansion. Several studies 
report glomerular capillary lengthening after 5/6 nephrectomy but few have detected any increase in cross 
sectional area or diameter of the glomeruiar capillaries [125-128]. These observations should, however. 
be considered in the light of important technical considerations. In vitro perfusion of isolated glomeruli 
demonstrates that VG increases as perfusion pressure is raised through physiological and 
pathophysiological ranges. Moreover. glomerular capillary "compliance" in these studies was a function of 
the baseline VG such that glomeruli obtained from remnant kidneys post 5/6 nephrectomy had a higher 
compliance than those from control animals [129]. These findings have two important implications. 
Firstly, glomerular pressures are only minimally elevated after uninephrectomy yet the glomerular capillary 
hypertension associated with more extensive renal ablation is likely to contribute significantly to the 
increase in VG. Secondly, estimates of VG in tissues that have not been perfusion-fixed at the appropriate 
blood pressure should be interpreted with caution. Direct comparison of VG in perfusion-fixed versus 
immersion-fixed kidney from the same rats yielded estimates of VG in immersion-fixed samples that were 
61 % lower than those from perfusion-fixed kidneys [130]. 
1.2.3.3. Mechanisms of Renal Hyperlrophy 
Despite more than a century of research that has identified a large number of mediators or modulators of 
renal hypertrophy. the identities of the specific factors that regulate hypertrophy and the stimuli to which 
these factors respond remain elusive. Several hypotheses have been advanced to account for the 
observed changes that are associated with renal hypertrophy but none is able to explain satisfactorily all of 
the reported observations. A detailed discussion of these hypotheses is beyond the scope of this 
dissertation and here they are summarised briefly. The "solute load" hypothesis proposes that ren~1 
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hypertrophy is a response to the increased demand for water and solute reabsorption imposed by 
increased SNGFR [72. 131]. In contrast. others have proposed that renal growth is under the control of 
specific growth andlor inhibitory factors and that the primary stimulus for renal hypertrophy is a change in 
renal mass. Whereas a substantial body of evidence supports a role for a putative "renotropin". such a 
molecule has to date not been identified [132]. Several of the major endocrine systems influence renal 
growth but each lacks selective effects on the kidney. At least three growth factors, insulin-like growth 
factor-I (IGF-I) [133-137], epidermal growth factor (EGF) [138, 139] and hepatocyte growth factor (HGF) 
[140, 141] appear to be associated with renal hypertrophy [142. 143]. Nevertheless, the timing of changes 
in growth factor levels in relation to hypertrophy remains unclear. Whereas some investigators report 
early increases [135, 138J. several others report changes only at time points when significant hypertrophy 
is already present. thus failing to provide convincing evidence that they represent the proximal effectors in 
a renotropic system [133.134.136.137. 139J. 
1.3. Adverse long-term consequences of adaptations to nephron loss 
The above haemodynamic and hypertrophic responses to renal mass ablation may readily be regarded as 
appropriate adaptations that allow the remnant kidney to partially compensate for nephron loss. However, 
a considerable body of evidence suggests that in the long-term, these adaptations may result in injury to 
remaining nephrons and thus provoke a vicious cycle of progressive renal injury. The adverse effects of 
extensive renal mass reduction have been appreciated since 1932. when rats subjected to partial 
nephrectomy were observed to develop hypertension, albuminuria. remnant kidney hypertrophy and 
azotemia [144]. Detailed histopathological studies performed several decades later revealed that early 
hypertrophy in rat remnant kidneys after 5/6 nephrectomy was followed by mesangial accumulation of 
hyaline material that progressively encroached on capillary lumina, obliterating Bowman's space and 
finally resulting in global sclerosis of the glomerulus [145]. These findings, together with the observation 
that sclerosed glomeruli are a common finding in human CKD of diverse aetiology, led the authors to 
speculate that the pathological findings described were a consequence of glomerular hyperfiltration 
resulting from a reduction in nephron number [145]. The 5/6 nephrectomy model has been extensively 
studied over several decades and considerable progress has been made in elUCidating how the 
physiological adaptations of remaining nephrons that initially permit greatly augmented function per 
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nephron, ultimately produce a complex series of adverse effects that eventuate in progressive renal injury 
and an inexorable decline in function. 
1.3.1. Haemodynamic Factors 
As early as 1 week after extensive renal mass ablation, glomerular hyperfiltration and glomerular capillary 
hypertension are associated with morphological changes including cytoplasmic attenuation, protein 
reabsorption droplets and foot process fusion in visceral epithelial cells, mesangial expansion and focal 
lifting of endothelial cells from the basement membrane [15J. Evidence that these morphological changes 
were indeed a consequence of the glomerular haemodynamic alterations was provided by studies in rats 
subjected to extensive renal mass ablation and fed a low protein diet. This intervention prevented the 
haemodynamic changes, effectively normalizing QA, PGC and SNGFR and also largely attenuated the 
structural lesions observed in rats on a standard diet. Dietary protein restriction also prevented the 
proteinuria and glomerulosclerosis that subsequently developed in rats on a standard diet [15). Similar 
findings were subsequently described in a variety of animal models of CKD including diabetic nephropathy 
[146, 147] and deoxycorticosterone (DOCA)-salt hypertension [148]. Together, these observations led 
Brenner et al. to propose that the haemodynamic adaptations following renal mass ablation ultimately 
prove injurious to glomeruli and initiate processes that result in glomerulosclerosis. Loss of further 
glomeruli would induce hyperfiltration in remaining, less affected glomeruli, thereby establishing a vicious 
cycle of progressive nephron loss. This vicious cycle therefore constitutes a "common pathway" for renal 
damage that could account for the inexorable progression of CKD, independent of the cause of the initial 
renal injury (Figure 1.1.) [149]. The hypothesis also explained the typical finding of both atrophic and 
hypertrophic nephrons in chronically diseased kidneys. Further evidence supportive of the "hyperfiltration 
hypothesis" was gleaned from· the study of experimental diabetic nephropathy in which glomerular 
hyperfiltration was also found to be a forerunner of glomerular pathology [15, 147]. Manoeuvres such as 
unilateral nephrectomy, which exacerbates hyperfiltration in the remaining kidney, were found to 
exacerbate diabetic renal injury in the remaining kidney [150]. When a kidney was shielded from 
hyperfiltration and glomerular capillary hypertension by creating unilateral renal artery stenosis, the 
ipsilateral kidney was protected against development of diabetic injury, which progressed unabated in the 
contralateral kidney [151]. In addition, when glomerular hyperfiltration was reversed in 5/6 
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nephrectomized rats by transplantation of an isogeneic kidney. hypertension and proteinuria were 
ameliorated and glomerular injury was limited [152]. Similarly. augmenting renal mass in the 
Fisher~Lewis rat transplantation model normalized PGC and greatly reduced the development of chronic 
renal allograft injury [153. 154]. Direct evidence that similar mechanisms may operate in human kidneys 
is derived from a study of 14 patients with solitary kidneys who had undergone varying degrees of partial 
nephrectomy of the remaining kidney for malignancy [155]. Before surgery proteinuria was absent in all 
patients. Although serum creatinine remained stable after an initial rise of 50% in 12 patients. 2 patients 
subjected to the most extensive nephrectomy (75% and 67%. respectively) developed progressive renal 
failure and required long-term dialysis. Moreover, among the remaining patients, 7 developed proteinuria, 
the levels of which were inversely related to the amount of renal tissue preserved. Renal biopsy 
specimens in 4 patients with moderate to severe proteinuria showed FSGS [155], which later 
morphometric analysis revealed to involve virtually all glomeruli examined [156]. 
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Figure 1.1. Schema illustrating the "haemodynamic hypothesis' proposed by Brenner et al. to explain the 
mechanisms underlying progressive nephron loss in CKD [149]. 
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The importance of glomerular haemodynamic factors in the development of progressive renal injury was 
further illustrated by studies that reported dramatic protective effects against the development of 
glomerulosclerosis after chronic inhibition of the RAS with either ACEI or AT1RA in 5/6 nephrectomized 
rats [26-29J. Micropuncture studies showed that, as with low protein diet, the renal protective effects of 
RAS inhibition were associated with near normalization of the PGc. In contrast to the effects of dietary 
protein restriction, SNGFR remained elevated [26]. This suggested that glomerular capillary hypertenSion, 
rather that hyperfiltration per se was the key factor in the initiation and progression of glomerular injury. 
Confirmation of this view came from an experiment in which rats were treated with a combination of 
reserpine, hydralazine and hydrochlorothiazide ("triple therapy") to lower arterial pressure to levels similar 
to those obtained with an ACEI. In contrast to the glomerular haemodynamic effects of the ACEI, triple 
therapy did not alleviate glomerular hypertension or proteinuria and glomerular injury progressed unabated 
[27, 28]. The effectiveness of both ACEI and AT1RA in lowering glomerular pressure and ameliorating 
glomerular injury has since been observed in several other animal models of chronic renal disease. 
These include models of diabetic nephropathy [146, 157, 158], hypertenSive renal disease [159, 160], 
experimental chronic renal allograft failure (a model that lacks systemic hypertenSion but exhibits 
glomerular capillary hypertension) [161-163]; age-related glomerulosclerosis [164, 165] and obesity-
related glomerulosclerosis [166]. It is noteworthy that the phase of transition from an acute, 
non hypertensive experimental injury induced by puromycin aminonucleoside (PAN) administration, to a 
chronic nephropathy characterized by proteinuria and glomerulosclerosis, is also associated with the 
development of glomerular capillary hypertension [167]. Clinical trials showing substantial renal protective 
effects with ACEI and AT1RA treatment strongly suggest that similar mechanisms are relevant in human 
CKD progression [168-171]. In contrast to the RAS, the role of endothelins in mediating glomerular 
capillary hypertension and experimental renal disease progression is less well defined. Pharmacological 
blockade of endothelin receptors has been shown to ameliorate disease progression in some studies but 
glomerular haemodynamics were not investigated and the mechanisms involved therefore require further 
elucidation [172-174]. 
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1.3.2. Mechanisms of haemodynamically - induced injury 
1.3.2.1. Mechanical Stress 
Whereas the importance of glomerular haemodynamic factors in the pathogenesis of glomerular injury 
has been appreciated for two decades, the specific mechanisms whereby elevated PGC may result in 
glomerular cell injury have only recently been elucidated. According to the Law of Laplace (which states 
that wall tension of a cylinder is proportional to the product of its radius and the intraluminal pressure), a 
rise in PGC produces an increase in capillary wall tension that results in stretching of the glomerular 
capillary wall [129]. Owing to the pulsatile nature of glomerular perfusion, glomerular cells are exposed to 
cyclical stretching. In addition, endothelial cells are exposed to barostress and shear stress that result 
from increased glomerular pressure and flow. Experimental evidence suggests that excessive 
mechanical forces may have adverse consequences for all three major cell types in the glomerulus. 
Furthermore, advances in the study of cellular responses to mechanical stress raise the possibility that 
glomerular hyperperfusion may promote the development of glomerulosclerosis through more subtle and 
complex pathways that induce profibrotic phenotypiC alterations in glomerular cells [175]. 
1.3.2.2. Endothelial Cells 
The vascular endothelium serves multiple complex functions including acting as a dynamic barrier to 
leukocytes [176] and plasma proteins, secretion of vasoactive molecules (prostacyclin, nitric oxide (NO) 
and endothelin), conversion of Ang I to Ang II [177] and expression of cell adhesion molecules. It is also 
the first cellular structure in the kidney that encounters the mechanical forces resulting from glomerular 
hyperperfusion. After extensive renal mass ablation endothelial cells are activated or injured, resulting in 
detachment and exposure of the basement membrane. This in turn may induce platelet aggregation, 
deposition of fibrin and intracapillary microthrombus formation [15, 178, 179]. In addition to direct cellular 
injury, exposure of endothelial cells to the shear stress, cyclic stretch or pulsatile barostress that results 
from glomerular hyperperfusion may also increase expression of cell surface adhesion molecules, 
cytokines, MHC molecules, increase platelet adhesiveness and alter endothelial barrier functions [180-
182]. In vitro, shear stress can stimulate expression of the adhesion molecule, intercellular adhesion 
molecule (ICAM)-1, on endothelial cell surfaces [183]. Ambient barometric pressure has been shown to 
enhance expression of endothelin [184] and basic fibroblast growth factor bFGF [185] by endothelial cells. 
28 
Exposure to cyclic stretch induced cell proliferation, increased cAMP generation [186] and enhanced 
endothelin release in endothelial cell cultures [187, 188]. These effects may be mediated by calcium entry 
into endothelial cells via mechanosensitive ion channels in the cell surface membrane [189, 190]. 
Mechanical stress - induced alterations in endothelial cell synthesis of vasoactive and growth promoting 
factors may shift the local balance to favour the vasoconstrictive and growth-promoting effects of factors 
such as endothelins and Ang II over the vasodilating and growth-inhibitory properties of molecules such as 
prostacyclin, heparan sulphate and NO [191]. Transforming growth factor (TGF)-~, another product of 
activated endothelial cells that is upregulated in the glomerular endothelium of 5/6 nephrectomized rats 
[192], may have a dual role, having the potential to act as a growth promoter at low levels and a 
suppresser at higher levels [193]. The complexity of endothelial responses to mechanical stress is 
underscored by the finding that the supernatant of cells cultured under sustained shear stress conditions 
has an antiproliferative effect on cultured mesangial cells [194]. Macrophage chemoattractant protein 
(MCP)-1, as well as being responsive to its classic cytokine inducers, interleukin (IL)-1, tumour necrosis 
factor (TNF)-a interferon (IFN)-y and lipopolysaccharide [195], is also upregulated in endothelial cells 
exposed to laminar shear stress [196] and is overexpressed in the arteries of rats with hypertension [197]. 
Furthermore, endothelial cells may contribute autocrine and paracrine effects via classic cytokine 
Signalling mechanisms. For example, activated endothelial cells may release TNF-a, an autocrine inducer 
of endothelial cell adhesion molecule expression [198-200]. Expression of endothelial cell adhesion 
molecules could in turn lead to indirect amplification of endothelial cell activation via TNF-a or IL-1 derived 
from adjacent glomerular cells or monocytes tethered to the endothelium [201]. It is clear from the above 
why biomechanical activation has been described as an "emerging paradigm" in endothelial cell biology 
[202] and there is now considerable support for the notion of endothelial activation as a mechanism for 
transducing the adverse effects of glomerular hyperperfusion. 
Recent studies have shed further light on the potential importance of endothelial cell injury in progressive 
renal injury. It has been recognized for some time, that segmental glomerulosclerosis is associated with 
focal obliteration of capillary loops [203] and that interstitial fibrosis is associated with loss of peritubular 
capillaries [204]. This loss of capillaries in the remnant kidney is associated with a decrease in endothelial 
cell proliferation and reduced constitutive expression of vascular endothelial growth factor (VEGF) by 
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podocytes and renal tubule cells as well as increased expression of the anti-angiogenic factor, 
thrombospondin-1, by the renal interstitium [205]. Since VEGF is an important endothelial cell angiogenic, 
survival and trophic factor, these findings suggest that capillary loss may be in part due to failure of 
recovery from haemodynamically mediated endothelial cell injury. Furthermore, short-term treatment of 
rats with VEGF reduced both glomerular and peritubular capillary loss after 5/6 nephrectomy [206]. This 
preservation of capillaries was associated with a trend towards less glomerulosclerosis and significantly 
less interstitial deposition of type III collagen as well as better preservation of renal function. Long-term 
studies are required to evaluate further the potential benefit of improving renal angiogenesis in the setting 
of progressive renal injury. 
1.3.2.3. Mesangial Cells 
Subjecting mesangial cells to cyclical stretch or strain in vitro induces proliferation [207] and synthesis of 
matrix constituents including collagen [208, 209], or switches mesangial cell phenotype to overexpress 
extracellular matrix constituents and promote fibrogenesis [210]. Transduction of mechanical forces by 
mesangial cells has been associated with tyrOSine phosphorylation [211] and protein kinase C-induced 
increases in S-6 kinase activity [212]. Mesangial cells cultured at ambient pressures of 50-60mmHg 
(levels corresponding to glomerular capillary hypertension) show enhanced synthesis and secretion of 
extracellular matrix when compared with cells grown at "normal" pressures of 40-50mmHg [213]. When 
this intervention was applied to cultured macrophages. the higher pressure was associated with increased 
secretion of factors that induced mesangial cell proliferation [213]. Cyclic stretch stimulates mesangial cell 
synthesis of the profibrotic growth factors TGF-~ [214] and connective tissue growth factor (CTGF) [215] 
as well as increased expression of TGF-~ receptors [216]. Since TGF-~ is closely associated with fibrotic 
states, it has been suggested that TGF-~ may represent an important link between glomerular capillary 
hypertension and glomerulosclerosis [217]. Cyclical stretch also activates the RAS within cultured 
mesangial cells [218] and Ang II in turn may induce TGF-~ synthesis [219]. Exposure of mesangial cells 
to barostress, achieved by culture under increased barometric pressure, also stimulates expression of 
cytokines including platelet derived growth factor (PDGF)-B [220] and MCP-1 [221]. 
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1.3.2.4. Podocytes 
As mentioned above, podocytes display morphological evidence of injury as early as 1 week after 
extensive renal mass ablation [15]. Subsequent studies have identified similar evidence of podocyte injury 
at six months after uninephrectomy [2221 and after renal ablation in rats with adriamycin-induced 
nephropathy [223]. Detailed in vitro studies have recently revealed that podocytes respond to cyclical 
stretching by undergoing reversible Ca2+ influx- and Rho kinase-dependent reorganization of the actin 
cytoskeleton, a response not seen in fibroblast or epithelial cell lines [224J. This specific 
mechanosensitivity suggests that podocytes may also respond to mechanical forces resulting from 
glomerular hypertension, but further studies are required to elucidate the nature and relevance of this 
response. 
1.3.2.5. Inflammatory cell infiltration 
A cellular infiltrate composed predominantly of macrophages and smaller numbers of lymphocytes 
accompanies clinical and experimental FSGS [225-229]. The presence of glomerular macrophages has 
led the development of secondary focal glomerulosclerosis following extensive renal mass ablation to be 
compared to the pathogenesis of atherosclerosis [230]. In the latter setting, over expression of endothelial 
adhesion molecules [231] is associated with passage of leukocytes across the endothelium, where 
monocytic infiltrates are thought to contribute to subintimal proliferation by releasing cytokines and growth 
factors [232]. Similarly, the observed upregulation of renal endothelial adhesion molecules may facilitate 
egress of leukocytes from the circulation into the mesangium, where they may participate in further renal 
injury. The recruited cellular infiltrate represents an abundant source of potent pleiotropic cytokine 
products that may influence other infiltrating leukocytes and kidney cells, further stimulating cell 
proliferation, elaboration of extracellular matrix components and increased endothelial adhesiveness as 
well as alterations in renal haemodynamics. Evidence is now emerging that these proposed mechanisms, 
based largely on in vitro observations, are indeed relevant in vivo. In the 2-kidney 1-clip model of 
renovascular hypertension, up regulated expression of adhesion molecules and TGF-~ as well as cell 
infiltration is observed only in the non-clipped kidney that is exposed to the hypertensive perfusion 
pressure [233, 234]. In the 5/6 nephrectomy model a prominent monocyte/macrophage infiltrate has been 
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reported by several authors [235, 236] and in one study these macrophages showed enhanced TGF-~ 
expression [237]. 
Several lines of evidence suggest that this cellular infiltrate does contribute to renal injury and is not 
merely a consequence of it. In one study multiple linear regression analysis identified glomerular 
macrophage infiltration in the remnant kidney as a major determinant of mesangial matrix expansion and 
adhesion formation between Bowman's capsule and glomerular tufts [238]. Furthermore, depletion of 
leukocytes in rats by irradiation delayed the onset of glomerular injury after renal ablative surgery [226]. 
Several studies have reported amelioration of the cellular infiltrate and renal injury in the 5/6 nephrectomy 
model following treatment with the immunosuppressive agent, mycophenolate mofetil [239-242]. 
Together, these data are consistent with the notion that chronic inflammatory processes are activated in 
the remnant kidney and contribute to progressive renal injury. 
Infiltrating cells, although present in the glomeruli of remnant kidney, are chiefly distributed in the 
tubulointerstitial regions [225-227]. Their role in the development of tubulointerstitial fibrosis that 
accompanies glomerulosclerosis is unclear. It is possible that interstitial infiltrates are recruited as the 
result of tubulointerstitial cell activation by the downstream effects of cytokines released in the glomeruli. 
More recently, it has been proposed that the proinflammatory phenotype of tubule epithelial cells that take 
up filtered proteins may account for the expression of cell adhesion and chemoattractant molecules that 
recruit macrophages and other monocytic cells to tubulointerstitial areas [243]. The finding that renal 
tubule cells in the remnant kidney of 5/6 nephrectomized rats expressed a-smooth muscle actin, a 
myofibroblast marker not usually expressed by epithelial cells [244], suggests that transdifferentiation of 
renal tubule epithelial cells to a myofibroblast phenotype may have an important role in the development of 
tUbulointerstitial fibrosis [245]. Interstitial myofibroblasts are thought to contribute to tubulointerstitial 
fibrosis in association with increased expression of platelet derived growth factor (PDGF) by distal tubule 
and collecting duct epithelial cells [246]. The significance of these observations remains to be 
determined. 
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The importance of inflammatory factors acting "downstream" from the haemodynamic changes in the 
common pathway mechanisms of CKD progression has recently been demonstrated by studies using a 
peroxisome proliferator-activated receptor y (PPARy) receptor agonist [247]. These compounds have 
recently been introduced as antidiabetic agents that improve insulin resistance in type 2 diabetes mellitus. 
The PPARy receptor is a member of the nuclear receptor superfamily of transcriptional factors and in vitro 
studies suggest that PPARy receptor agonists may have a wide range of effects including modulation of 
adipocyte differentiation, macrophage function and activation of other transcription factors [247]. Rats 
treated with a PPARy receptor agonist after 5/6 nephrectomy showed significant attenuation of the 
proteinuria and glomerulosclerosis observed in untreated rats, despite the failure of treatment to lower 
blood pressure. This renal protection was observed in association with marked reductions in glomerular 
cell proliferation, glomerular macrophage infiltration, and renal expression of plasminogen activation 
inhibitor (PAI)-1 and TGF-~ [2471. The authors speculate that some of these effects may have resulted 
from the known actions of PPARy receptor activation to antagonize the activities of the transcription 
factors AP-1 and NF-KB. These findings strongly support the hypothesis that downstream cellular and 
molecular mediators of the effects of glomerular haemodynamic adaptations are critical to progressive 
renal injury after nephron loss. Treatments that antagonize these mediators may therefore be of benefit in 
slowing the rate of progression of CKD. 
1.3.3. Non-haemodynamic factors in the development of nephron injury following extensive renal 
mass ablation 
The weight of evidence in support of the hypothesis that glomerular haemodynamic adaptations are 
central to progressive renal injury does not exclude the possibility that the kidney may also be affected by 
a variety of factors not directly attributable to haemodynamic changes. These non-haemodynamic factors 
have been extensively studied in recent years and may offer new therapeutic targets for future renal 
protective interventions. 
1.3.3.1. Hypertrophy 
The consistent observation of renal and in particular glomerular hypertrophy after renal mass ablation, has 
prompted investigators to propose that processes involved in, or resulting from hypertrophy may 
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contribute to progressive renal injury in CKD [248, 249]. The well documented observation that renal and 
glomerular hypertrophy precede the development of diabetic nephropathy [250] and the finding of a 
positive association between glomerular size and early sclerosis in rats subjected to renal mass ablation 
[251] suggested that hypertrophy may playa direct role in pathogenesis of glomerulosclerosis. This notion 
was further supported by the observation that PVG/c rats, which show the same increase in whole kidney 
GFR as Wistar rats after unilateral nephrectomy, do not develop the glomerular hypertrophy or the lesions 
of FSGS seen in the remaining kidney of Wistar rats at 1 year after nephrectomy [252]. On the other 
hand, the same study reported greater numbers of nephrons per kidney in PVG/c than Wistar rats and 
since glomerular haemodynamics were not studied, these data should be interpreted with caution. 
Several clinical observations also support an association between glomerular hypertrophy and renal injury. 
Oligomeganephronia is a rare congenital condition in which nephron number is 25% of normal or less. 
Such kidneys are characterized by marked hypertrophy of the glomeruli and development of proteinuria 
and renal failure in adolescence, with FSGS as the typical renal biopsy finding [253-255]. In children with 
minimal change disease, a glomerulopathy generally associated with spontaneous remission and lack of 
progression to renal failure, investigators noted an association between glomerular size and the risk of 
developing FSGS and renal failure [256]. 
Two forms of intervention have been employed in an attempt to interrupt the developme,nt of glomerular 
hypertrophy after renal mass ablation and thereby assess its role in renal disease progression. Rats 
subjected to 5/6 nephrectomy were compared to rats in which 2/3 of the left kidney was infarcted and the 
right ureter drained into the peritoneal cavity (an intervention that apparently results in decreased renal 
clearance without compensatory renal hypertrophy). Micropuncture studies confirmed similar degrees of 
elevation of PGC and SNGFR in both models. At 4 weeks the maximal planar area of the glomerulus was, 
however, significantly less and glomerular injury as assessed by sclerosis index, significantly reduced in 
ureteroperitoneostomized rats vs, 5/6 nephrectomized controls. Accordingly the authors concluded that 
glomerular hypertrophy was more important than glomerular capillary hypertension in the progression of 
glomerular injury in this model [257]. Dietary sodium restriction has also been utilized to inhibit renal 
hypertrophy after 5/6 nephrectomy. Although sodium restriction had no effect on glomerular 
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haemodynamics. glomerular volume was significantly reduced in 5/6 nephrectomized rats fed low versus 
normal sodium diets. Moreover. urinary protein excretion was lower and glomerulosclerosis was less 
severe in rats on restricted sodium intake [127]. These findings were extended by another study in which 
the effect of sodium restriction in preventing glomerular hypertrophy and ameliorating glomerular injury 
was confirmed, but which also found that these benefits were overcome by administration of an androgen 
that stimulated glomerular hypertrophy despite sodium restriction. Glomerular haemodynamics were 
similar among the groups [258]. 
Glomerular hypertrophy may contribute to glomerulosclerosis through a number of different mechanisms. 
According to the Law of Laplace, the increase in glomerular volume could result in an increase in capillary 
wall tension only if the capillary wall diameter was also increased. Cyclic stretch would then exert degrees 
of stress capable of damaging epithelial. mesangial and endothelial cells as described above. 
Alternatively. glomerulosclerosis may be viewed as a maladaptive growth response following loss of renal 
mass and resulting in excessive mesangial proliferation and extracellular matrix production [248]. In the 
past there has tended to be a dichotomy of viewpoints regarding the relative importance of haemodynamic 
factors or hypertrophy in the pathogenesis of glomerulosclerosis [248, 249. 259]. Proponents of the 
"hypertrophy hypothesis" have pOinted out that in some experiments a disassociation between glomerular 
haemodynamic changes and glomerulosclerosis has been observed [260-262] and that in one study. 
antihypertensive therapy was renal protective without lowering PGC [251]. On the other hand. those 
favouring the "haemodynamic hypothesis" have noted that treatment with ACEI [27] or AT1RA [29] in 5/6 
nephrectomized rats resulted in renal protection without preventing glomerular enlargement [27]. 
Furthermore, in the experiment of Yoshida et al. rats subjected to ureteroperitoneostomy developed 
significantly more glomerulosclerosis than sham-operated controls despite a lack of increase in glomerular 
size [257]. Moreover, many studies purporting to show a positive association between glomerular 
hypertrophy and sclerosis failed to report glomerular haemodynamic data [259]. In recent years there has 
developed a growing consensus that the above views are not necessarily contradictory. Whereas raised 
glomerular capillary pressure is still regarded as the critical factor in initiating glomerulosclerosis, it is also 
acknowledged that glomerular hypertrophy and other pathogenetic mechanisms may act in concert with 
haemodynamic factors in a complex interplay that eventuates in progressive renal injury [175, 263]. 
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1.3.3.2. Transforming Growth Factor-j3 
TGF-~ is increasingly being associated with chronic fibrotic states including chronic renal disease [264]. 
In vitro TGF-~ elicits overproduction of extracellular matrix constituents by mesangial cells and its 
expression is increased in several experimental models of renal disease including diabetic nephropathy 
[265, 266], anti-Thy-1 glomerulonephritis [217], adriamycin-induced nephropathy [267] and chronic 
allograft nephropathy [268] as well as in human glomerulonephritis [269, 270], HIV nephropathy [271], 
diabetic nephropathy [265] and chronic allograft nephropathy [272]. The role of TGF-~ in renal fibrosis is 
further illustrated by experiments in which transfection of the gene for TGF-~ into one renal artery resulted 
in ipsilateral renal fibrosis [273]. Moreover, transfection of the gene for decorin, a naturally occurring 
inhibitor of TGF-~, into skeletal muscle limited progression of renal injury in anti Thy-1 glomerulonephritis 
[274]. In 5/6 nephrectomized rats a 2-3 fold increase in remnant kidney mRNA levels for TGF-~ was 
observed and in situ hybridization revealed elevations in TGF-~ mRNA throughout glomeruli, tubules and 
interstitium [237]. Recently, another fibrogenic molecule, connective tissue growth factor (CTGF), that has 
been associated with tissue fibrosis, has also been observed to be overexpressed in kidney biopsies from 
patients with a variety of renal diseases [275]. The specific induction of CTGF expression by exogenous 
TGF-~ in mesangial cells [215, 276] and fibroblasts [277], together with the finding that blocking antibodies 
to TGF-~ inhibited increased CTGF expression in mesangial cells exposed to high glucose concentrations 
[276], suggests that CTGF may serve as a downstream mediator of the profibrotic effects of TGF-p [278]. 
1.3.3.3. Angiotensin /I 
As discussed above, Ang II plays a central role in glomerular haemodynamic adaptations observed after 
renal mass ablation. Nevertheless, experimental studies have revealed several non-haemodynamic 
effects of Ang II that may also be important in CKD progression (Figure 1.2.). In isolated, perfused 
kidneys, infusion of Ang II results in loss of glomerular size perm selectivity and proteinuria, an effect that 
has been attributed to both haemodynamic effects of Ang II resulting in elevations in PGC, and a direct 
effect of Ang II on glomerular permselectivity [279]. In vitro, Ang II has been shown to stimUlate mesangial 
cell proliferation and induce expression of TGF-~, resulting in increased synthesis of 
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Figure 1.2. Schema depicting the central role of angiotensin II, through hemodynamic and non-
hemodynamic effects, in the pathogenesis of progressive renal injury and fibrosis following nephron loss. 
(ECM: extracellular matrix; mel>: macrophage; PAI-1: plasminogen activator inhibitor-1; PGc: glomerular 
capillary hydraulic pressure; TGF-j3: transforming growth factor-j3) 
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extracellular matrix (ECM) [219]. In vivo, transfection of rat kidneys with human genes for renin and 
angiotensinogen, resulted in glomerular ECM expansion within 7 days [280]. Ang II also stimulates 
production of PAI-1 by endothelial cells and vascular smooth muscle cells [281-283] and may therefore 
further increase accumulation of ECM through inhibition of ECM breakdown by matrix metalloproteinases 
that require conversion to an active form by plasmin. Recent reports indicate that Ang II may directly 
induce transcription of a variety of cell adhesion molecules and cytokines via activation of the transcription 
factor, NF-KB [284] and may also directly stimulate monocyte activation [285]. Finally, Ang II may have 
fibrogenic effects via mineralocorticoids (see below). 
1.3.3.4. Aldosterone 
Aldosterone has been shown to stimulate collagen synthesis in the myocardium and myocardial fibrosis 
may be inhibited by spironolactone [286, 287]. Such observations provided the rationale for clinical 
studies that reported a significant improvement in survival of patients with cardiac failure who received an 
ACEI plus spironolactone, versus those receiving ACEI alone [288]. These findings in turn gave impetus 
to studies that investigated the potential role of aldosterone in renal fibrosis. In the remnant kidney model, 
adrenal hypertrophy and markedly elevated plasma aldosterone levels have been reported. Furthermore, 
administration of exogenous aldosterone during inhibition of the RAS with combination ACEI and AT1RA 
therapy in the 5/6 nephrectomy model negates the renal protective effects of the latter [289]. Further 
evidence of the role of aldosterone in progressive renal injury is provided by experiments in which rats 
subjected to adrenelectomy after 5/6 nephrectomy received replacement glucocorticoid but not 
mineralocorticoid therapy, resulting in less severe renal injury than rats with intact adrenal glands [290]. 
To date the experimental use of aldosterone receptor blockers has yielded only modest renal protective 
effects, likely due to a further compensatory rise in aldosterone levels [289, 291]. Nevertheless one 
preliminary clinical study has reported a similar reduction in proteinuria following treatment with the 
spironolactone receptor blocker, eplerenone, or an ACEI, among patients with type 2 diabetes and 
microalbuminuria [292]. It has been proposed that aldosterone contributes to renal injury through a 
combination of haemodynamic (maintenance of hypertension) non-haemodynamic effects, including 
induction of TGF-~ and PAI-1 expression [293]. 
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1.3.3.5. Hepatocyte Growth Factor 
Recent investigations have shed light on the role of HGF as a potential anti-fibrotic factor in CKD. Initial 
studies focused on the property of HGF to ameliorate tubule cell injury in models of renal ischaemia [294. 
295] but studies in models of CKD suggest that HGF may also ameliorate chronic renal injury through its 
mitogenic and anti-apoptotic actions [296]. As discussed above, HGF is upregulated in the remaining 
kidney after uninephrectomy and may playa role in compensatory renal hypertrophy [141]. A recent study 
has . confirmed that HGF and its receptor, c-met. are also upregulated in the remnant kidney after 5/6 
nephrectomy [297]. Furthermore, blockade of HGF action with anti-HGF antibodies resulted in a more 
rapid decline in GFR and more severe renal fibrosis that was associated with increased extracellular 
matrix accumulation and a greater number of myofibroblasts in the interstitium and tubules. Moreover, in 
vitro studies revealed that HGF decreased ECM accumulation in proximal tubule cell cultures by 
increasing expression of collagenases such as matrix metalloproteinase-9 (MMP-9) and decreasing 
expression of the endogenous inhibitors of MMPs. tissue inhibitor of matrix metalloproteinase (TIMP)-1 
and TIMP-2 [297]. Further experiments provide support for a possible renal protective of HGF: the renal 
protective effects of ACEI and AT1RA are associated with increased renal expression on HGF mRNA 
[298]; treatment with anti-HGF antibodies resulted in increased TGF-~ levels in a mouse model of chronic 
glomerulonephritis [299]; HGF treatment ameliorated the progression of chronic allograft nephropathy in a 
renal transplant model [300]; HGF blocked the TGF-~ induced transdifferentiation of tubule epithelial cells 
to myofibroblasts [301]; exogenous HGF administration [301] or HGF over-expression [302] blocked 
myofibroblast activation and prevented interstitial fibrosis in the unilateral ureteric obstruction model. In 
contrast. other studies have reported adverse renal effects associated with excess HGF exposure: 
Transgenic mice that over-expressed HGF developed progressive renal disease characterized by tubular 
hypertrophy. glomerulosclerosis and cyst formation [303] and HGF administration resulted in more rapid 
deterioration of creatinine clearance as well as increased albuminuria in obese db diabetic mice [304]. 
Available evidence thus suggests that HGF may playa role in ameliorating chronic renal injury but that 
inappropriate or excessive exposure to HGF may have adverse renal effects. 
39 
1.3.3.6. Altered glomerular pennselectivity to proteins 
Abnormal excretion of protein in the urine has long been regarded as the hallmark of glomerular disease. 
Whereas immune complex deposition and resulting inflammation account for abnormal permeability of the 
glomerular filtration barrier to proteins in glomerulonephritis, studies in rats subjected to extensive renal 
ablation have shown loss of glomerular barrier function to proteins of similar molecular size in the absence 
of primary immune-mediated renal injury or inflammatory response. Sieving studies using dextrans and 
other macromolecules in rats 7 or 14 days after 5/6 nephrectomy revealed loss of both size and charge-
selectivity of the glomerular filtration barrier. Ultrastructural examination of the remnant kidneys revealed 
detachment of glomerular endothelial cells and visceral epithelial cells from the glomerular basement 
membrane. In addition, protein reabsorption droplets and attenuation of cytoplasm resulting in bleb 
formation was observed in pOdocytes. The authors concluded that altered perm selectivity may be due, in 
part, to separation of endothelial cells from the glomerular basement membrane allowing access of 
macromolecules and, in part, to loss of anionic sites in the lamina rara externa resulting in both loss of 
charge-selectivity and detachment of podocytes [305]. A direct role for Ang II in modulating glomerular 
capillary permselectivity is suggested by the observation of marked increases in urinary protein excretion 
during infusion of Ang II in normal rats [306, 307]. While one group of investigators has attributed this to a 
direct effect of Ang II on the cellular components of the glomerular filtration barrier, resulting in opening of 
interendothelial junctions and epithelial cell disruption [306], others have shown that the increase in 
proteinuria may be accounted for almost completely by the associated haemodynamic changes, prinCipally 
a reduction in QA and an increase in filtration fraction [307]. On the other hand, the notion that Ang " may 
mediate changes in glomerular permselectivity independent of its effects on glomerular haemodynamics is 
supported by studies in an isolated perfused rat kidney preparation in which infusion of Ang II augmented 
urinary protein excretion and enhanced the clearance of tracer macromolecules independent of any 
change in filtration fraction [279]. 
Proteinuria has recently been implicated in experimental studies as an important effector of injury 
processes involved in renal disease progression, especially those resulting in tubulointerstitial fibrosis. In 
rats with aminonucleoside-induced nephrotic syndrome the proteinuric phase of the disease was 
associated with an acute interstitial nephritis, the intenSity of which correlated closely with the severity of 
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the proteinuria [308, 309]. Furthermore, in an overload proteinuria model induced by daily intraperitoneal 
administration of bovine serum albumin to uninephrectomized rats, proximal tubule cell injury and 
interstitial infiltration of macrophages and lymphocytes were evident after 1 week [310]. The severity of 
proteinuria showed a positive correlation with the intensity of the infiltrate. At 4 weeks, focal areas of 
chronic interstitial inflammation were noted [310]. A causative association between excessive proteinuria 
and interstitial inflammation has been suggested by in vitro studies of proximal tubule epithelial cells 
cultured in media supplemented with high concentrations of albumin, immunoglobulin G (lgG) or 
transferrin. Cellular uptake of these proteins was observed to increase secretion of endothelin-1 [311], 
MCP-1 [312] and RANTES [313]. Electrophoretic mobility shift assay of cell nucleus extracts in the latter 
study revealed intense activation of the transcription factor NF-ICB that was dependent on the 
concentration of protein in the medium. Furthermore, the liberation of these molecules was noted to be 
predominantly from the basolateral aspect of the cells. This would be in keeping with secretion into the 
renal interstitium in vivo, thereby contributing to the development of tubulo-interstitial inflammation and 
fibrosis. It has been proposed that the mechanism for cytokine induction in renal tubule epithelial cells 
that ingest excessive amounts of protein resembles that operating in virus-infected cells, where 
accumulation of viral protein in the endoplasmic reticulum activates the transcription factor NF-ICB [243, 
314]. Alternatively. increased lysosomal enzyme activity associated with protein ingestion may result in 
leakage of lysosomal enzymes into cell cytoplasm causing cell injury which could then provoke reactive 
inflammation and scarring [315-318]. 
The relevance of these findings to the processes occurring in vivo has been borne out by studies in rats. 
In the protein-overload model, the development of proteinuria at 1 week was associated with significant 
increases in TGF-J3 at both protein and mRNA levels, in interstitial as well as proximal tubule cells [319]. 
Similarly, renal cortical mRNA levels encoding the macrophage chemoattractant, osteopontin, were 
increased on day 4 and immunofluorescence localized increased osteopontin staining to cortical tubules at 
day 7. MCP-1 and osteopontin mRNA and protein levels were elevated at 2 and 3 weeks. Furthermore, a 
significant effect of proteinuria on molecules involved in extracellular matrix protein turnover was 
observed. Although mRNA levels for renal matrix proteins were variable, staining for the proteins in the 
cortical interstitium increased progressively. Levels of mRNA for the protease inhibitors PAI-1 and tissue 
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inhibitor of metalloproteinases-1 (TIMP-1) were elevated at 2 weeks, at which time significant renal 
fibrosis was present [319]. In other models of proteinuric renal disease including 5/6 nephrectomy and 
passive Heymann nephritis, accumulation of albumin and IgG by proximal tubule cells occurred before 
infiltration of the interstitium by macrophages and MHC-II positive mononuclear cells. The infiltrates 
localized to areas where proximal tubule cells stained positive for intracellular IgG, or where luminal casts 
were present. Furthermore, proximal tubule cells that stained positive for IgG also showed evidence of 
increased osteopontin production [320]. Studies in the 5/6 nephrectomy model have suggested that 
tUbulo-interstitial injury may play an important role in the decline of GFR, especially in the late stages of 
progressive renal injury [321]. By examining serial sections of remnant kidneys, investigators were able to 
show that in association with a doubling in serum creatinine, there was a substantial increase in the 
proportion of glomeruli no longer connected to glomeruli (atubular glomeruli) or connected to atrophic 
tubules. The majority of these glomeruli were not globally sclerosed, implying that tubular injury was 
responsible for the final loss of function in these glomeruli. The authors speculate that absorption of 
excess filtered protein may play an important role in this tubular injury [321]. Earlier findings that renal 
function is associated more closely with tubulointerstitial injury than glomerulosclerosis in human renal 
disease suggest that similar mechanisms may operate in human renal disease [322, 323]. 
Proteins other than albumin or immunoglobulin may also play a role in the progression of chronic 
nephropathies. Although normally absent from tubular fluid, complement components C3 and C5b-9 
neoantigen were observed along the luminal border of tubule epithelial cells in the protein overload 
proteinuria model [310]. To examine the role of filtered complement in renal injury, rats with puromycin 
aminonucleoside nephrosis were subjected to complement depletion with cobra venom factor or inhibition 
of complement activation by administration of soluble recombinant human complement receptor type 1, 
before the onset of proteinuria. In control rats proximal tubular degeneration, interstitial leukocyte infiltrate 
and renal impairment (as assessed by inulin and para-aminohippurate (PAH) clearances) occurred at 7 
days, together with positive staining for C3 and C5b-9 along the proximal tubule brush border. Both 
interventions were associated with significantly less tubulointerstitial pathology and greater clearance of 
PAH but not inulin, whereas the severity of proteinuria was unaffected, suggesting that filtered 
complement plays a significant role in tubulointerstitial injury associated with proteinuria [324]. The 
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lipoproteins HDL and LDL have been identified in the urine, renal interstitium and tubule cells in renal 
biopsies of patients with nephrotiC syndrome [325] and may also have a role in renal injury. In vitro, 
cultured "human proximal tubule epithelial cells take up LDL and HDL [326]. Oxidized LDL may cause 
tubule cell injury and exposure of tubule epithelial cells to HDL is associated with increased synthesis of 
endothelin-1 [326, 327]. Finally, a role has also been proposed for compounds bound to filtered proteins 
such as IGF-1, which has been detected in increased amounts in the proximal tubular fluid of rats with 
adriamycin nephrosis. Proximal tubule cells cultured in the presence of proximal tubular fluid from 
nephrotic rats exhibit enhanced cell proliferation and increased secretion of Type I and Type IV collagen. 
Both effects were inhibited by neutralizing IGF-1 receptor antibodies [328]. 
In experimental models of proteinuric renal disease, filtered proteins have also been found to accumulate 
in the glomerular mesangium [305, 329, 330] and may contribute to glomerular as well as tubulointerstitial 
injury. Further support for this notion is derived from a meta-analysis of 57 studies of experimental CKD 
that found a consistent positive correlation between the severity of proteinuria and extent of 
glomerulosclerosis [331]. Lipoproteins, in particular, accumulate in the glomeruli of patients with 
glomerulonephritis [332, 333]. Furthermore, low density lipoprotein (LDL) stimulates mesangial cells to 
prOliferate in vitro [334, 335] and enhances mesangial cell synthesis of the extracellular matrix protein 
fibronectin [336]. LDL exposure is also associated with increased mesangial cell mRNA levels for MCP-1 
[336] and PDGF [335]. Oxidation of LDL by mesangial cells or macrophages may enhance its toxicity 
[334]. Thus, accumulation of proteins in the mesangium may stimulate a number of different mechanisms 
that contribute to glomerulosclerosis. 
While establishing cause-effect relationship between proteinuria and renal injury in humans is difficult, 
several recent clinical studies provide strong evidence in support of this notion. A meta-analysis of 17 
clinical studies of chronic renal disease revealed a positive correlation between the severity of proteinuria 
and extent of biopsy-proven glomerulosclerosis [331]. Observations from the Modification of Diet in Renal 
Disease (MDRD) trial also suggest that proteinuria is an independent determinant of CKD progression: 
Greater levels of baseline proteinuria were strongly associated with more rapid declines in GFR; reduction 
of proteinuria, independent of reduction in blood pressure, was associated with lesser rates of decline in 
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GFR. Furthermore, the degree of benefit achieved by lowering blood pressure below usual target levels, 
was highly dependent on the level of baseline proteinuria [337]. Similar findings were obtained in the 
Ramipril Efficacy In Nephropathy (REIN) trial where higher baseline proteinuria was associated with more 
rapid rates of decline in GFR. In patients with pretreatment urinary protein excretion in excess of 3g/day, 
treatment with ramipril reduced proteinuria to an extent that correlated inversely with the subsequent rate 
of decline in GFR. Treatment with other antihypertensives to achieve equivalent levels of blood pressure 
control did not decrease proteinuria and was associated with a higher rate of decline in GFR and an 
increased risk of reaching the combined end-point of doubling of the baseline serum creatinine or end-
stage renal failure [169]. Reanalysis of data from both strata of the REIN study found that the percentage 
reduction in proteinuria over the first 3 months as well as the absolute level of proteinuria at 3 months 
were strong independent predictors of the subsequent rate of decline in GFR [338]. A meta-analysis that 
included data from 1860 patients with non-diabetic CKD confirmed these findings and showed that during 
antihypertensive treatment, the current level of proteinuria was a powerful predictor of the combined end-
point of doubling of baseline serum creatinine or onset of ESRD (relative risk 5.56 for each 1.0g/day of 
proteinuria) [339]. Analysis of data from the RENAAL study reported that among type 2 diabetics with 
nephropathy, baseline urinary albumin:creatinine ratio was the strongest predictor of the risk of reaching 
the combined end-point of doubling of baseline serum creatinine or onset of ESRD [340]. Taken together, 
the evidence from experimental and clinical studies provides strong support for the hypotheSiS that 
excessive filtration of proteins due to impaired glomerular perm selectivity directly damages the kidney. 
Whether or not this is so, the close association between the severity of proteinuria and renal prognosis 
implies that reduction of proteinuria should be regarded as an important independent therapeutic goal in 
clinical strategies seeking to slow the rate of progression of CKD. 
1.4. Strategies for Achieving Renal Protection 
1.4.1. Control of Systemic Hypertension 
There is clear evidence that hypertension accelerates the rate of progression of pre-existing renal disease, 
most likely through transmission of raised blood pressure to the glomerulus, resulting in exacerbation the 
glomerular capillary hypertension associated with progressive nephron loss [149]. The treatment of 
systemic hypertenSion was the first intervention shown to Significantly slow the rate of CKD progression 
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and it remains fundamental to renal protective strategies. Among insulin-dependent diabetic patients with 
diabetic nephropathy, initiation of antihypertensive therapy resulted in marked reductions in the rates of 
GFR decline [341, 342] implying that hypertension, an almost universal consequence of impaired renal 
function, also contributes to the progression of CKD. Similar observations were subsequently reported 
among patients with non-diabetic forms of CKD {343-345]. Uncertainty remained, however, as to what 
level of blood pressure lowering was required to achieve optimal renal protection. The Modification of Diet 
in Renal Disease (MDRD) Study sought to resolve this issue by directly evaluating whether lower than 
previously recommended blood pressure targets afforded greater renal protection than "usual" blood 
pressure control among patients with predominantly non-diabetic CKD. In addition to the dietary 
interventions described below, patients were randomized to a target mean arterial pressure (MAP) of 
107mmHg or 92mmHg. Whereas the primary analysis did not show any overall difference in rate of GFR 
decline between these groups, patients randomized to the low blood pressure group showed an early 
rapid decrease in GFR, probably due to associated renal haemodynamic effects. that obscured a later 
significantly slower rate of GFR decline than observed in the "usual" blood pressure target group. 
Furthermore, a higher level of baseline proteinuria was associated with a greater difference in GFR 
decline between ·usual" and low blood pressure groups [346]. Secondary analysis revealed significant 
correlations between the rate of GFR decline and achieved blood pressure, an effect that was also more 
marked among those with greater baseline proteinuria. In study 1 (patients with GFR of 25-
55mllmin/1.73m2), rates of GFR decline increased above a MAP of 98mmHg among patients with 
baseline proteinuria of O.25-3.0g/day. and above 92mmHg in those with baseline proteinuria >3.0g/day. In 
study 2 (patients with GFR of 13-24ml/min/m2). among patients with baseline proteinuria >1g/day, higher 
achieved blood pressure was associated with greater rates of GFR decline at all levels. The authors 
concluded by recommending a blood pressure goal of <125175 (MAP=92mmHg) for CKD patients with 
>1g/day of proteinuria, and a goal of <130/80 (MAP=98mmHg) for those with proteinuria of O.25-1.0g/d 
[337]. A second major study has recently investigated the potential benefit of a lower blood pressure goal 
on the rate of GFR decline among 1094 African American patients with hypertensive renal disease, 
randomized in a 2 x 3 factorial design to a MAP target of 102-107mmHg or :s;92mmHg and treatment with 
ramipril, amlodipine or metoprolol. Similar to the primary findings in the MDRD study, no significant 
difference in the rate of decline in GFR was observed between the two blood pressure target groups [347J. 
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Since not all the patients in the MDRD Study received ACEI. it remains unclear to what extent the level of 
blood pressure attained remains important in CKD patients receiving ACEI or angiotensin receptor 
antagonists (AT1RA). At least one experimental study has found systolic blood pressure to be a major 
determinant of glomerular injury in rats receiving ACEI treatment [348]. Moreover among patients with 
type 1 diabetes and established nephropathy receiving ACEI. randomisation to a low (MAP=92mmHg) vs. 
"usuar (MAP=100-107mmHg) target blood pressure was associated with significantly lower levels of 
proteinuria after 2 years. although there was no significant difference in the rate of GFR decline [349]. A 
recent finding that intensive blood pressure control was not associated with significantly improved renal 
function among patients with autosomal dominant polycystic kidney disease appears to contradict the 
above findings but. by the authors' own admission, the study may not have had adequate statistical power 
to detect such a difference [350]. Furthermore not all patients in this study received an ACEI 
(approximately 70% did). 
There has been some controversy over the role of calcium channel blockers (CCB) as antihypertensive 
agents in patients with CKD. There is concern that the dihydropyridine class of CCB may in fact have 
adverse effects on the progreSSion of CKD. In experimental studies dihydropyridine CCB allowed greater 
transmission of systemic blood pressure to the renal microcirculation and were associated with more rapid 
progression of renal injury than ACEI treatment in the 5/6 nephrectomy model [351]. Whereas one 
relatively small study found no difference between the renal protective effects of the dihydropyridine CCB. 
nifedipine. and the ACEI, captopril [352], two larger studies have reported adverse outcomes associated 
with the use of dihydropyridine CCB. A secondary analysis of data from the Ramipril Efficacy In 
Nephropathy (REIN) Study found that treatment with a dihydropyridine CCB (nifedipine or amlodipine) was 
associated with higher levels of proteinuria and more rapid GFR decline than other antihypertensives in 
those patients who failed to achieve a MAP of <1 OOmmHg and who were not receiving an ACEI [353]. In 
the African American Study of Kidney Disease and Hypertension (AASK) [354] patients with CKD and 
hypertenSion were randomized to treatment with an ACEI or amlodipine or a l3-blocker and diuretic in 
combination. The amlodipine arm of the study was stopped prematurely due to a more rapid decline in 
GFR among these patients versus those receiving the l3-blocker or ACEI, particularly among those with 
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>1g/day of proteinuria. The AASK Study implies that this is particularly true for African American patients. 
On the other hand available data suggest that the non-dihydropyridine eeB do contribute to renal 
protection. Experimental data have shown that non-dihydropyridine eeB lower PGC, reduce proteinuria 
and afford renal protection. Furthermore, in one non-randomized study non-dihydropyridine CCB reduced 
proteinuria in patients with type 2 diabetes and overt nephropathy, an effect that was additive to that of 
ACEI alone [355]. 
1.4.2. Pharmacological inhibition of the Renin-Angiotensin System 
Following the observation of dramatic renal protective effects associated with ACEI treatment in 
experimental models, investigators sought to establish whether similar effects could be achieved in human 
CKD. Over the past decade several of clinical studies have been published that together provide strong 
support for the use of pharmacological inhibitors of the RAS as an essential component of any strategy 
aiming to achieve maximal renal protection in patients with CKD (summarized in table 1.2.). 
1.4.2.1. Angiotensin-Converling Enzyme Inhibitors 
1.4.2.1.1. Diabetic Nephropathy 
Following experimental evidence of the specific renal protective effects of ACEI, several reports and one 
small prospective study suggested that ACEI afforded renal protection in type 1 diabetics with established 
nephropathy [356]. In 1993, the Captopril Collaborative Study Group published the first large prospective 
randomized controlled trial to clearly show speCific renal protection attributable to ACEI treatment in 
human CKD [168]. Four hundred and nine patients with type 1 diabetes and established nephropathy 
(proteinuria >0.5g/day; serum creatinine <2.5mg/dl) were randomized to receive captopril or placebo with 
a blood pressure goal of <140/90mmHg. After a median follow-of 3 years, captopril treatment was 
associated with a 50% reduction in the risk of the combined end-point of death, dialysis and renal 
transplantation and a 48% reduction in the risk of a doubling of serum creatinine. Moreover, this 
additional renal protection was not attributable simply to the antihypertensive effects of ACEI as blood 
pressure control was not statistically different between the groups. This landmark study prompted several 
further studies to investigate whether ACEI may also benefit type 1 diabetic patients with the increased 
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risk of developing nephropathy associated with microalbuminuria. A meta-analysis of 12 such studies 
including 689 patients with type 1 diabetes that were followed for at least a year found that ACE I treatment 
was associated with a significant reduction in the risk of progression to overt nephropathy (odds ratio 0.38) 
and three times the incidence of complete normalization of the microalbuminuria [357]. In another study, 
the effect of ACEI in preventing progression to overt nephropathy was sustained over 8 years and was 
associated with preservation of a normal GFR [358]. Finally, subgroup analysis of the EUCLID Study 
found that ACEI treatment reduced albuminuria by 12.7% among normotensive, normoalbuminuric type 1 
diabetics. However, this trend was not statistically significant and was associated with a statistically lower 
blood pressure in the ACEI-treated group [359]. 
Data on the renal protective effects of ACEI in patients with type 2 diabetes are, to some extent, 
conflicting. Studies comparing ACEI and other antihypertensives among type 2 diabetics with overt 
nephropathy have included relatively small numbers of patients and only one [360] was able to show a 
greater reduction in GFR decline associated with ACEI versus other antihypertensives [361-363]. In 
contrast, several studies including the diabetic subgroup analysis of the Heart Outcomes Prevention 
Evaluation (HOPE) Study, have reported beneficial effects of ACEI treatment in decreasing 
microalbuminuria [364-367] or reducing the number of patients progressing from microalbuminuria to overt 
proteinuria among type 2 diabetics (risk reduction 24-67%) [368-370]. In addition, the HOPE Study 
reported a 25% reduction in the combined primary endpoint of myocardial infarction, stroke or 
cardiovascular death in Ramipril-treated type 2 diabetics with risk factors for cardiovascular disease. 
Finally, at least one study has reported a beneficial role for ACEI in primary prevention of nephropathy 
among 156 normotensive, normoalbuminuric type 2 diabetics. Patients receiving enalapril over a 6-year 
period had an absolute risk reduction of 12.5% versus placebo for developing microalbuminuria [371]. On 
the other hand, one relatively large study found no renal protective benefit of ACEI over J3-blocker 
treatment among hypertensive type 2 diabetics with normo- or microalbuminuria [372]. 
1.4.2.1.2. Non-Diabetic CKD 
Following the publication of studies showing the renal protective effects of ACEI in diabetics, investigators 
sought to study the potential of ACEI to afford renal protection in non-diabetic forms of CKD. Maschio et 
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al. randomized 583 patients with CKD of diverse aetiology to treatment with benazepril or placebo. After 3 
years of follow-up, the study found a 53% reduction in the risk of reaching the combined end point of 
doubling of base-line serum creatinine or the need for dialysis associated with ACEI treatment. However, 
a significantly lower blood pressure among patients receiving ACEI vs. placebo made it impossible to 
separate the beneficial effects of lowering blood pressure from any unique effects of ACEI treatment [373J. 
By contrast, in the REIN Study, 352 patients with non-diabetic CKD randomized to either ACEI or placebo 
achieved similar control of blood pressure. Among patients with ~3g/day of proteinuria at base line, the 
study was stopped early due to a significantly lower rate of decline in GFR in patients receiving the ACEI 
(0.53 vs. 0.88mVmin/month) [169]. Further analysis showed a significant reduction in the risk of the 
combined end-point of a doubling of serum creatinine or ESRD in the ACEI group (risk ratio = 1.91 for the 
placebo group). In the next phase of this study, patients who had received placebo were switched to ACEI 
and those already on ACEI continued treatment. Consistent with the findings of the first phase of the 
study, there was a significant reduction in the rate of decline in GFR of patients switched to ACE/. In 
addition. patients continuing on ACEI treatment showed a further reduction in the rate of GFR decline. to 
levels similar to those associated with normal aging. Patients who received ACEI from the start of the 
REIN study had a significantly lower risk of reaching end-stage renal failure (ESRF) than those switched to 
ACEI after the initial phase of the study (relative risk for placebo group = 1.86). Indeed from 36 to 54 
months of follow up, no further patients in the former group reached ESRF [374]. Interestingly, a small 
number of patients continued on ACEI actually showed an increase in GFR after prolonged treatment 
[375]. REIN Study patients with <3g/day of proteinuria (n=186) were followed for a median of 31 months 
after randomisation. Similar to the findings among those with more severe proteinuria, ACEI treatment 
significantly reduced the incidence of ESRF (relative risk for placebo group = 2.72), particularly among 
those with a GFR of <45ml/min at baseline [376]. The findings of these individual stUdies have recently 
been confirmed by a meta-analysis of 11 studies that included 1860 patients with non-diabetic CKD [377J. 
Antihypertensive regimens that included ACEI resulted in significantly greater reductions in blood pressure 
and proteinuria, but even after statistical adjustment for these factors, ACEI treatment was associated with 
significantly lower risks of reaching ESRD (relative risk = 0.69; CI 0.51-0.94) and the combined end-point 
of a doubling in baseline serum creatinine or ESRD (relative risk = 0.70; CI = 0.55-0.88). These data 
indicate that the renal protective effects of ACEI are mediated by factors in addition to their. 
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antihypertensive and antiproteinuric effects. Moreover, further analysis showed that the benefits of ACEI 
treatments were greater in patients with higher levels of baseline proteinuria. The recent AASK study has 
shown that the renal protective benefits of ACEI therapy also apply to African American patients, a group 
who tend to be resistant to the antihypertensive effects of ACEI. Patients with hypertensive renal disease 
randomized to ACEI treatment showed a significant risk reduction for the combined outcome of reduction 
of baseline GFR by ~50%, ESRD or death versus patients treated with a /3-blocker (22% risk reduction) or 
a non-dihydropyridine CCB (38% risk reduction) [347]. 
In addition to the renal protective benefits of ACEI treatment, the HOPE Study reported substantial 
reductions in overall (relative risk = 0.84) and cardiovascular mortality (relative risk = 0.74) as well as 
reductions in myocardial infarction (relative risk = 0.80) and stroke (relative risk = 0.68) in patients 
receiving an ACEI vs. placebo among 9297 who were at increased risk of cardiovascular disease [378]. 
Although the HOPE Study did not include large numbers of patients with non-diabetic CKD, cardiovascular 
disease remains the single largest cause of morbidity and mortality among these patients and the data 
therefore provide a further rationale for the use of ACEI therapy as the single most important intervention 
in patients with CKD. 
1.4.2.2. Angiotensin Receptor Antagonists 
Angiotensin (subtype 1) receptor antagonists inhibit the RAS by blocking angiotensin II subtype 1 (AT 1) 
receptors. Thus ACEI and AT1RA differ significantly in their effects on the RAS in ways that may be 
therapeutically relevant (discussed in detail in section 1.5.2.). In small preliminary clinical studies, AT1RA 
and ACEI produced similar antihypertensive and antiproteinuric effects among patients with essential 
hypertenSion [379], non-diabetic CKD [380J or type 2 diabetes and early nephropathy [3811. The 
publication of 3 large randomized studies has established a clear role for AT1RA therapy in achieving renal 
protection for patients with type 2 diabetes. In the Reduction of Endpoints in NIDDM with Angiotensin II 
Antagonist Losartan (RENAAL) Trial, 1513 patients with established diabetic nephropathy were 
randomized to losartan or placebo and followed for a mean of 3.4 years [171]. Losartan treatment was 
associated with Significant reductions in the incidence of a doubling of baseline serum creatinine (risk 
reduction = 25%) and ESRD (risk reduction = 28%) as well as a 35% reduction in proteinuria. In the 
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Irbesartan Diabetic Nephropathy Trial (lDNT) 1715 patients with hypertension and established diabetic 
nephropathy were randomized to treatment with irbesartan, amlodipine or placebo [170]. After a mean of 
2.6 years, irbesartan was associated with a 33% lower risk of a doubling of baseline serum creatinine vs. 
placebo and a 37% reduction vs. amlodipine. Although not statistically significant, irbesartan was 
associated with a 23% reduction in the risk of ESRD vs. placebo and amlodipine. Importantly, close 
matching of achieved blood pressure between groups in both these trials implies that, as with the ACEI 
studies, the additional renal protective effects of AT1RA treatment could not be attributed merely to their 
antihypertensive effects. A third study examined the renal protective effects of irbesartan in 590 type 2 
diabetics with hypertension and microalbuminuria [382]. Patients were randomized to irbesartan at 2 
different doses (300 or 150mg/day) or placebo and followed up for 2 years. During this period significant 
differences emerged in the incidence of overt proteinuria (5.2% vs. 9.7% vs. 14.9%) and the higher dose 
of irbesartan was associated with a sUbstantial reduction in the risk of developing overt nephropathy 
(hazard ratio = 0.30; CI 0.14-0.61 vs. placebo). Although significantly lower blood pressures were 
achieved with irbesartan, the risk reduction was similar after adjustment for the baseline level of 
microalbuminuria and blood pressure. In summary, whereas clear evidence of the renal protective effects 
of ACEI in type 2 diabetics with overt nephropathy is lacking, there are now 2 large studies showing the 
benefits of AT1RA in this population. Second, a single large study supports the notion that AT1RA 
treatment is similarly effective as ACEI treatment in preventing progression from microalbuminuria to overt 
nephropathy in type 2 diabetes mellitus. 
Although large randomized clinical trials of the renal protective effects of AT1RA in type 1 diabetics or non-
diabetic CKD are not yet available the above data suggest that the AT1RA will duplicate the renal 
protection achieved by ACEI in these populations. In addition, one important advantage of AT1RA over 
ACEI is their more favourable side effect profile. In clinical trials AT1RA have been reported to have side 
effect profiles similar to placebo [383, 384]. Importantly, AT1RA are not associated with the cough that 
may occur in up to 20% of patients receiving ACEI. Among patients converted from ACEI to AT1RA 
therapy, recurrence of a cough was significantly lower than in patients rechallenged with an ACEI [385, 
386]. Thus even in the absence of clinical trials in type 1 diabetes or non-diabetic CKD, available 
evidence supports the use of AT1RA as an alternative in patients groups who are unable to tolerate ACEI 
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due to side effects. Furthermore, the favourable side effect profile of AT1RA suggests that it may be 
possible to employ higher doses. Preliminary data have shown that doubling the dose of an AT1RA may 
result in greater lowering of proteinuria without a further reduction in blood pressure [380]. Finally, the 
differing effects of ACEI and AT1RA on the RAS imply that in combination they may have additive or even 
synergistic effects. Among 8 patients with IgA nephropathy treated consecutively with an ACEI, AT1RA 
and combination therapy, the combination was associated with greater antiproteinuric effects than either 
treatment alone, without significant additional antihypertensive effects [387]. Addition of an AT1RA to prior 
ACEI therapy in 11 patients with CKD was associated with a 6mmHg fall in MAP and a further 30% 
reduction in proteinuria [388]. In the largest study to date, combination ACEI and AT1RA therapy afforded 
greater reductions in blood pressure and albuminuria than either treatment alone among 199 type 2 
diabetic patients with hypertension and microalbuminuria [389]. Thus, although more data are required 
before firm recommendations can be made, evidence is accumulating that combination ACEI and AT1RA 
therapy may offer additional renal protection to that afforded by either agent alone. 
Table 1.2. Summary of studies showing the renal protective effects of ACEI and AT 1RA in diabetic and 
non-diabetic CKD. 
Angiotensin-Converting Enzyme Inhibitors 
CROType 
Type 1 OM + CKO 
Type 1 OM + ~ 
Type 1 OM + NA 
Type 2 OM + CKO 
Type 2 OM + ~ 
Type 2 OM + NA 
Non-diabetic CKO 
Trial Outcome 
50% ,J.. risk of dialysis, Tx or death 
,J.. risk of overt nephropathy (OR=0.38) 
12.7% ,J.. in albuminuria (NS) 
Benefit in only 1 study 
24-67% ,/.. risk of overt nephropathy 
12.5% ,J.. risk of developing f.1A 
,J.. creatinine doubling I ESRD (RR=0.52) 
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Reference 
168 
357, 358 
359 
360-363 
364-370 
371 
169, 347, 374, 
376,377 
Angiotensin Receptor Antagonists 
CKOType 
Type 2 OM + JJA 
Type 2 OM + CKO 
Trial Outcome 
~ risk of overt nephropathy (HR=0.30) 
25-37% ~ risk of creatinine doubling 
23-28% ~ risk of ESRD 
Reference 
382 
170,171 
Abbreviations: HR - hazard ratio; OR - odds ratio; ~ - microalbuminuria; NA - normoalbuminuria; RR -
risk ratio; Tx - transplant 
1.4.3. Dietary Protein Restriction 
Increases dietary protein intake or intravenous protein loading in animals or humans with intact kidneys 
are associated with increases in renal mass, renal blood flow and GFR, as well as a decrease in renal 
vascular resistance [390-393], changes similar to those observed after renal mass ablation. It has been 
proposed that the augmented renal function induced by dietary protein may be an evolutionary adaptation 
of the kidney to the intermittent heavy protein intake of the hunter-gatherer [149J. Thus renal 
hyperfunction following a protein load would allow excretion of the waste products of protein catabolism, 
thereby achieving homeostasis in the face of an abrupt increase in protein intake. The subsequent 
decline of GFR to baseline during the intervals between meals would facilitate conservation of fluid and 
electrolytes in times of scarcity. Continuous excessive protein intake that results in persistent renal 
hyperfunction, however, leads to renal injury in experimental models. Laboratory animals with intact 
kidneys and ingesting food ad libitum become proteinuric and develop glomerulosclerosis with age [149, 
394, 395]. Furthermore, dietary protein intake has been shown to influence the rate of progression of 
established renal disease in experimental models. This progression was significantly accelerated by a 
high protein diet and attenuated by dietary protein restriction or alternate day feeding [394]. Similarly, in 
diabetic rats, progression of nephropathy was markedly accelerated in the setting of a high protein diet 
and substantially attenuated by a low protein diet [147]. Similar renal protection was observed after dietary 
protein restriction in the 5/6 nephrectomy model {15]. In both the diabetic nephropathy and 5/6 
nephrectomy models, the renal protective effects of dietary protein restriction in experimental animals are 
associated with virtual normalization of PGC and SNGFR. 
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Despite unambiguous evidence from experimental studies, confirmation of a beneficial effect of protein 
restriction in clinical trials has proved elusive. Following the publication of several smaller studies that 
generally suggested a beneficial effect from protein restriction but that suffered from deficiencies in design 
or patient compliance, a large, multicenter, randomized study, the MDRD study, was conducted to resolve 
the issue [346]. 585 patients with moderate chronic renal failure (GFR=25-55mllmin/1.73m2) were 
randomized to "usual" (1.3g/kg/day) or "low· (0.58g/kg/day) protein diet (study 1) and 255 patients with 
severe chronic renal failure (GFR=13-24ml/minl1.73m2) to "low· (0. 58g/kg/day) or "very low· 
(0.28g/kg/day) protein diet. All causes of CKD were included but patients with diabetes mellitus requiring 
insulin therapy were excluded. Patients were also assigned to different levels of blood pressure control. 
After a mean of 2.2 years fOllOW-Up, the primary analysis revealed no difference in the mean rate of GFR 
decline in study 1, and only a trend towards a slower rate of decline in the "very low· protein group in study 
2. Secondary analyses of the MDRD data, however, revealed that dietary protein restriction probably did 
achieve beneficial effects. In study 1 "low" protein diet was associated with an initial reduction in GFR that 
likely resulted from the functional effects of decreased protein intake and not from loss of nephrons. This 
initial reduction in GFR obscured a later reduction in the rate of GFR decline that was evident after 4 
months in the "low" protein group and that may have resulted in more robust evidence of renal protection 
had follow-up been continued for a longer period [396]. Further evidence to support a beneficial effect of 
dietary protein restriction in CKD is derived from a meta-analysis of five randomized, controlled trials 
(including MDRD Study 1). Despite inconclusive findings in several of the individual studies, Pedrini, et al. 
[397] determined that the overall relative risk for renal failure or death was reduced to 0.67 (CI 0.50-0.89) 
with protein restriction, an effect that was not attributable to differences in blood pressure control between 
the groups. 
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1.4.4. Treatment of Hyperllpldaemla 
CKD is commonly associated with abnormalities of plasma lipids characterized by elevated levels of the 
triglyceride-rich lipoproteins VLDL and LDL, and reduced levels of HDL [398]. In addition to contributing to 
the increased risk of cardiovascular disease associated with CKD, these lipid abnormalities may also 
accelerate the progression of CKD. In the MDRD Study, low serum HDL cholesterol was an independent 
predictor of more rapid decline in GFR [399J and in another study elevated triglyceride-rich apo-B 
containing lipoprotein levels correlated significantly with the rate of deterioration of renal function [400]. 
Hypercholesterolemia has been associated with more rapid progression of renal disease among patients 
with diabetic [401-403J and non-diabetic forms of CKD [404]. Analysis of data from 12,728 patients 
without significant renal disease found that elevated baseline serum triglyceride levels and low HDL 
cholesterol levels were independent predictors of a rise in serum creatinine over the following 2.9 years, 
suggesting that dyslipemias may also be involved in the initiation of CKD [405J. The mechanisms whereby 
hyperlipidemia my contribute to renal injury are the subject of ongoing research, but studies to date have 
identified several different mechanisms, including stimulation of mesangial cell proliferation, cytokine 
expression and extracellular matrix synthesis [335, 336], oxidation of LDL to form reactive oxygen species 
[406] and elevations in PGC [407]. In experimental studies treatment of hyperlipidemia has resulted in 
attenuation of renal injury in a variety of models of CKD [17, 408]. Although large randomized clinical trials 
of lipid-lowering therapy in CKD are awaited, a recent meta-analysis of 12 small studies that included both 
diabetic and non-diabetic renal disease found that lipid-lowering therapy Significantly reduced the rate of 
decline in GFR (mean reduction 1.9mllmin/year) [409]. Further studies are required to confirm this finding 
in larger numbers of patients and to identify appropriate levels for intervention as well as therapeutic 
targets. 
1.4.5. Smoking Cessation 
Smoking has been identified as a risk factor for the development of microalbuminuria, overt proteinuria 
and renal disease progression in type 1 and 2 diabetics [410-412]. Similarly, smoking is a risk factor for 
progression in a variety of forms of non-diabetic CKD: Among patients with adult polycystic kidney disease 
or IgA nephropathy, smokers had a 10-fold increased risk of progression to ESRD vs. non-smokers [413]; 
the median time to ESRD was almost halved in smokers vs. non-smokers in patients with lupus nephritis 
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[4141; patients with a primary glomerulonephritis and serum creatinine >1.7mg/dl were significantly more 
likely to be smokers than those with normal creatinine [4151; smoking was the most powerful predictor of a 
rise in serum creatinine among patients with severe essential hypertension [416]. Moreover, smoking has 
been associated with increased albuminuria and both increased and decreased GFR in a large 
population-based study of non-diabetic subjects [417]. Proposed mechanisms whereby smoking may 
exacerbate renal injury include glomerular hyperfiltation, endothelial dysfunction and increased 
albuminuria. Though prospective studies showing renal benefit from smoking cessation are lacking, the 
above evidence suggests that the kidney is another organ that may be adversely affected by smoking. 
1.5. Unanswered Questions 
Two decades of research has shed considerable light on the multiplicity of factors that may contribute to 
the common pathway of mechanisms that drive the relentless decline in renal function characteristic of 
CKD. Following the land-mark studies that identified glomerular capillary haemodynamic adaptations as 
the primary driving force behind CKD progression, detailed in-vitro studies have suggested mechanisms 
whereby haemodynamic forces may provoke pro-inflammatory and fibrotic responses in glomerular cells. 
Considerable progress has also been made in understanding the potential role of non-haemodynamic 
factors such as hypertrophy, proteinuria and the non-haemodynamic effects of angiotensin II. 
Nevertheless. several areas require further elucidation and many questions remain unanswered. The 
work presented in the following chapters is an attempt to contribute to our understanding of CKD 
progression in some of these areas. 
1.5.1. In vivo expression of pro-inflammatory and fibrotic growth factors 
Several studies have reported the induction of cell adhesion molecules. proinflammatory cytokines and 
profibrotic growth factors in glomerular cells exposed to mechanical forces such as shear stress or 
barostress in vitro. Few studies have. however, attempted to confirm that these molecules are also 
upregulated in vivo in models of CKD. Whereas some studies have focused on individual cytokines or 
growth factors. none has previously attempted to examine the expression of multiple molecules over time 
in a single model. In Chapter 2 we present a series of experiments that examine the expression of six 
different molecules over time in the 5/6 nephrectomy model. In Chapter 3 we investigate the expression 
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of cytokines in the 5/6 nephrectomy model with prolonged follow-up and show correlations between the 
level of expression and the extent of renal injury. 
1.5.2. Pharmacological inhibition of the Renin-Angiotensin System 
Experimental and clinical studies have clearly established the central role of angiotensin II in the 
pathogenesis of CKD progression. Most of these studies are based on observations after the inhibition of 
Ang II synthesis by treatment with an ACEI. Nevertheless, ACEI do have effects in addition to the 
inhibition of ACE. The development of pharmacological inhibitors of the AT1 receptor provided the 
opportunity to examine the effects of inhibiting the RAS by a different mechanism that does not affect the 
metabolism of other vasoactive molecules. Inhibition of angiotensin-converting enzyme results in reduced 
conversion of angiotensin I to angiotensin" and a compensatory rise in renin levels due to loss of 
negative feedback inhibition of renin production by juxtaglomerular apparatus (JGA) cells [418]. By 
contrast AT1RAs produce elevations in both renin and Ang II because normal feedback inhibition of JGA 
cells through stimulation of AT1 receptors is blocked [419]. These differences in the level of inhibition of 
the RAS may have important implications for the therapeutic efficacy of AT1RA vs. ACEI in at least two 
respects. 
First, ACEls are able to reduce only ACE-dependent Ang II production whereas AT1 RAs block the effect of 
Ang " from any source at the receptor level. In the presence of ACE inhibition, studies have shown that 
Ang " may be produced by other proteases including chymase and other serine proteases [420-422]. 
Indeed, despite reduced plasma concentrations of Ang II, normal tissue levels of Ang II were found in 
mice following homozygous deletion of the ACE gene [423]. These normal tissue levels of Ang II were 
associated with a 14 fold increase in chymase activity in the kidneys of the knock-out mice. 
Second, it is now known that there are at least two subtypes of AT receptor. Thus blockade of subtype 1 
(AT1) receptors in the presence of elevated Ang II levels can be expected to result in stimulation of 
subtype 2 (AT2) receptors. AT1 receptors mediate most of the known effects of Ang " including 
vasoconstriction, stimulation of aldosterone synthesis and release, and renal tubule sodium and water 
reabsorption [424-426]. The role of AT2 receptors on the other hand, is not clearly defined. Although they 
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do not appear to be involved in any of the main effects of Ang II, AT2 receptors are important in foetal 
kidney development [427, 428] modulate pressure-natriuresis [429, 430], mediate Ang II-induced renal 
production of nitric oxide [431] and renal conversion of prostaglandin E2 to prostaglandin F2a [432]. In 
addition, experimental evidence suggests that AT2 receptors may counterbalance some of the effects 
mediated by AT1 receptors. In cell culture, Ang II suppresses the proliferation of fibroblasts selectively 
expressing AT2 receptors [433]. Furthermore, vascular smooth muscle cells transfected with an AT2 
receptor expression vector attenuate neointimal proliferation following balloon injury [434]. Pharmacogical 
inhibition of AT 2 receptors and deletion of the gene for the AT 2 receptor have each been associated with 
enhanced interstitial fibrosis in models of unilateral ureteric obstruction [435, 436]. Disruption of the AT 2 
receptor gene in mice results in a significant increase in blood pressure and an enhanced pressor 
response to exogenous Ang II [437]. In the isolated microperfused rabbit afferent arteriole, pretreatment 
with an AT2 receptor antagonist completely abolishes the vasodilation associated with the administration 
of an AT1RA [438]. Taken together, these data suggest that stimulation of AT2 receptors may produce 
antiproliferative, anti-fibrotic and antihypertensive effects that might prove beneficial in the context of CKD. 
In one relatively short-term study, treatment with an AT2 receptor antagonist (AT2RA) had no effect on the 
renal protective effects of losartan in rats subjected to partial renal ablation [439]. On the other hand, a 
recent study has reported partial attenuation of proteinuria with AT2RA treatment in the 5/6 nephrectomy 
model, together with a similar reduction in expression of osteopontin and proliferating cell nuclear antigen 
(PCNA) as well as macrophage infiltration to that achieved with an AT1RA, but no effect on blood pressure 
or histological markers of renal injury. As reported in the earlier study combination AT1RA and AT2RA 
therapy conferred no additional renal protection to the already complete protection afforded by the AT1RA 
alone, although the combination did produce a greater lowering of PCNA expression than either 
monotherapy [440]. 
Differences between ACEls and AT1RAs have also been observed with respect to their effects on 
aldosterone levels. Among normotensive human subjects during low sodium intake, both ACEI and 
AT1RA treatment lowered serum aldosterone levels, but this effect was significantly greater for ACEI, 
despite equivalent hypotensive effects between the groups [441]. The same study also found that ACEI 
treatment lowered plasma PAI-1 antigen levels and activity whereas no effect on PAI-1 was observed with 
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AT1RA. However, both ACEI and AT1RA lowered PAI-1 expression in an experimental model of 
glomerulonephritis [442]. Since both aldosterone [289] and the fibrinolytic system may be involved in the 
pathogenesis of renal fibrosis, these differences may have significant implications for the relative efficacy 
of these agents as renal protective drugs. 
ACEI effects on hormonal systems other than the RAS may also contribute to some of their therapeutic 
effects. Thus angiotensin-converting enzyme, also termed kininase II, is responsible for the breakdown of 
bradykinin; ACE inhibition therefore results in elevated bradykinin levels [418, 443]. AT1RAs on the other 
hand, have no direct effect on bradykinin levels [419]. In several experimental models evidence suggests 
that elevated kinins are responsible for at least some of the effects of ACEls. Neointima formation 
following balloon injury to the carotid artery is inhibited by ACEI but the effect is lost in animals cotreated 
with a kinin receptor antagonist [444]. Similarly, in an animal model of cardiac failure the combination of 
bradykinin receptor blockade with ACE inhibition significantly reduces the benefit of the latter [445]. 
Furthermore, several of the effects of ACEI which may contribute to renal protection have been attributed 
to the associated rise in kinins, including: antihypertensive effects in normal and hypertensive patients 
[446-449]; renal vasodilation resulting in increased renal blood flow [450-453]; dilation of the efferent 
arteriole and the associated fall in PGC in normal rats subjected to intravascular volume depletion [454] 
and salt-depleted rats with 1-kidney, 1-clip hypertension [455]; antiproteinuric effects in rats with passive 
Heymann nephritis [456] and puromycin aminonucleoside (PAN) nephrosis [457]; tissue plasminogen 
activator release with resultant stimulation of ECM degradation [458, 459]; and inhibition of 
monocyte/macrophage infiltration in unilateral ureteric obstruction [460]. It is important to note, however, 
that the above kinin-mediated effects of ACEI have been observed only in specific experimental models 
and are therefore not necessarily relevant to the mechanisms involved in the progression of clinical CKD. 
On the contrary, the observation that chronic administration of a kinin receptor blocker did not decrease 
the renal protective effects of an ACEI in rats after 5/6 nephrectomy [461, 462] or in streptozotocin-
induced diabetes [463] suggests that kinin-mediated effects are not necessary for renal protection. 
Despite the above theoretical considerations, many studies have detected no significant differences in the 
renal protective effects of ACEI vs. AT1RA in experimental models of CKD, when treatment was initiated 
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before the onset of substantial renal injury [28, 160, 163, 164, 266, 463-467]. A single study however, 
purports to show an advantage of AT1RA over ACEI in 5/6 nephrectomized rats [468]. In small 
preliminary clinical studies, AT1RA and ACEI produced similar antihypertensive and antiproteinuric effects 
among patients with essential hypertension [379], non-diabetic CKD [380] or type 2 diabetes and early 
nephropathy [381]. The experiments presented in Chapter 2 examine the comparative effects of ACEI 
and AT1RA treatment on the renal expression of pro-inflammatory and fibrotic cytokines in the 5/6 
nephrectomy model in order to identify possible differences on this level. In Chapter 3 we compare the 
renal protective effects of ACEI and AT1RA treatment after 5/6 nephrectomy in a study in which treatment 
is delayed until after renal injury is established, a model more likely to identify subtle differences between 
the efficacy of ACEI and AT1RA treatment. 
1.5.3. Extent of Blood Pressure and Proteinuria Reduction 
The importance of blood pressure control in achieving renal protection has been appreciated for several 
decades. Nevertheless the optimum level of blood pressure remains to be determined. Moreover, the 
importance of the level of blood pressure in the setting of treatment with ACEI or AT1RA is uncertain. In 
the studies presented in Chapter 3 we exploited the relatively large number of subjects and long duration 
of follow-up to examine the effect of achieved blood pressure during ACE I and AT1RA treatment on renal 
injury. In the light of evidence suggesting that proteinuria may contribute directly to progressive renal 
injury we also examine the association between proteinuria and renal injury in this model. 
1.5.4. New Pharmacological Agents for lowering Glomerular Capillary Pressure 
To date ACEls and AT1RAs are the only pharmacological agents that have been found to lower glomerular 
capillary pressure and afford effective renal protection. Nevertheless, ACEI or AT1RA treatment slows but 
does not arrest the progression of CKD. A novel class of antihypertensive agents, the vasopeptidase 
inhibitors (VPI), shows promise as a renal protective agent. VPls are single molecules that simultaneously 
inhibit both ACE and neutral endopeptidase, an ecto-enzyme that catabolizes several vasoactive 
molecules. In Chapter 4 we present studies in which we compared VPI treatment and the current "gold 
standard" of ACEI treatment with respect to glomerular haemodynamic and renal protective effects. 
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2. Proinflammatory gene expression and macrophage infiltration in the rat 
remnant kidney. 
2.1. Introduction 
Land-mark research into mechanisms contributing to the progression of CKD provided compelling 
evidence of the importance of glomerular haemodynamic adaptations to nephron loss, in particular, 
glomerular hyperperfusion and glomerular capillary hypertension [15] in the development of a vicious cycle 
of progressive nephron loss. Nevertheless, subsequent studies have identified non-haemodynamic 
factors that may also contribute to progressive renal injury. Prominent among these are proinflammatory 
and fibrotic cytokines. Further evidence of the importance of inflammatory factors is provided by the 
observation of macrophage (mcp) infiltration in the remnant kidneys of rats subjected to extensive renal 
mass ablation [229, 238,469-471]. 
A growing body of evidence suggests that mcp may participate in chronic renal injury processes not 
conventionally considered inflammatory in nature. A possible link between altered glomerular 
haemodynamics and m<jl recruitment is suggested by in vitro studies showing that exposure of glomerular 
cells to mechanical stresses results in the induction of cell adhesion molecule (CAM) and proinflammatory 
cytokine expression [183, 196, 214, 472]. Angiotensin II, an important mediator of glomerular capillary 
hypertension in CKD progressi,on, may also contribute directly to the development of a proinflammatory 
microenvironment in the remnant kidney by activating monocytes [285], stimulating TGF-p1 expression (in 
mesangial cells) [219] and activating the proinflammatory transcription factor, nuclear factor-kappa B (NF-
KB) [473]. Tubular absorption of the increased amounts of filtered protein resulting from impaired 
glomerular barrier function to macromolecules may induce proinflammatory gene expression in renal 
tubule cells [312,313,319,471], providing a link between augmented glomerular haemodynamics and the 
activation of chronic low grade tubulointerstitial inflammation. 
Thus, a substantial body of in vitro data suggests that the expression of CAM and chemotactic molecules, 
necessary for monocyte recruitment and activation, may be induced in vivo in response to glomerular 
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capillary hypertension in the absence of classic "immune" or acute inflammatory stimuli. Previous in vivo 
studies have examined the expression of only 1 or 2 cytokines in temporal relation to macrophage 
infiltration in the remnant kidney model. In this study we sought to test the hypothesis that coordinated 
upregulation of several pro-inflammatory factors is a fundamental response to renal mass ablation and 
that inhibition of the RAS, which leads to virtually complete protection from progressive renal injury after 
5/6 nephrectomy [27-29], suppresses this coordinated response. Our aims therefore were: 
1. To describe changes in the expression of a selection of CAM and cytokines in relation to mel> 
infiltration in the remnant kidney following 5/6 nephrectomy. 
2. To examine the effect of renal protective treatment with inhibitors of the RAS on the expression of 
CAM and cytokines in the remnant kidney. 
3. To compare the effect of RAS inhibition with ACEI vs. AT1RA on the expression of CAM and 
cytokines in the remnant kidney. 
2.2. Methods 
2.2.1. Animals 
Male Munich-Wistar rats (weight 230-310g) were obtained from Simonsen Laboratories (Gilroy, California, 
USA), housed under standard conditions and given unrestricted access to standard rodent chow and 
water. Rats were subjected either to renal mass ablation by right nephrectomy and ligation of two or three 
branches of the left renal artery, producing infarction of approximately two-thirds of the left kidney (n=60), 
or to sham operation by laparotomy and mobilization of the renal vessels (SHM; n=18). All surgical 
procedures were performed under pentobarbital anaesthesia (Nembutal 50mg/kg by intraperitoneal 
injection; Abbott Laboratories, Chicago, Illinois, USA). On day 4 after renal mass ablation, rats were 
started on candesartan cilexetil (Takeda Chemical Industries, Osaka, Japan) 70mgll (4-10 mg/kg/day) in 
the drinking water with vehicle [ethanol (O.1%v/v), polyethylene glycol (O.1%v/v) and sodium bicarbonate 
(1 mmolll)] added to solubilize candesartan (CSN; n=24) or enalapril (Merck Research Laboratories, 
Rahway, New Jersey, USA) 100mgll (6-14 mglkg/day) in drinking water (ENA; n=18). Controls received 
vehicle alone (VEH; n=18). Drug doses were determined during a pilot study and were chosen to achieve 
equivalent control of blood pressure in the ACEI and AT1RA groups. At 4-week intervals, systolic blood 
pressure (SSP) was measured in conscious rats by the tail-cuff method. The mean of 5 readings was 
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taken to represent the SBP. Daily urinary protein excretion rate (UprV) determined by spectrophotometry 
after precipitation with 3% sulfosalicylic acid on urine collected from rats individually housed in metabolic 
cages for 24 hours. Rats from each group were sacrificed at 4, 8 and 12 weeks after surgery. Before 
sacrifice, rats were anaesthetized and portions of renal cortex from areas that were distant from the infarct 
scar were excised and snap-frozen in liquid nitrogen for subsequent extraction of RNA. The rest of the 
remnant kidney was then remov~d and fixed in 10% phosphate buffered formalin. 
The above study protocols and those described in Chapters 3 and 4 were approved by the Standing 
Committee on Animals at Harvard Medical School. 
2.2.2. Competitive reverse transcription polymerase chain reaction (RT-PCR). 
Total RNA was extracted from frozen portions of renal cortex by the cesium chloride ultracentrifugation 
method [474]. RNA was quantitated by determination of ultraviolet absorbance at 260 nm, and its purity 
was assessed by measuring the optical density ratio at 260 and 280 nm. For preparation of cDNAs, 4 IJg 
of heat-denatured RNA was used in the reverse transcription (RT) reaction. The entire sample in a total 
volume of 20 1-11 contained 4 I-Ig of RNA; 0.5 mM each of dATP, dCTP, dGTP and dTTP (Pharmacia 
Biotech Inc., Piscataway, NJ); 0.5 IJg 0Iigo-d(T)12-18 (Pharmacia Biotech Inc.); 40U RNasin ribonuclease 
inhibitor (Promega, Madison, WI); 200U M-MLV reverse transcriptase (Life Technologies, Gaithersburg, 
MD) in a buffer of 50 mM Tris-HCI (pH 8.3); 75 mM KCI, 3 mM MgCI2 and 10 mM dithiothreitol. The 
solution was incubated for 60 minutes at 37 °C, and then held at 95 °C for 5 minutes to arrest the reaction. 
Preparations of cDNA were then used as substrate for competitive PCR reaction using competitive DNA 
mimics and oligonucleotide primer sets (Genosys Biotechnologies, Inc., Woodlands, TX). Competitive 
DNA mimics for each factor, comprising a segment of neutral DNA with sequences complementary to the 
gene specific primers attached to each end, were constructed using a PCR MIMIC Construction Kit 
(CLONTECH Laboratories, Inc., Palo Alto, CA). Primer sets were designed for rat VCAM-1, ICAM-1, 
MCP-1, IL-1~, TNF-u, TGF-~1 and GAPDH based on published cDNA sequences [266, 475]. An equal 
volume of each cDNA solution was used for amplification in 20 IJI of reaction mixture containing 
competitive DNA mimic, 0.5 IlM primer sets; 0.5 U Taq DNA polymerase (Pharmacia Biotech Inc.); 250 
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IJM each of dATP, dCTP, dGTP and dTTP (Pharmacia Biotech )nc.) in a buffer of 10 mM Tris-HCI (pH 
9.0) and optimal concentration of MgCI2. PCR was performed using a Peltier Thermal Cycler (MJ 
Research Inc, Watertown, MA). Optimal PCR conditions, namely concentration of competitive DNA 
mimic, annealing temperature and amplification cycles, were determined for each factor in preliminary 
studies. Amplification was initiated with incubation at 94°C for 2 minutes followed by amplification cycles 
as follows: 94°C for 15 seconds, annealing temperature for 30 seconds, 72 °c for 1 minute. Sequences 
of oligonucleotide primer sets and optimal conditions are listed in Table 2.1. PCR products (7 1-11) were 
subjected to gel electrophoresis (5 % polyacrylamide) and then DNA bands were visualized under 
ultraviolet light after ethidium bromide staining (0.05 I-Ig/ml for 10 minutes) and photographed (Fig. 2.1A). 
Densities of competitive mimic and target gene DNA bands were measured by scanning denSitometry 
using ScanJet 4c (Hewlett Packard, Corvallis, OR) with NIH Image software. The ratios of the densities of 
the respective bands were plotted to establish a linear relationship of the ratios over serial dilutions of 
template (Fig. 2.1 B). Thus, absolute amounts of mRNA from unknown samples were calculated as 
previously described [266, 476], from the known amount of the mimic in the starting reaction using the 
formula: 
[target gene] = [mimic] X ([target gene product] + [mimic product])lla: 
where a. = gradient of the log plot of [target gene product]:[mimic product] vs. serial dilutions of starting 
cDNA (Fig 2.1 B). Specimens were run in duplicate and the average value used. In addition, for 1 
specimen, extra tubes were added containing half and double the standard amount of cDNA. Figure 2.1 C 
confirms the linear relationship between the amount of cDNA added to the reaction and the estimated 
target gene concentration and shows that the assay is conSistently capable of detecting a two-fold 
difference in target gene concentration [266]. As the number of specimens exceeded the capacity of the 
thermal cycler (n=96), all specimens from the study could not be included in a single PCR reaction. 
Specimens from VEH and SHM groups at each time point were initially run together to determine the time 
course of gene expression after 5/6 nephrectomy. To assess the effect of treatment group on gene 
expression, all specimens from a given time point were then assayed together in single PCR reactions. 
To provide uniformity in these latter 3 cross-group data sets, data were expressed as ratios to the mean 
value for the SHM group at each time pOint. Levels of mRNA for glyceraldehyde phosphate 
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dehydrogenase (GAPDH), a gene constitutively expressed at constant levels in cells, were used to 
confirm that starting amounts of cDNA were similar among groups. 
2.2.3. Immunohistochemistry 
Macrophage infiltration and expression of ICAM-1. MCP-1. IL-1j3. TNF-a. and TGF-j31 proteins was 
assessed by immunohistochemistry. For this purpose, 4 jJm thick paraffin sections of formalin-fixed 
tissues were used for immunoperoxidase analysis after baking at 60°C for one hour, deparaffinization and 
rehydration (100% xylene X 4 for three minutes each, 100% ethanol X 4 for three minutes each and 
running water for five minutes). The sections were then microwave treated at 93°C for 30 minutes in 
preheated 10 mM citrate buffer, pH 6.0, cooled for 15 minutes and transferred to phosphate buffered 
saline (PBS). Sections were then blocked with a 1.5% solution of serum of the species from which the 
secondary antibody was derived at room temperature for 15 minutes. Next, sections were incubated with 
mouse monoclonal antibodies against rat ICAM-1 (clone CD54, 1:150 dilution, Biosurface International, 
Camarilla, CAl, hamster antimouse MCP-1 which cross-reacts with rat MCP-1 (clone 2H5. 1:50 dilution, 
Biosurface International). rabbit polyclonal antibodies against rat IL-1j3 (1 :100 dilution, Endogen, Woburn, 
MA). TNF-a. (1:50 dilution, Endogen), TGF-j31(V) (1:150 dilution, Santa Cruz Biotechnology Inc., Santa 
Cruz, CAl and mouse monoclonal antibodies to the rat monocyte/macrophage marker ED1 (clone ED1, 
1:150 dilution, Biosurface International) for 1 hour in a humid chamber at room temperature. The 
secondary antibody (Vectastain Elite ABC Kit, Vector Laboratories Inc., Burlington, CAl was used 
according to manufacturer's instructions. Slides were rinsed with PBS between each incubation. Sections 
were developed using 3,3'-diaminobenzidine (Sigma Chemical Company, S1. Louis, MO) as substrate and 
counter stained with Gill's Hematoxylin (Fisher SCientific, Pittsburgh, PA). Specimens in which the above 
procedure was repeated but with the primary antibody omitted or SUbstituted with pre-immune serum from 
the respective species of the primary antibody, served as negative controls. 
Macrophage infiltration was assessed by counting the number of ED1-positive cells in 30 glomerular 
profiles and in 20 randomly chosen 0.25 X 0.2Smm areas of tubulointerstitium for each kidney. 
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2.2.4. Morphology 
Renal tissue was embedded in paraffin and processed for light microscopy. The frequency of FSGS was 
estimated by examining all glomeruli seen in one or two coronal sections from each kidney stained by the 
periodic acid-Schiff method. Segmental sclerosis was defined as glomerular capillary collapse with 
hyaline deposition and/or adhesion to the parietal layer of Bowman's capsule. A glomerulosclerosis score 
was determined by expressing the number of glomeruli with segmental or global sclerosis as a percentage 
of the total number of glomeruli counted for each rat (>70 per rat). Tubulointerstitial injury was assessed 
at medium power on the same sections. Each of 3 aspects of tubulointerstitial injury (tubule 
proteinaceous casts and dilation; interstitial inflammation; interstitial fibrosis) was assigned a score from 0 
to 3 according to severity (O=no abnormality; 1=mild; 2=moderate; 3=severe), and these scores added to 
yield an overall Tubulointerstitial Score (TIS) from 0 to 9 (arbitrary units). The pathologist was unaware of 
the group assignment of individual rats. 
2.2.5. Statistical Analysis 
Continuous variables are expressed as mean(SEM). Differences among multiple groups were assessed 
using the Kruskal-Wallis test; between two groups, with the Mann-Whitney test. The null hypothesis was 
rejected at P<O.OS. Statistical analyses were conducted using Statview 4.01 (Abacus Concepts Inc., 
Berkley, California, USA). 
2.3. Results 
2.3.1. General Data 
Before surgery, there were no differences among groups with respect to body weight. SBP or UprV (Table 
2.2.). Body weight increased in all groups throughout the study but was marginally lower in ENA and CSN 
rats than SHM rats at 12 weeks. Following S/6 NPX. SBP increased in VEH, but not in ENA or CSN rats. 
Indeed, treatment with enalaprit or candesartan lowered SBP to levels below those observed in SHM rats. 
A progressive rise in uprV was observed in VEH, but not in SHM, ENA or CSN rats. Although UprV levels 
at 4 weeks were lower in ENA and CSN than SHM rats, similar tendencies were not significant at 8 and 12 
weeks. Severe, progressive FSGS and tubulointerstitial fibrosis developed in the remnant kidneys of VEH 
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rats over time whereas treatment with enalapril or candesartan markedly limited renal injury to levels not 
significantly different to those observed in SHM rats (Table 2.3.). 
2.3.2. Competitive RT-PCR 
Mean values for GAPDH mRNA levels, determined by competitive RT -PCR, were similar among the 
groups in each set of PCR reactions, confirming that the starting concentrations of cDNA were not 
significantly different. Data for each gene are presented here as absolute values (and not as a ratio to 
GAPDH) because it is not possible to determine GAPDH and target gene mRNA levels on the same 
aliquot of cDNA with competitive RT -PCR. Nevertheless, when calculated as a ratio to GAPDH, the 
patterns of expression obtained were very similar to the patterns seen with the absolute values. Although 
no differences in mRNA levels for VCAM-1, ICAM-1, IL-113 or TNF-a. between VEH and SHM rats were 
observed at 4 weeks, approximately 2 fold statistically significant increases became evident for each of 
these factors in VEH rats at 8 and 12 weeks (Figure 2.2.). By contrast, marked increases in renal cortical 
mRNA levels for TGF-131 (approximately 3 fold vs. SHM) and MCP-1 (approximately 4 fold) were observed 
at 4 weeks after surgery in VEH rats, elevations that were sustained at 8 and 12 weeks (Figure 2.2.). 
Treatment with enalapril or candesartan virtually abrogated the respective elevations in mRNA levels for . 
VCAM-1, ICAM-1, MCP-1, IL-113 and TGF-Jj1 at 12 weeks, such that each remained similar to the values 
observed in SHM rats (Figure 2.3.). mRNA levels for MCP-1 and TGF-131 were marginally higher in CSN 
vs. SHM rats at 12 weeks, but values in both treated groups were markedly lower than those of VEH. The 
tendency for TNF-a. mRNA levels to be lower in both ENA and CSN rats vs. VEH did not achieve statistical 
significance. Indeed, TNF-a. levels remained significantly greater in CSN than SHM rats. When mRNA 
levels for each molecule were expressed as a ratio to the respective mean SHM value, trends among the 
groups at earlier time pOints were similar to those observed at 12 weeks (Table 2.4.). The upregulation of 
TGF-131 at 4 weeks was effectively prevented by enalapril and candesartan, whereas the increase in 
mRNA levels for MCP-1 was only partially inhibited by enalapril and candesartan. At 8 weeks after 
surgery the upreguJation of VCAM-1, ICAM-1 and MCP-1 was largely blocked in both ENA and CSN 
groups. Increases in TGF-131, IL-113 and TNF-a. mRNA levels at 8 weeks were significantly inhibited in 
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ENA but not in CSN rats: Similar patterns of expression were obtained without factoring gene expression 
for the mean SHMvalue (data not shown). 
2.3.3. Immunohistochemistry 
Immunohistology confirmed that the increases in mRNA levels described above were accompanied by 
corresponding increases in protein expression in VEH rats and allowed localization of the enhanced 
expression within the remnant kidney (Figure 2.4.). TGF-J)1 staining was strongly positive in the glomeruli, 
tubules and interstitium of remnant kidneys in VEH rats at all time points. Staining for MCP-1 was present 
in tubule cells and interstitial cells within areas of cellular infiltration in VEH rats at 4, 8 and 12 weeks. 
Staining for IL-1J) and TNF-a. also was largely localized to tubule epithelial cells. For TNF-a., occasional 
positive-staining cells were also present in glomeruli and areas of interstitial inflammation. By contrast, 
staining for ICAM-1 was localized to the glomeruli of VEH rats, in particular to the glomerular capillary 
loops, and was strongly positive at all time points. Peritubular capillaries were also positive for ICAM-1. 
Weak staining for ICAM-1 was accompanied, in some tubules, by positive staining of the epithelial cell 
brush border. Staining for TGF-J)1, MCP-1, ICAM-1, and IL-1J) appeared much weaker in kidneys from 
SHM or those from ENA and CSN rats. For TGF-J)1, glomerular staining was absent in SHM and treated 
rats and tubule staining was only weakly positive. Glomeruli of SHM rats were generally negative for 
ICAM-1 and although some stained positive in ENA and CSN rats, staining was of lesser intensity than in 
VEH rats. By contrast, immunostaining of tubules for TNF-a. did not appear to be reduced either in ENA 
or CSN rats. Controls in which the primary antibody was omitted, were negative apart from some staining 
of erythrocytes. Controls in which pre-immune serum from the appropriate species was substituted for the 
primary antibody showed only minimal background staining. The use of pre-immune mouse serum was 
associated with positive staining of intraluminal tubular proteinaceous casts (Figure 2.4.). 
2.3.4. Macrophage infiltration 
Macrophage infiltration was evident in both the glomeruli and interstitium of remnant kidneys in VEH rats. 
At 4 weeks after surgery the number of macrophages was markedly increased in VEH vs. SHM rats, by 
approximately 10 fold in glomeruli and 20 fold in the interstitium. These increases were sustained at 8 and 
12 weeks. Treatment with enalapril or candesartan largely prevented glomerular and tubulointerstitial m~ 
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infiltration although mcp numbers were marginally but significantly higher in the treated groups VB. SHM. 
There were no differences in mcp numbers between ENA and CSN rats (Table 2.3.). 
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Table 2.1. Summary of primer sequences and PCR conditions. 
Primer Sense sequence Antisense sequence Size Annealing 
(bp) Temp. (0C) 
MCP-1 ATG CAG GTC TCT GTC ACG CTA GTT CTC TGT CAT ACT 447 55 
TGF-p1 CTT CAG CTC CAC AGA GAA GAA CTG C CAC GAT CAT GTT GGA CAA CTG CTC C 298 64 
TNF-a TAC TGA ACT TCG GGG TGA TTG GTC C CAG CCT TGT CCC TTG AAG AGA ACC 295 65 
IL-1P TGA TGT TCC CAT TAG ACA GC GAG GTG CTG ATG TAC CAG TT 378 55 
ICAM-1 AGA AGG ACT GCT TGG GGA A CCT CTG GCG GTA ATA GGT G 332 60 
VCAM-1 CTG ACC TGC TCA AGT GAT GG GTG TCT CCC TCT TTG ACG CT 260 60 
GAPDH AAT GCA TCC TGC ACC ACC AA GTA GCC ATA TTC ATT GTC ATA 516 55 
Table 2.2. Physiological data; mean(SEM) 
n Baseline n 4 weeks n Sweeks n 12 weeks 
Weight (g) SHM 18 267(2) 6 273(11) 6 322(14) 6 360(4) 
VEH 18 272(4) 6 264(16) 6 317(10) 6 342(18) 
ENA 18 272(3) 6 249(13) 6 317(4) 6 338(7)b 
CSN 24 267(3) 9 282(5) 6 301(7) 9 334(6)b 
SBP (mmHg) SHM 18 130(4) 6 123(3)a 6 123(3)a 6 109(2)a 
VEH 18 131(3) 6 173(13) 6 156(9) 6 172(8) 
ENA 18 124(3) 5 100(5)a,b 6 105(3)8,b 6 105(6)8 
CSN 24 128(2) 9 96(7)a,b 6 100(5)a,b 9 97(3)8,b 
UprV (mg/day) SHM 18 4.7(0.4) 6 6.0(1.2)8 6 7.4(2.4)8 6 9.4(1.3)a 
VEH 15 4.9(0.5) 6 58(14) 6 44(2.9) 6 93(12) 
ENA 18 5.4(0.5) 6 2.0(0.3)a.b.c 6 4.6(1.0t 6 8.4(0.9)8.C 
CSN 24 4.5(0.4) 9 3.4(0.3t·b 6 6.1(3.4)a 9 5.7(0.8)8 
8 P<0.05 versus VEH; b P<0.05 versus SHM; C P<0.05 versus CSN by Kruskal-Wallis and 
Mann-Whitney tests. 
SHM: sham-operated rats; VEH: rats treated with vehicle after 5/6 nephrectomy; ENA: rats 
treated with enalapril after 5/6 nephrectomy; CSN: rats treated with candesartan after 5/6 
nephrectomy 
Table 2.3. Histological data; mean(SEM) 
4 weeks 8 weeks 12 weeks 
GS(%) SHM 0.1(0.06)8 1.1(0.6)8 2.1 (0.S)8 
VEH 27.1(S.6) 34.6(S.4) 62.3(4.1) 
ENA 1.7(1.0)8.b 1.7(0.6)8 3.3(0.9)8 
CSN 1.0(0.2tb 4.9(2.1)8 1.3(0.4)8 
TIS (0-9) SHM O.O(O.ot 0.0(0.0)8 0.0(0.0)8 
VEH 1.3(0.4) 1.1(0.3) 3.6(0.7) 
ENA 0.0(0.0)8 0.0(0.0)8 0.0(0.0)8 
CSN 0.3(0.1) 0.0(0.0)8 0.0(0.0)8 
glomerular m4> SHM 0.3(0.1)a 0.3(0.1)8 0.3(0.04)a 
(cells/glomerular profile) VEH 3.2(0.4) 3.3(0.S) 3.7(0.3) 
ENA 0.8(0.1t·b 0.7(0.1t·b 0.S(0.2)8 
CSN 0.6(0.1 )8.b 1.0(0.1 )a.b 0.7(0.1 )a.b 
interstitial m4> SHM 0.2(0.1t 0.S(0.2t 0.2(0.04)8 
(cells/0.062S mm2) VEH 3.9(0.S) 4.7(0.9) 4.2(1.2) 
ENA 0.9(0.2)a.b 0.7(0.1)a 0.6(0.1 )8.b 
CSN 0.9(0.2)8.b 1.2(0.2)a.b 0.6(0.07)8.b 
8 P<O.OS versus VEH; b P<O.OS versus SHM by Kruskal-Wallis and Mann-Whitney tests. 
GS: glomerulosclerosis expressed as percentage of glomeruli with segmental or global 
sclerosis; TIS: tubulointerstitial score indicating tubulointerstitial damage on a scale from 0-9; 
m4>: macrophage. 
SHM: sham-operated rats; VEH: rats treated with vehicle after S/6 nephrectomy; ENA: rats 
treated with enalapril after S/6 nephrectomy; CSN: rats treated with candesartan after S/6 
nephrectomy. 
Table 2.4. Renal cortical mRNA levels for CAMs and cytokines in rats after 
5/6 nephrectomy expressed as a ratio to levels in sham-operated rats; data=mean(SEM). 
4 weeks 8 weeks 12 weeks 
VCAM-1 VEH 1.85(0.18) 1.36(0.08) 2.15(0.43) 
ENA 0.88(0.10)a 1.03(0.1)a 1.39(0.11) 
CSN 1.30(0.19) 1.14(0.13) 1.28(0.20) 
ICAM-1 VEH 1.41(0.20) 1.50(0.14) 2.14(0.29) 
ENA 0.88(0.09)a 0.66(0.06)a 1.33(0.21) 
CSN 1.02(0.14) 0.85(0.14t 1.31(0.24)a 
MCP-1 VEH 11.9(3.53) 2.64(0.18) 2.67(0.23) 
ENA 7.25(1.60) 1.29(0.12)a 1.00(0.11 )a.b 
CSN 5.12(1.06)a 1.39(0.31)8 1.41(0.16)8 
IL-1f3 VEH 2.08(0.45) 3.44(0.58) 1.80(0.20) 
ENA 2.53(0.57) 0.75(0.13)a.b 1.02(0.17t 
CSN 3.04(0.72) 2.66(0.85) 1.10(0.13)8 
TNF-a VEH 2.02(0.27) 1.44(0.17) 3.40(0.52) 
ENA 1.33(0.26) 0.55(0.08)a.b 1.82(0.35t 
CSN 1.24(0.07t 1.04(0.16) 2.46(0.40) 
TGF-f31 VEH 2.87(0.35 2.78(0.42 3.76(0.63 
ENA 0.73(0. 16)8.b 0.55(0.08t·b 1.27(0.18)8 
CSN 1.34(0.20)8 2.11(0.32) 1.63(0.18t 
GAPDH VEH 1.23(0.13) 0.96(0.16) 1.19(0.19) 
ENA 1.11(0.17) 1.03(0.14) 0.90(0.06) 
CSN 1.24(0.14) 1.22(0.28) 1.04(0.15) 
8 P<0.05 versus VEH; b P<0.05 versus CSN by Kruskal-Wallis and Mann-Whitney tests. 
VEH: rats treated with vehicle after 5/6 nephrectomy; ENA: rats treated with enalapril after 5/6 
nephrectomy; CSN: rats treated with candesartan after 5/6 nephrectomy. 
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Figure 2.2. Renal cortex mRNA levels for studied genes in VEH (open bars) and 
SHM (filled bars) rats at time paints post surgery. Levels for MCP-1 and TGF-~1 
were significantly increased in VEH rats at 4 weeks and at subsequent time 
points. ICAM-1, VCAM-1, IL-1~ and TNF-a. levels were upregulated in VEH rats 
from 8 weeks. There were no significant differences in GAPDH mRNA levels 
among the groups. (* P<O.05 vs. SHM; t P<O.05 vs. VEH at 4 weeks; § P<O.05 
vs. SHM at 4 weeks) 
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o 14 mRNA for VCAM-1. ICAM-1. MCP-1, IL-1~ and TGF-!31 observed in VEH rats 
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Figure 2.4. Immunohistology: 
A-D: MCP-1 immunostaining was evident in tubule cells (A) and infiltrating interstitial cells (8) 
but was weakly positive or negative in glomeruli (A) of remnant kidneys from VEH rats at 12 
weeks after 5/6 NPX. Weak tubule staining was obseNed in CSN rats (C) and negative 
staining, in sham-operated SHM rats (D). 
E-H: ICAM-1 immunostaining was strongly positive in glomeruli of VEH rats at 4 weeks, 
particularly in endothelial cells of glomerular capillaries (E). Positive staining was also 
obseNed along the brush border of tubule cells (E) and in endothelial cells of peritubular 
capillaries (F). CSN rats displayed only weak glomerular and tubule brush border staining (G) 
and kidneys from SHM rats were negative for ICAM-1 (H). 
I, K, L: TNF-a immunostaining was positive in tubule cells and infiltrating cells in VEH rats (I) 
and tubule cells in CSN rats (K) at 12 weeks after 5/6 NPX. Staining was negative in kidneys 
from SHM rats (L). 
Panel J shows a negative control in which the primary antibody was omitted to exclude non-
specific binding of the secondary antibody to renal tissue. 
(All panels 250X magnification) 
2.5. Discussion 
Macrophages represent a prominent component of inflammatory cell infiltrates in several forms of 
experimental and human glomerulonephritis and are thought to contribute directly to glomerular injury 
through secretion of reactive oxygen species. proteases. eicosanoids and cytokines [477, 478]. Our data 
confirm previous observations that m~ infiltrate the remnant kidney in response to extensive renal mass 
ablation [229. 238. 469-4711. attaining near-maximum levels at 4 weeks after surgery. a time point at 
which renal injury is relatively mild [238. 469]. The infiltration of m~ in advance of renal injury in this model 
suggests that m~ recruitment is a response to nephron loss per se and not merely part of the healing 
response to renal injury. When taken together with observations that short-term depletion of m~ by 
irradiation results in a transient reduction in mesangial matrix expansion in partially nephrectomized rats 
[2261. our findings are consistent with the hypothesis that the recruitment of m~ plays an important role in 
the pathogenesis of chronic progressive renal injury resulting from extensive nephron loss. 
Recruitment of m~ in acute inflammatory settings is thought to involve cytokine-induced endothelial CAM 
expression. margination. diapedesis and migration of m~ into tissues down a chemotactic gradient 
(reviewed in [478, 479]). In the remnant kidney. alternative mechanisms may operate to initiate m~ 
accumulation in the absence of major acute inflammatory or immune stimuli. As discussed in more detail 
in Chapter 1, these include induction of CAMs and chemoattractants in glomerular cells exposed to 
mechanical forces [183, 196], in situ proliferation of m~ [229, 470] and renal tubule cell complement 
activation as well as expression of CAMs and chemoattractants following their uptake of abnormal 
amounts of protein [319, 320,471]. 
We have observed approximately 2 fold increases in renal cortex mRNA levels for VCAM-1 and ICAM-1, 
adhesion molecules critical for monocyte recruitment. in untreated rats at 8 and 12 weeks after 5/6 
nephrectomy. Increases in ICAM-1 and VCAM-1 mRNA were observed also in kidneys from rats 
subjected to unilateral ureteric obstruction (UUO) [480], a model characterized by interstitial m~ infiltration 
and fibrosis [460]. Immunohistochemistry revealed positive staining for ICAM-1 in glomeruli and to a 
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lesser extent in tubules, a pattern similar to that observed in immune-complex mediated nephropathies 
[481-483]. ICAM-1 expression may be induced in endothelial cells exposed in vitro to shear stress [1831. 
In vivo, shear stress due to altered glomerular haemodynamics in the remnant kidney may conceivably 
therefore account for the induction ICAM-1 in the glomerular endothelium. Although we anticipated that 
ICAM-1 would be upreglJlated at 4 weeks after 5/6 nephrectomy in VEH rats due to glomerular 
hyperperfusion, we did not detect a significant increase in ICAM-1 mRNA levels in renal cortex. However, 
increased glomerular ICAM-1 immunostaining was observed at 4 weeks. This apparent contradiction may 
be explained by difficulty in detecting relatively small increments in glomerular ICAM-1 mRNA due to 
"dilution" in the face of stable levels of ICAM-1 mRNA in the non-glomerular portions of the cortex. An 
alternative explanation is that post-transcriptional regulation of glomerular ICAM-1 expression may occur. 
Ingestion by renal tubule cells of grossly elevated amounts of filtered protein, as occurs in the protein 
overload model, results in interstitial macrophage infiltration associated with increased tubule expression 
of both VCAM-1 and ICAM-1 [319]. Similar mechanisms may playa role in the 5/6 nephrectomy model 
after 4 weeks, in response to the cumulative effects of significant proteinuria [320. 471]. 
MCP-1 is a specific monocyte chemoattractant associated with renal m~ infiltration in several experimental 
models of glomerulonephritis [484-486], UUO [480] and human glomerulonephritis [487-489]. In vitro 
observations suggest that MCP-1 may also contribute to tissue injury by stimulating monocyte activation 
[490] and IL-1 production [491] as well as production of TGF-J3 and collagen by fibroblasts [492]. Our data 
confirm and extend the findings of previous investigators who have detected increases in renal MCP-1 
mRNA levels at 2 weeks after 5/6 nephrectomy by northern blot analysis [469]. We observed a 4 fold 
increase in renal cortex MCP-1 mRNA levels at 4 weeks which was sustained at 8 and 12 weeks. Like 
ICAM-1, expression of MCP-1 is induced in endothelial cells exposed to shear stress [1961. Elevated 
MCP-1 mRNA levels have also been observed in glomeruli from DOCA-salt hypertensive rats [493] and 
from aortas of hypertensive rats [494], strongly suggesting that mechanical forces also induce MCP-1 
expression in vivo. Renal tubule cells cultured with abnormally high extracellular protein concentrations 
synthesize MCP-1 [312]. suggesting that MCP-1 expression by tubule epithelial cells and interstitial m~ 
accumulation in the remnant kidney may also occur in response to proteinuria. Although immunostaining 
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was limited to tubule cells in our study, previous studies in diabetic rats [266] and 5/6 nephrectomized rats 
[469] have observed positive staining for MCP-1 in glomeruli. 
TNF-a and IL-1rJ are important inflammatory cytokines that may be produced by infiltrating m~ or intrinsic 
renal cells (reviewed in [495, 496]). Both TNF-a and IL-1 rJ may playa role in sustaining inflammation 
through autocrine and paracrine induction of CAMs [479], chemotactic factors [487, 497, 498] and 
cytokines [499, 500]. A previous study was unable to detect TNF-a or IL-1rJ expression in the remnant 
kidney using northern analysis of whole kidney RNA [469], a technique that may fail to detect genes with 
very low levels of expression. Using RT-PCR, we have observed approximately 2 fold increases in renal 
cortex mRNA levels for TNF-a and IL-1 rJ at 8 and 12 weeks after 5/6 nephrectomy, at which time points 
m~ infiltration and renal injury were well established. Confirmatory immunohistology revealed positive 
staining for TNF-a and IL-1rJ localized mainly to tubule and interstitial cells with occasional positive 
glomerular cells. These findings are consistent with TNF-a and IL-1rJ playing a "down-stream" role in 
maintaining mcjl infiltration and activation in the remnant kidney, but perhaps not a critical role in initiating 
mcjl recruitment. The apparent discrepancy between mcjl infiltration and expression of the m~ products, 
TNF-a and IL-1j3 at 4 weeks may be due to difficulty in detecting increases in mcjl gene expression in the 
presence of unchanged expression in the much larger mass of renal parenchyma. Later increases in 
TNF-a and IL-1j3 mRNA likely reflect expression by intrinsic renal cells as well as m~. 
A large body of experimental and clinical evidence supports the view that the profibrotic cytokine, TGF-j31, 
plays a major role in renal fibrosis resulting from a wide range of causes (reviewed in [501]). On the other 
hand, evidence suggests that this cytokine may also playa counter-regulatory, anti-inflammatory role in 
the kidney and may suppress cytokine production by glomerular m~ [502-504]. Increased TGF-rJ1 
expression has been observed in the remnant kidney using northem blot analysis [237, 505], in situ 
hybridization [237], immunohistology [237, 506] and ELISA [505]. Notably. Wu et al. localized TGF-j31 
expression to infiltrating m~. using combined in situ hybridization and immunohistology techniques [237]. 
TGF-j31 mRNA has also been localized to endothelial cells and mesangial cells early in the development 
of glomerulosclerosis [192]. Our competitive RT-PCR data confirm that TGF-rJ1 mRNA levels were 
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increased approximately 3 fold at 4 weeks and sustained at 12 weeks. Immunostaining revealed TGF-~1 
expression in glomeruli, tubules and interstitial cells. Several mechanisms may account for the induction 
of TGF-~1 expression in this model: exposure of endothelial cells to shear stress [472] and mesangial 
cells to cyclical stretching [214]; exposure of tubule cells to excess filtered protein [319); direct effects of 
Ang lion mesangial cells [219). Although TGF-~ 1 production has often been associated with primary 
immune-complex mediated injury, the interplay of several antigen-independent mechanisms may account 
for upregulation of TGF-~1 in the 5/6 nephrectomy mode/. 
As reported in previous studies, we found that treatment with an ACEI or AT1RA resulted in almost 
complete protection of the remnant kidney from progressive injury when started soon after 5/6 
nephrectomy [27-29). Further, the renal protection achieved by RAS inhibition was associated with 
significantly fewer infiltrating m$ and less proinflammatory gene expression, suggesting that these latter 
processes are also dependent, directly or indirectly on the actions of Ang II. As discussed in Chapter 1, 
Ang /I occupies a central role in many pathways thought to contribute to the pathogenesis of chronic injury 
in the remnant kidney. Renal protection with either ACEI or AT,RA is therefore likely to be achieved 
through the consequences of reduced effects of Ang II at multiple sites. Since enalapril and candesartan 
achieved similar effects on all variables studied, we may also conclude that despite differences in the 
pharmacology of ACEls and AT1RAs, both agents exert their renal protective effects primarily through 
inhibition of the AT, receptor-mediated effects of Ang II. Findings of differences between ACEI and 
AT1RA treatment on m$ infiltration and VCAIVI-1 expression in the UUO model, but lack of effect of either 
treatment on ICAM-1 expression, suggest that ATl receptor independent mechanisms playa role in m$ 
recruitment in this model of interstitial fibrosis [460, 480]. 
Our results extend the findings of other investigators who observed inhibition of renal TGF-~1 expression 
[505] and m$ infiltration [237, Abbate, 1999 #368) with ACEI or AT1RA treatment. Interestingly, MCP-1 
upregulation is also inhibited by dietary protein restriction [469], which inhibits the RAS by decreasing renin 
mRNA levels [507]. Furthermore, inhibition of MCP-1 expression by low protein diet was only partial at 2 
weeks after 5/6 nephrectomy. This is reminiscent of our current observation of partial inhibition of MCP-1 
81 
at 4 weeks by both ACEI and AT1RA, suggesting that significant RAS-independent stimuli may also 
contribute to MCP-1 expression, at least in the early phases after 5/6 nephrectomy. 
The lack of suppression of IL-1~ and TGF-~1 with candesartan treatment at 8 weeks after surgery 
appears to be transient and of questionable significance since inhibition of TGF-~1 was evident at 4 and 
12 weeks and inhibition of IL-1~, at 12 weeks. The absence of consistent suppression of TNF-o: by either 
treatment on the other hand, strongly suggests that TNF-o: expression is largely independent of both 
haemodynamic factors and the RAS in this setting and further implies that TNF-a: alone is insufficient to 
promote the development of chronic injury in 5/6 nephrectomized rats receiving RAS inhibitors. While the 
concordance of RAS-inhibitor-associated suppression of proinflammatory gene expression and mq, 
infiltration supports the notion that the group of factors studied are involved in the pathogenesis of 
progressive renal injury, data from this study cannot address the issue of the roles of specific cytokines. 
More direct evidence of the role of individual factors awaits experiments in which the effects of individual 
molecules or transcription factors are specifically inhibited or enhanced. 
Our data provide further support for the hypothesis that following extensive renal mass ablation, RAS-
dependent adaptive changes in the remnant kidney provoke the coordinated upregulation of various 
proinflammatory genes, resulting in recruitment and activation of mq,. Further, the data suggest that m~ 
may play an important contributory role in the pathogenesis of progressive FSGS and TIF. Although both 
ACEI and AT 1 RA were effective in preventing or attenuating upregulation of several proinflammatory 
genes in this model, additional interventions that specifically inhibit proinflammatory gene expression may 
lead to increased therapeutic options for patients with established CKD progression. Indeed, in a recent 
study of rats with diabetic nephropathy'the addition of treatment with monoclonal anti-TGF-~ antibodies to 
ACEI treatment tended to produce more effective renal protection than either treatment alone [508]. 
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3. Renal Protection in the Setting of Established Renal Injury 
3.1. Introduction 
The majority of experimental studies into mechanisms contributing to CKD progression have employed 
protocols in which renal protective strategies were introduced prior to the development of renal injury. 
This approach provides a useful experimental model but differs critically from clinical CKD because in 
patients. treatment is typically started only after renal injury is established. Early treatment of rats 
subjected to extensive renal mass ablation with ACEI effectively prevents the focal and segmental 
glomerulosclerosis and tubulointerstitial fibrosis that ensues in untreated rats [26, 27]. AT 1 RAs, a novel 
class of antihypertensive drugs, inhibit the RAS distal to angiotensin-converting enzyme (ACE) and may 
offer therapeutic advantages over ACE I. Nevertheless, previous studies from this and other laboratories 
detected no significant differences in the renal protective effects of ACEI vs. AT1RA in experimental 
models of CKD, when treatment was initiated before the onset of sUbstantial renal injury [28, 160, 163, 
164,266,463-467]. A single study however, purports to show an advantage of AT1RA over ACEI in 5/6 
nephrectomized rats [468]. In this study treatment was initiated only after renal injury was evident and was 
of considerably longer duration than previous studies, raiSing the possibility that subtle benefits of AT1RA 
over ACEI may become evident only over an extended time period in a model where RAS blockade 
results in slowing but not arrest of CKD progression. This is particularly important because clinical trials of 
ACEI treatment in CKD have also observed slowing rather than arrest of CKD progression [168, 169, 373] 
implying that there is a need for more effeq~ive renal protective therapies. 
Since the therapeutic ideal is to arrest or even reverse CKD progression, it is important to examine all 
factors that may contribute to slow progression of CKD during RAS inhibition. Systemic blood pressure 
has been shown in experimental [509] and clinical [337, 341, 342, 346, 510, 511] studies to be an 
important determinant of chronic renal injury but the role of blood pressure in the context of ACEI 
treatment requires further elucidation. Proteinuria, long regarded as a marker of glomerular injury, has 
recently been proposed as an important factor contributing to the pathogenesis of CKD progression [243]. 
Finally, as shown in the studies presented in Chapter 2 and others {237, 469], extensive renal mass 
ablation results in an apparently coordinated induction of several proinfiammatory genes and infiltration of 
the remnant kidney by macrophages (m<p). These chronic inflammatory responses are prevented by early 
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treatment with ACEI or AT1RA, suggesting that m~ and a variety of proinflammatory molecules may 
contribute to the pathogenesis of progressive renal fibrosis [237]. If this is indeed so, we hypothesized 
that the slow progression of renal injury that can be predicted to ensue when ACEI or AT1RA therapy is 
started only after renal injury is established, would be associated with persistent upregulation of 
proinflammatory and fibrotic gene expression. 
In this study we utilized relatively large numbers of rats in a delayed treatment protocol with prolonged 
follow up with the following objectives: 
1. To determine whether, at doses that produce equivalent antihypertensive effects, the AT1RA, 
candesartan and the ACEI, enalapril, share equivalent renal protective effects. 
2. To examine the relationships between systemic blood pressure. proteinuria and renal injury during 
RAS inhibition in this model. 
3. To examine the expression of selected inflammatory and profibrotic genes in the remnant kidney 
and the relationship between expression of these genes and renal injury. 
3.2. Methods 
3.2.1. Animals 
Adult male Munich-Wistar rats (weight 218-278g) were obtained from Simonsen Laboratories (Gilroy, 
California, USA), housed under standard conditions and given unrestricted access to standard rodent 
chow and water. Rats were subjected either to S/6 nephrectomy as described in Chapter 2 (n=63), or to 
sham operation (SHM rats; n=1S). At 2-week intervals, systolic blood pressure (SSP) was measured by 
the tail-cuff method and daily urinary protein excretion rate (UprV) determined on urine collected from rats 
individually housed in metabolic cages for 24 hours. At five weeks after renal mass ablation, rats were 
stratified according to SSP and uprV and allocated to the following groups: CSN rats (n=30) received 
candesartan cilexetil (TCV-116; Takeda Chemical Industries, Osaka, Japan) SOmgll (3-7 mg/kg/day) in 
the drinking water. Vehicle comprising ethanol (0.1 %v/v) , polyethylene glycol (0.1 %v/v) and sodium 
bicarbonate (S mmoVI) was added to achieve water solubility of candesartan; ENA rats (n=27) received 
enalapril (Merck Research Laboratories, Rahway, New Jersey, USA) 110mgll (7 -1S mg/kg/day) in the 
drinking water with sodium bicarbonate (S mmolll). Some dosage adjustments were made initially to 
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achieve equivalent blood pressure control in the treatment groups. Six rats were sacrificed at 5 weeks 
after renal ablation and the remnant kidneys harvested to provide pretreatment data (5WK rats; n=6). The 
remaining rats were studied for a total of 12 weeks (Set A: CSNA n=11; ENAA n=11; SHMA n=6) or 24 
weeks (Set B: CSNs n=19; ENAs n=16; SHMs n=9). At the end of the observation period, rats were 
anaesthetized with pentobarbital and portions of renal cortex distant from the infarct scar were excised 
and snap-frozen in liquid nitrogen for subsequent RNA extraction and immunohistology. The remnant 
kidney was then perfusion-fixed with 1.25% glutaraldehyde in 0.1 mmolll sodium cacodylate buffer (pH7.4), 
delivered through a catheter in the abdominal aorta at the measured systolic blood pressure of each rat. 
Kidneys were weighed after perfusion fixation. In order to evaluate renal hypertrophy, final remnant kidney 
weight, corrected for the increase in weight associated with perfusion fixation, was compared to an 
estimate of baseline remnant kidney weight taken as 1/3 of the weight of the right kidney removed at the 
time of renal mass ablation. The correction factor (1.38) was derived by comparing the weights of the 
unfixed right kidney with those of the perfusion-fixed left kidneys removed contemporaneously from 15 
sham-operated rats. 
Untreated controls were not included in the study because, based on previous experience in our 
laboratory, survival to 24 weeks was expected to be close to zero. For purposes of comparison, data from 
untreated control rats after 5/6 nephrectomy were pooled from previous 12-week studies recently 
performed in this laboratory. The percentage of glomeruli affected by sclerosis in 22 untreated rats at 12 
weeks after 5/6 nephrectomy was 43(4)% (mean(SEM» [29, 465]. 
3.2.2. Morphology 
Renal tissue was postfixed in 10% phosphate buffered formalin. embedded in paraffin and processed for 
light microscopy. The frequency of FSGS was estimated by examining all glomeruli seen in one or two 
coronal sections from each kidney stained by the periodic acid-Schiff method. Segmental sclerosis was 
defined as glomerular capillary collapse with hyaline deposition and/or adhesion to the parietal layer of 
Bowman's capsule. A glomerulosclerosis score (GS) was determined by expressing the number of 
glomeruli with segm~ntal or global sclerosis as a percentage of the total number of glomeruli coupted for 
each rat (mean 13.2; range 73-274 per rat). Tubulointerstitial injury, as evidenced by dilated tubules 
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containing protein casts and interstitial inflammation or fibrosis, was assessed at medium power on the 
same sections prior to evaluation of glomerulosclerosis. A scoring system (Tubulointerstitial Score - TIS) 
was used to grade the injury from 0 to 3 based on the percentage of abnormal tissue (0%, <20%, 20-50% 
and >50% respectively). The pathologist was unaware of the group assignment of individual rats. 
3.2.3. Chemical Analysis 
The concentration of protein in the urine was determined by spectophotometry after precipitation with 3% 
sulphosalicylic acid. 
3.2.4. Competitive reverse transcription polymerase chain reaction (RT-PCR). 
Total RNA was extracted from frozen portions of renal cortex by the cesium chloride ultracentrifugation 
method [474] and RT-PCR performed according to the protocol described in Chapter 2. Sequences of 
oligonucleotide primer sets and optimal conditions are listed in Table 3.1. As the number of specimens 
exceeded the capacity of the thermal cycler (n=96) all specimens from the study could not be included in 
a single PCR reaction. Specimens from SWK, CSNA, ENAA and SHMA were therefore included in one set 
of PCR reactions and specimens from SWK, CSNB and ENAB, in a separate set of PCR reactions. To 
allow direct comparison of results from different PCR reactions data were expressed as ratios to the 
mean value for the SWK group. p-actin mRNA levels were used to confirm that starting amounts of cDNA 
were similar among groups. 
3.2.S. Immunohistochemistry 
Expression of TGF-Pl, MCP-1 and IL-1P proteins and macrophage infiltration was assessed by 
immunohistochemistry. For macrophage staining, 4 iJm paraffin sections of fixed tissues were used for 
immunoperoxidase analysis after baking at 60 DC for one hour, deparaffinization and rehydration (xylene X 
4 for three minutes each, 100% ethanol X 4 for three minutes each and running water for five minutes). 
Sections were then microwave treated at 93 DC for 30 minutes in preheated 10 mM citrate buffer, pH 6.0, 
cooled for 15 minutes and transferred to phosphate buffered saline (PBS). They were then blocked (for 
15 min) with a 1.5% solution of serum from the animal source of the secondary antibody at room 
temperature. Next, sections were incubated with mouse monoclonal antibodies to the 
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monocyte/macrophage marker ED1 (clone ED1, 1:150 dilution, Biosurface International, Camarilla, CA) 
for 1 hour in a humid chamber at room temperature. The secondary antibody (Vectastain Elite ABC Kit, 
Vector Laboratories Inc., Burlington, CA) was used according to manufacturer's instructions. Slides were 
rinsed with PBS between each incubation. Sections were developed using 3,3'-diaminobenzidine (Sigma 
Chemical Company, St. Louis, MO) as substrate and counter stained with Gill's Hematoxylin (Fisher 
Scientific, Pittsburgh, PA). Macrophage infiltration was assessed by counting the number of ED1-positive 
cells in 10 glomerular profiles and in 10 randomly chosen 0.25 X 0.25mm areas of tubulointerstitium for 
each kidney. Owing to a shortage of tissue not all kidneys in the 12 week set could be assessed for m~ 
infiltration (n=5 for CSNA and ENAA). All kidneys were assessed for CSNB (n=19) and ENA8 (n=16). 
For TGF-~1, MCP-1 and IL-1 ~ staining, 4 J..lm sections of frozen tissues were fixed in acetone for 10 min 
at -20°C and then rinsed with PBS. Sections were then blocked with a 1.5% solution of serum and 
incubated with primary antibodies (hamster anti-mouse antibody against MCP-1 (clone 2H5, 1 :50 dilution, 
Biosurface International), rabbit polyclonal antibodies against IL-1~ (1:100 dilution, Endogen, Woburn, 
MA) and TGF-~1(V) (1:150 dilution, Santa Cruz Biotechnology Inc., Santa Cruz, CA» and then secondary 
antibody as described above. Methyl Green was used as a counterstain. 
3.2.6. Statistical Analysis 
Continuous variables, expressed as mean(SEM), were compared with analysis of variance (ANOVA) 
derived from general linear models. Pairwise comparisons of physiological data from weeks 4, 12 and 24 
were performed using the Student-Neuman-Keuls procedure. Determinants of proteinuria, 
glomerulosclerosis and tubulointerstitial injury were analyzed using multivariable linear regression with 
stepwise variable selection. Multiplicative interaction terms were tested to evaluate whether estimated 
effects of blood pressure and degree of proteinuria on glomerulosclerosis were uniform across treatment 
modality. Dependent variable distributions approximated the normal, and regression diagnostics showed 
no outliers. Repeated measures ANOVA, factorial ANOVA and paired t-tests were employed for other 
comparisons. For PCR data, which were not normally distributed, differences among multiple groups 
were assessed using the Kruskal-Wallis test; between two groups, with the Mann-Whitney test. P-values 
less than 0.05 were considered significant. Statistical analyses were conducted using Statview 4.01 
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(Abacus Concepts Inc., Berkley, California, USA) and SAS 6.08 (SAS Institute, Cary, North Carolina, 
USA) 
3.3. Results 
3.3.1. Chronic Studies 
Mean body weight increased in all groups during the study and no statistical differences in body weight 
developed between candesartan- and enalapril-treated rats over time in either the 12 or 24 week sets. 
Sham-operated rats attained significantly greater body weight than partially nephrectomized rats in the 
pre-treatment period and continued to maintain significantly higher average body weight than enalapril-
treated rats in the 24 week set. In the 12 week set only the body weight difference between sham-
operated and enalapril-treated rats in the pre-treatment period was statistically significant. (Table 3.2.). 
Mean SBP increased in all groups after 5/6 nephrectomy and did not differ statistically among the groups 
before initiation of therapy at week 5. Treatment with either candesartan or enalapril resulted in an initial 
fall in SBP to levels similar to those of sham-operated rats. SBP remained similar among treated groups 
and sham-operated rats over weeks 6 to 12 in both 12 and 24 week sets. Thereafter, there was a gradual 
increase in SBP such that from 18 weeks, SBP levels were statistically higher than the lowest values, 
observed at 8 weeks, in both CSNs and ENAs. There were no statistically significant differences in SBP 
between treatment groups over time, in either 12 or 24 week sets (mean differences: CSNA vs. ENAA = 
11mmHg, P=0.26; CSNs vs. ENAs = 7mmHg, P=0.41). Sham-operated rats remained normotensive 
throughout the study (Figure 3.2A and 3.3A). UpN increased after 5/6 nephrectomy to levels 7 to 8 fold 
higher than in sham operated rats and was similar among the groups before initiation of therapy at week 
5. In both candesartan- and enalapril-treated rats UpN declined at first, but later increased progressively 
to reach levels approximately 2 fold those of pretreatment values and 8 to 9 fold those of sham-operated 
rats at 24 weeks. No statistically significant differences were observed in UpN between treatment groups 
over time, in either the 12 or 24 week sets (mean differences: CSNA vs. ENAA = 8.8 mglday, P=0.16; 
CSNs vs. ENAs = 8.4 mg/day, P=0.31). In sham-operated rats, mean UpN remained low, although a 
small increase was evident over time (Figure 3.2B and 3.3B). UpN was directly correlated with SBP in 
combined data from CSNs and ENAs rats at 12 and 24 weeks (r=0.60 and 0.73, respectively; P<0.0001 
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for both). There were still no differences in uprV between the treatment groups after adjusting for the 
effects of SBP (P=0.50 and P=0.70 at 12 and 24 weeks, respectively). Furthermore, there was no effect 
of treatment group on the relationship between UprV and SBP (interactive terms: P=0.78 and P=0.30 at 12 
and 24 weeks, respectively). 
Remnant kidneys hypertrophied considerably in all groups such that the weight increased 3 to 4 fold over 
baseline. There were no statistically significant differences in final remnant kidney weight among the 
groups. Analysis of remnant kidney weights, expressed as kidney:body weight ratio, yielded similar results 
(Table 3.3.). 
3.3.2. Morphology 
Histological data are summarized in Table 4. Five weeks after partial nephrectomy and before initiation of 
therapy, glomerulosclerosis was evident in a mean of 26(6)% of glomeruli (5WK rats). At 12 weeks post 
surgery, the extent of glomerulosclerosis in candesartan- and enalapril-treated rats was similar to that 
observed before treatment in the 5WK group; moreover there was no statistical difference in mean GS 
between CSNA and ENAA. At 24 weeks after surgery, there was again no statistically significant 
difference in the mean GS of CSNB vs. ENAB rats. Comparison of combined CSNB and ENAB data with 
combined CSNA and ENAA data, revealed a trend towards more extensive glomerulosclerosis at 24 
weeks vs. 12 weeks (P=0.06 by ANOVA). When these data are viewed in the context of data for 
untreated 5/6 nephrectomized controls at 12 weeks, it is evident that both treatments slowed the 
progression of secondary FSGS such that the extent of glomerulosclerosis previously observed at 12 
weeks after 5/6 nephrectomy (GS=43(4)%; mean(SEM», was attained only after 24 weeks in CSNB and 
ENAB rats (Figure 3.4.), Minimal glomerulosclerosis was noted in sham-operated rats. 
Tubulointerstitial injury showed similar patterns of change to those of glomerulosclerosis and was also not 
statistically different between CSN and ENA rats at 12 or 24 weeks. There was a direct and highly 
significant correlation between GS and TIS in pooled data from CSNB and ENAB rats (r=0.85; P<0.001). 
As with glomerulosclerosis minimal tubulointerstitial injury developed in sham-operated rats. 
89 
3.3.3. Multivariable Analysis 
Analysis of data from rats sacrificed at S weeks after surgery revealed statistically significant correlations 
between UprV and GS (r=O.87; P=0.02) or TIS (r=O.87; P=O.02). There were no statistically significant 
correlations between SBP and GS or TIS in this group. 
Since there were no significant differences between enalapril and candesartan treated rats with respect to 
the relationship between UprV and SBP or extent of histological injury, data from these two groups were 
combined to allow analysis of relationships between SBP, uprV and histological injury during RAS 
inhibition. At 24 weeks direct and highly significant correlations were evident between SBP and GS 
(r=O.81; P<O.0001) (Figure 3.SA). Similarly, UprV was highly correlated with GS (r=0.86; P<0.0001) 
(Figure 3.5B). By contrast, there was no statistical effect of ACEI vs. AT1RA treatment on GS at 24 weeks 
(P=0.9). Stepwise multiple linear regression analysis with GS as the dependent variable and SBP, UprV. 
and remnant kidney/body weight ratio as independent variables, entered only SBP and uprV into the 
model. These variables together accounted for 72% of the variance in glomerulosclerosis observed at 24 
weeks. The magnitude of the effects of SBP and UprV as determinants of glomerulosclerosis was such 
that a 10 mmHg change in SBP or a 10mg/day change in UprV were each associated with a change of 3 
percentage points in GS at 24 weeks. 
TIS at 24 weeks also correlated with SBP and UprV (r=0.78 and r=0.69 respectively; P<0.0001 for both). 
Stepwise multiple linear regression analysis with TIS as the dependent variable and the same 
independent variables as above entered only SBP into the model. 
3.3.4. Competitive RT PCR 
Mean levels of f)-actin mRNA were similar among groups for each set of PCR reactions, confirming that 
starting concentrations of cDNA were similar and not subject to systematic error. Renal cortex mRNA 
levels for TGF-f)1 and MCP-1 in S/6 nephrectomized rats before treatment (i.e. at S weeks) were 
approximately 2 fold higher than those of sham-operated rats. At 12 weeks after surgery, TGF-f)1 and 
MCP-1 mRNA levels were similar to pretreatment 5WK values in both CSNA, and ENAA rats and were 
Significantly higher than in SHMA rats. For IL-1 f). mRNA levels were similar in 5WK and SHMA rats. At 12 
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weeks, IL-1J3 mRNA exhibited a trend towards higher levels in CSNA and ENAA vs. SHMA rats that was 
not statistically significant. At 24 weeks after 5/6 nephrectomy, TGF-J31 mRNA levels were significantly 
lower than pretreatment values in CSNB and ENAB rats, but were still significantly higher than those of 
sham-operated rats. By contrast, MCP-1 mRNA levels were not different from pretreatment values in 
CSNB and ENAB rats and remained higher than SHMA levels. IL-1J3 mRNA levels in both CSNB and 
ENAB rats were similar to those of SHMA rats (Figure 3.6.). There were no statistically significant 
differences in mRNA levels for any of the genes examined between CSN and ENA rats at either 12 or 24 
weeks. 
Since there were no differences between candesartan- and enalapril-treated rats with respect to any of the 
variables determined in this study, data from both groups were pooled for further analysis. In this 
combined group, strong and highly statistically significant correlations were evident between 24-week 
renal cortex mRNA levels for TGF-J31, MCP-1 and IL-1J3, and the extent of FSGS (Figure 3.7.) or TIF 
(Table3.S.). Somewhat weaker but nevertheless statistically significant correlations were evident among 
TGF-J31, MCP-1 and IL-1J3, and SBP or uprV (Table 3.5.). Analysis of pooled CSNA, and ENAA data 
revealed only weak or absent correlations among these parameters at 12 weeks after surgery (data not 
shown). 
3.3.5. Immunohistology 
Immunohistology confirmed that the increases in gene expression detected by competitive RT -PCR were 
accompanied by qualitative increases in expression of the gene product and localized the protein 
expression within the renal cortex. Negative controls, in which no primary antibody was used, showed 
minimal staining of tubules and no glomerular staining. For TGF-J31, kidneys from SHM rats exhibited 
moderate staining of tubules and negative staining of glomeruli. Among 5 WK rats, positive TGF-J31 
staining of both tubules and glomeruli was observed. Patterns of staining similar to those of 5 WK rats 
were observed among rats in both treatment groups with particularly strong staining seen in areas of 
segmental glomerulosclerosis (Figures 3.B. A. B, C). MCP-1 staining was limited to minimal positivity of 
tubule cells in SHM rats. Positive MCP-1 staining of tubules and glomeruli was observed in 5WK rats and 
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among rats from both treatment groups (Figures 3.8. D, E, F). Positive staining for IL-1 ~ was localized 
mainly to tubule cells in specimens from all groups. However, among 5 WK rats and rats from the 
treatment groups, focal areas of positive staining for IL-1 ~ were observed in some glomeruli (Figures 3.8. 
G, H, I). (This observation is consistent with staining of individual cells within glomeruli but due to the 
limitations of histology performed on frozen tissue sections, this could not be confirmed.). 
3.3.6. Macrophage Infiltration 
Extensive infiltration of glomeruli and remnant kidney interstitium by m~ was evident prior to initiation of 
therapy at 5 weeks after surgery. Whereas m~ were virtually absent from the kidneys of sham-operated 
rats, a mean of 5.7(0.22) m~ per glomerular profile and 6.6(0.19) m~ per 0.0625mm2 area of interstitium 
were observed in 5WK rats. Treatment with candesartan or enalapril was associated with 2 to 5 fold 
reductions in glomerular m~ infiltration and an approximately 4-fold reductions in interstitial m~ at 12 
weeks after surgery. Nevertheless the extent of m~ infiltration of both glomeruli and interstitium remained 
Significantly higher in treated rats vs. sham-operated rats at 12 and 24 weeks. Glomerular m, counts 
were slightly, albeit significantly, higher in enalapril- vs. candesartan- treated rats at 12 and 24 weeks. 
There was no difference in interstitial m, counts between treatment groups at either time point (Figure 
3.9.). 
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Table 3.1. Summary of primer sequences and PCR conditions. 
Primer Sense sequence Antisense sequence Size (bp) Temp (OCl" 
TGF-J31 CTTCAGCTCCACAGAGAAGAACTGC CACGATCATGTTGGACAACTGCTCC 298 64 
MCP-1 ATGCAGGTCTCTGTCACG CTAGTTCTCTGTCATACT 447 55 
IL-1 J3 TGATGTTCCCATTAGACAGC GAGGTGCTGATGTACCAGTT 378 55 
J3-Actin TTGTAACCAACTGGGACGATATGG GATCTTGATCTTCATGGTGCTAGG 764 60 
* Annealing temperature 
Table 3.2. Body weights (g); data=mean(SEM) 
weeks post surgery 
Group 0 4 8 12 16 20 24 
WK5 (n=6) 2S9(2} 272(7} 
CSNA (n=11) 260(3) 282(7} 306(4} 330(S) 
ENAA (n=11) 2S3(S) 270(7)* 312(9} 328(7) 
SHMA (n=6) 261(3) 301(6) 322(10) 331(15) 
CSNa (n=19) 262(2) 282(3)t 309(4) 331(5) 347(4) 360(4) 360(7} 
ENAa (n=16) 256(2) 278(3)t 309(4) 327(4) 344(5) 350(6) 3S9(6)* 
SHMB (n=9) 266(2) 298(7} 332(5) 350(4) 3S9(S) 369(4) 373(5) 
* P<O.OS vs. SHMA over weeks 0-4; t P<0.05 vs. SHM B over weeks 04; :f: P<O.OS vs. SHM B over weeks 6-24. 
WKS: untreated rats sacrificed at 5 weeks after S/6 nephrectomy; CSNA: rats treated with candesartan after 5/6 nephrectomy and sacrificed at 12 
weeks; ENAA: rats treated with enalapril after S/6 nephrectomy and sacrificed at 12 weeks; SHMA: sham-operated rats sacrificed at 12 weeks; 
CSNB: rats treated with candesartan after 5/6 nephrectomy and sacrificed at 24 weeks; ENAB: rats treated with enalapril after 5/6 nephrectomy and 
sacrificed at 24 weeks; SHMB: sham-operated rats sacrificed at 24 weeks. 
Table 3.3. Remnant kidney weight and kidney:body weight ratio at initial surgery and at sacrifice; data=mean(SEM) 
Remnant kidney weight (g) Remnant kidney:body weight (g/kg) 
Group baseline final baseline. final 
WK5 (n=6) 0.29(0.01 )* 1.16(0.08) 1.12(0.04)* 4.25(0.24) 
CSNA (n=11) 0.33(0.01) 1.28(0.03) 1.28(0.03) 3.87(0.09) 
ENAA (n=11) 0.35(0.01) 1.25(0.07) 1.37(0.03) 3.80(0.15) 
CSNe(n=19) 0.36(0.01) 1.43(0.06) 1.37(0.02) 3.95(0.11) 
ENAe (n=16) 0.35(0.01) 1.39(0.07) 1.37(0.04) 3.85(0.17) 
Final remnant kidney weights (or kidney weight: body weight ratios) were significantly greater than baseline in all groups (P<0.0001). Baseline 
kidney weights are an estimate calculated as one third of the weight of the kidney resected at the time of initial surgery. 
There were no statistically significant differences in final remnant kidney weight (or kidney weight. body weight ratio) among the groups. 
* P<O.OS VS. all treatment groups 
WKS: untreated rats sacrificed at 5 weeks after 5/6 nephrectomy; CSNA: rats treated with candesartan after 5/6 nephrectomy and sacrificed at 12 
weeks; ENAA: rats treated with enalapril after 5/6 nephrectomy and sacrificed at 12 weeks; SHMA: sham-operated rats sacrificed at 12 weeks; 
CSNB: rats treated with candesartan after 5/6 nephrectomy and sacrificed at 24 weeks; ENAa: rats treated with enalapril after 5/6 nephrectomy and 
sacrificed at 24 weeks; SHMB: sham-operated rats sacrificed at 24 weeks. 
Table 3.4. Histological analysis of remnant kidney tissue; data=mean(SEM) 
Group Time post surgery Glomerulosclerosis Tubulointerstitial 
(weeks) Score (%) Score (0-3)" 
WKS (n=6) 5 25.5(6.4) 0.6(0.3) 
CSNA (n=11) 12 32.1(4.2) 0.9(0.1) 
CSNe(n=19) 24 41.5(6.5) 1.3(0.3) 
ENAA (n=11) 12 29.2(4.6) 0.9(0.2) 
ENAe (n=16) 24 41.8(4.4) 1.2(0.2) 
SHMA (n=6) 12 0.2(0.1) 0.0(0.0) 
SHMB (n=9) 24 2.8(0.4) 0.0(0.0) 
There were no statistically significant differences in GS or TIS between CSN and ENA rats in 
either the 12 or 24 week set. A trend towards an increase in GS from 12 weeks to 24 weeks 
in combined data from CSN and ENA rats was not statistically significant (P=0.06). 
*Score from 0 to 3 based on estim{lted percentage abnormal tissue: 0%, <20%, 20-50% or 
>50% 
WKS: untreated rats sacrificed at 5 weeks after 5/6 nephrectomy; CSNA: rats treated with 
candesartan after 5/6 nephrectomy and sacrificed at 12 weeks; ENAA: rats treated with 
enalapril after 5/6 nephrectomy and sacrificed at 12 weeks; SHMA: sham-operated rats 
sacrificed at 12 weeks; CSNs: rats treated with candesartan after 5/6 nephrectomy and 
sacrificed at 24 weeks; ENAe: rats treated with enalapril after 5/6 nephrectomy and sacrificed 
at 24 weeks; SHMs: sham-operated rats sacrificed at 24 weeks. 
Table 3.5: Correlation coefficients (R) for renal cortex cytokine mRNA levels vs. measures of 
renal injury in a combined group of CSN and ENA rats at 24 weeks after 5/6 nephrectomy. 
TGF-131 
MCP-1 
IL-113 
* P<0.0005; t P<0.01 
SBP UprV GS TIS 
0.67* 0.77* 0.81* 0.78* 
0.57* 0.46t 0.57* 0.56* 
0.65* 0.57* 0.70* 0.73* 
GS: glomerulosclerosis score; TIS: tubulointerstitial score indicating tubulointerstitial damage 
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Figure 3.1. A: Polyacrylamide gel showing electrophoretic bands for mimic and gene-specific (TGF-j31) peR 
products at different amounts of starting cDNA. B: Log-log plot of starting cDNA amount versus the ratio of 
gene specific (TGF-j31 ):mimic peR product concentration (in duplicate) showing a linear relationship over 
serial dilutions of starting cDNA. C: Representative portion of a gel showing electrophoretic bands for mimic 
and gene-specific (TGF-j31) peR products for different samples of renal cortex mRNA. Specimens a and b 
were from rats who had low levels of glomerular injury after 24 weeks (GS= 24.2% and 18.0%, respectively) 
whereas specimen c was from a rat with severe glomerular injury at 24 weeks (GS=75.6%). Higher levels of 
TGF-j31 mRNA expression can be appreciated in the latter even on visual inspection. 
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Figure 3.2. A: Systolic blood pressures (SSP) (mean(SEM» of rats in the 12 week set over time. 
SSP increased in all groups after 5/6 nephrectomy and did not differ statistically among the groups 
before initiation of therapy at week 5. Treatment with either candesartan (CSN A - filled squares) or 
enalapril (ENAA - open circles) resulted a fall in SSP to levels similar to those of sham-operated 
rats (SHM A - open triangles). There were no statistically significant differences in SSP between 
CSN A and ENAA over weeks 6-12 (on treatment). Sham-operated rats remained normotensive 
over 12 weeks. 
B: Urinary protein excretion rate (UprV) (mean(SEM» of rats in the 12 week set over time. UprV 
increased in all groups after 5/6 nephrectomy and did not differ statistically among the groups 
before initiation of therapy at week 5. Treatment with either candesartan (CSN A - filled squares) or 
enalapril (ENAA - open circles) was associated with an initial decline in UprV which later increased 
from week 8 to week12. There were no statistically significant differences in UprV between CSN A 
and ENAA over weeks 6-12 (on treatment). UprV remained at normal levels in sham-operated rats 
over 12 weeks (SHMA - open triangles). 
A 200~----------~--------------------------------------~ 
180 
.-.. 
~ 160 
'E E CIl E / E '-" -a.. aJ III 140 ~ en 
120 
100 
2 4 6 8 10 12 14 16 18 20 22 24 
Time post surgery (weeks) 
B 120 
100 
.-.. 
!!! 80 ::;) 
0 
.J:. 
'<t 
N 60 
--
0) 
E 
...... 
~i :c:: 40 Q. :::> 
20 1ii ~ ~ ii- -n 0 D D ~ 
tr- ......0- -i:r= 0 
2 4 6 8 10 12 14 16 18 20 22 
Time post surgery (weeks) 
Figure 3.3. A: Systolic blood pressures (SBP) (mean(SEM» of rats in the 24 week set over 
time. SBP increased in all groups after 5/6 nephrectomy and did not diffet statistically among 
the groups before initiation of therapy at week 5. Treatment with either candesartan (CSNB -
filled squares) or enalapril (ENAB - open circles) resulted in an initial fall in SBP to levels 
similar to those of sham-operated rats (SHMB - open triangles). However, there was a 
gradual increase in SBP over time such that from 18 weeks, levels were signficantly higher 
than the lowest values, observed at 8 weeks in both CSNB and ENAB. There were no 
statistically significant differences in SBP between CSNB and ENAB over weeks 6-24 (on 
treatment). Sham-operated rats remained normotensive over 24 weeks. 
B: Urinary protein excretion rate (UprV) (mean(SEM»of rats in the 24 week set over time. 
UprV increased in all groups after 5/6 nephrectomy and did not differ statistically among the 
groups before initiation of therapy at week 5. Treatment with either candesartan (CSNB - filled 
squares) or enalapril (ENAB - open circles) was associated with an initial decline in UprV 
followed by a progressive increase over weeks 8-24. There were no statistically significant 
differences in UprV between CSNB and ENAB over weeks 6-24 (on treatment). uprV remained 
at normal levels in sham-operated rats over 24 weeks (SHMA - open triangles). 
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Figure 3.4. Glomerulosclerosis score (mean(SEM» at different time points in untreated rats 
(5WK: filled bar) and rats receiving candesartan (CSN: hatched bars) or enalapril (ENA: 
stippled bars). Filled bar at 12 weeks indicates GS at 12 weeks after 5/6 nephrectomy in 22 
untreated control rats from previous studies. 
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Figure 3.6. Renal cortex mRNA levels (mean(SEM» for TGF-f31, MCP-1 and IL-1f3 (expressed 
as a ratio to the mean value for untreated rats at S weeks) in S/6 nephrectomized rats receiving 
no treatment (SWK: filled bars), candesartan (CSN: hatched bars) or enalapril (ENA: stippled 
bars) and sham-operated rats (SHM: open bars). (* P<O.OS vs. SWK; t P<O.OS vs. SHM; § 
P=O.OS vs. SHM) 
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Figure 3.7. Scatter plots of renal cortex mRNA levels for TGF-~1f MCP-1 and IL-1~ vs. glomerulosclerosis score for 
pooled data from candesartan- and enalapril-treated rats (n=34) at 24 weeks. Regression lines and correlation 
coefficients are also shown. 
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A-C: TGF-131 immunostaining was positive only in tubule cells of SHM rats (A, 100X magnification) whereas tubule 
and glomerular staining was evident in 5WK rats (8, 100X magnification) and in rats from both treatment groups (C-
subject from CSNB shown. 100X magnification). Particularly strong staining was observed in glomeruli exhibiting 
extensive sclerosis. 
D-F: MCP-1 immunostaining was minimal in tubules and negative in glomeruli from SHM rats (D. 40X magnification). 
Among 5WK rats (E. 100X magnification) and rats from both treatment groups (F - subject from CSNB shown, 100X 
magnification). positive staining of tubules and glomeruli was observed. 
G-I: IL-113 immunostaining was localized mainly to tubule cells among SHM (G, 100X magnification). 5WK (H. 100X 
magnification) and treated rats (I - subject from CSNB shown, 100X magnification). However. among 5WK and 
treated rats, focal areas of positive staining. consistent with staining of individual cells. were observed in some 
glomeruli (H and I). 
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Figure 3.9. Glomerular and interstitial ED1 positive cell (macrophage) counts (mean(SEM» 
in 5/6 nephrectomized rats receiving no treatment (5WK: filled bars), candesartan (CSN: 
hatched bars) or enalapril (ENA: stippled bars) and sham-operated rats (SHM: open bars). 
" P<O.05 vs. 5WK; t P<O.05 vs. SHM; § P<O.05 vs. CSN 
3.4. Discussion 
These results show that even when started after the onset of renal injury, the renal protective effects of 
candesartan are equivalent to those of enalapril when dosing is adjusted to achieve similar levels of SBP 
control. Comparison with data for untreated rats from previous studies in this model shows that delayed 
treatment with either ACEI or AT 1 RA, appears to slow the rate of progression of glomerulosclerosis by 
about half, an effect reminiscent of that achieved in clinical trials [168, 169, 373]. Our study differs from 
the previous study comparing delayed therapy with ACEI and AT 1 RA in the 5/6 nephrectomy model by 
virtue of its longer duration and increased statistical power [468]. Furthermore, 5/6 nephrectomy was 
achieved by surgical excision of renal mass in the former study whereas we performed infarction of 2/3 of 
the left kidney, a model resulting in more severe renal injury as well as greater activation of the RAS [33, 
512] and therefore more likely to expose subtle differences in efficacy between ACEI and AT 1 RA. 
Nevertheless, we detected no differences between the treatment groups with respect to any of the 
markers of renal injury examined in this study (UprV, GS and TIS) or in the remnant kidney levels of 
cytokine gene expression. Moreover, no tendencies for differences to emerge were detected even over a 
prolonged observation period. The extent of hypertrophy of the remnant kidney also was similar between 
ACEI- and ATi RA-treated rats. Finally, the correlations among SBP, uprV and GS as assessed by linear 
regression techniques were not affected by treatment group. These data therefore provide the most 
conclusive evidence to date that ACEI and AT 1 RA are equivalent in their renal protective effects in this 
model of progressive CKD. 
Based on the differences in the mechanisms whereby ACEI and AT1RA inhibit the RAS, it has been 
suggested that AT1RA may have therapeutic benefits over ACEI because they inhibit the actions of Ang II 
formed by other serine proteases in the presence of ACEI, or because of the antihypertensive and anti-
proliferative effects that may result from stimulation of AT2 receptors by elevated Ang II levels during 
blockade of AT 1 receptors. On the other hand, it has been suggested that at least some of the therapeutic 
benefit of ACEls results from elevated bradykinin levels, which are not present during AT1RA treatment 
[419]. Our findings strongly suggest that although they inhibit the RAS at different levels, both ACEI and 
AT1RA exert their beneficial effects predominantly by inhibiting the effects of Ang II mediated by ATi 
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receptors. This conclusion is consistent with findings of previous studies showing that the elevated 
bradykinin levels associated with ACEI therapy do not appear to playa significant renal protective role 
[461-463]. Moreover, the AT2 receptor stimulation that results indirectly from blockade of AT1 receptors 
does not appear to afford AT1RA therapy any renal protective advantage or disadvantage over ACEI 
therapy. 
The success of RAS inhibitors in reducing renal injury in non-hypertensive models of renal disease [460] 
suggests that an unopposed RAS may itself be regarded as a risk factor for CKD progression. On the 
other hand, RAS inhibitors are highly effective antihypertensive and antiproteinuric agents. It is not yet 
clear to what extent blood pressure control retains its importance as a renal protective measure in the 
context of RAS inhibition. Nor is it clear whether reduction of proteinuria merely reflects blood pressure 
reduction or if lower levels of protein excretion at a given level of systemic blood pressure are associated 
with additive renal protective effects. The second major finding of this study is therefore the 
demonstration by linear regression techniques that systolic blood pressure and urinary protein excretion 
are independent determinants of glomerulosclerosis in rats receiving inhibitors of the RAS after extensive 
renal ablation. Together, SBP and uprV accounted for 72% of the variance in GS, implying that they 
represent major determinants of glomerulosclerosis in this model. 
While it is not possible from these data to exclude the possibility that higher levels of blood pressure 
merely reflect greater severity of ren~1 injury, it is true to say that failure to control blood pressure optimally 
in this model was associated with failure to achieve renal protection. Furthermore, the lack of any 
correlation between the level of SBP and severity of renal injury at an early time-point, before initiation of 
treatment, argues in favour of a direct effect of blood pressure on renal disease progression over time. 
Using radiotelemetry, Bidani et al. also found a strong correlation (r=0.88) between mean SBP and 
glomerulosclerosis in untreated 5/6 nephrectomized rats. In keeping with our observations, the correlation 
between SBP and glomerular injury was much weaker during the first 2 weeks after injury [509]. The renal 
protective effect of lowering blood pressure has been clearly established in clinical studies of CKD [337, 
341, 342, 346, 510, 511]. In diabetic patients treated with ACEI, lower target levels of blood pressure 
control have been shown to result in greater reduction of proteinuria in one randomized trial [349]. Our 
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data are therefore consistent with this clinical evidence that the level of blood pressure control remains an 
important determinant of progressive renal injury in CKD during treatment with inhibitors of the RAS. It 
should be remembered that micropuncture studies in 5/6 nephrectomized rats suggest that glomerular 
capillary hydraulic pressure (PGc) rather than systemic blood pressure per se, is the critical determinant of 
renal injury [27. 513] and that ACEls [27] and AT1RAs [28. 29] reduce both systemic and glomerular 
capillary pressures. Nevertheless, systemic blood pressure is partially transmitted to the glomerular 
capillaries and it is probably for this reason that it remains a significant determinant of renal injury in the 
setting of RAS inhibition. 
Proteinuria has traditionally been regarded merely as a marker of glomerular injury. Recent clinical 
studies, however. report that proteinuria may also be an independent epidemiological risk factor of CKD 
progression [169. 337, 514]. Furthermore, treatments which reduce proteinuria also slow the progression 
of CKD [168, 169,373] and a reduction in proteinuria. independent of blood pressure, was associated with 
slower progression of CKD in the MDRD study [337]. As discussed in Chapter 1, these and other 
experimental findings raise the possibility that proteinuria per se exacerbates renal injury. A meta-analysis 
of 57 animal studies including various models of renal disease reported consistent positive associations 
between the level of protein- or albuminuria and the severity of glomerulosclerosis (mean weighted 
correlation coefficients r=0.82 and 0.76) [331]. We have confirmed that a direct correlation exists between 
proteinuria and glomerular injury in 5/6 nephrectomized rats receiving RAS inhibitors (r=0.86). 
independent of the level of blood pressure. This implies that at a given level of blood pressure, rats with 
higher levels of proteinuria can be expected to have more severe renal injury, a conclusion similar to those 
supported by clinical studies [169, 337]. Although these data do not prove that proteinuria contributes 
directly to renal injury, they do reveal the extent to which the renal protective effects of ACEI and AT1RA 
are related to their antiproteinuric effects. 
The detection of proinflammatory and fibrotic gene induction and melt infiltration in the remnant kidney 
supports the notion that inflammatory processes may contribute to the progressive renal injury and fibrosis 
that follows 5/6 nephrectomy. As shown in Chapter 2 the protection from progressive renal injury afforded 
by ACEI or AT1RA treatment initiated early after 5/6 nephrectomy is associated with suppression of 
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proinflammatory gene induction to levels similar to those of sham-operated rats and inhibition of renal mq, 
infiltration to levels only slightly greater than sham. In this study we observed that when treatment was 
delayed until 5 weeks after 5/6 nephrectomy, a time point when remnant kidney mRNA levels for TGF-131 
and MCP-1 are known to be upregulated, ACEI or AT1RA did not suppress expression of these two 
cytokines to normal levels. At 12 weeks post surgery mRNA levels for TGF-131 and MCP-1 were similar to 
those observed before initiation of treatment, and remained significantly higher than those of sham-
operated rats. At 24 weeks after surgery, TGF-131 mRNA levels were significantly lower than pretreatment 
values but remained significantly higher than sham levels and MCP-1 mRNA levels remained at 
pretreatment values. Failure of suppression of the TGF-131 and MCP-1 responses at 12-weeks, when 
renal injury had not yet progressed beyond that observed before the initiation of treatment, was associated 
with slow progression of renal injury despite probable amelioration of adverse glomerular haemodynamic 
factors. IL-113 mRNA levels were not elevated in pretreatment vs. sham-operated rats. This is consistent 
with findings presented in Chapter 2, that IL-113 induction was not apparent until 8 weeks after 5/6 
nephrectomy. The trend towards higher IL-113 mRNA levels in both treatment groups vs. sham at 12-
weeks suggests that failure of suppression of this gene, a product of activated mq" may also be 
associated with subsequent progression of injury. Strong correlations observed between the extent of 
renal injury at 24 weeks (as measured by either GS or TIS) and mRNA levels for TGF-131, MCP-1 and IL-
113 further support the hypothesis that upregulation of these proinflammatory and profibrotic genes 
contributes to progressive renal injury. 
Together, these observations in remnant kidneys indicate that incomplete suppression of proinflammatory 
gene expression with ACEI or AT1RA treatment is associated with failure to arrest progression of renal 
injury and secondly, that the extent of progression is directly correlated with the level of gene expression. 
It should be stressed that these observations were made in rats receiving chronic treatment at doses of 
ACEI or AT1RA with documented success in normalizing PGC even when initiated after the onset of renal 
injury in this model [28, 515, 516]. This implies that the process of renal injury initiated by glomerular 
capillary hypertension and the direct or indirect effects of Ang II may eventually be sustained more by 
autonomous cellular and molecular factors and become less dependent on the initiating factors. This 
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notion is consistent with the observations of Ichikawa and others, that in glomeruli with severe established 
injury, treatment with enalapril did not prevent further progression to global sclerosis [515]. It is also 
possible that in the face of existing renal injury, treatment with ACEI or AT1RA did not completely 
normalize PGe in the long term or achieve total blockade of the RAS. In keeping with suggestions by other 
authors [517], these findings suggest that patients in whom progression of chronic renal injury persists 
during RAS blockade may benefit from additional therapy targeting the effects of proinflammatory and 
fibrotic cytokine gene expression [508]. 
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4. Glomerular Capillary Hydraulic Pressure Lowering Revisited with Novel 
Therapeutic Agents 
4.1. Introduction 
As shown in the preceding chapters, treatment with ACEI significantly retards the rate of progression of 
CKD and represents the standard with which novel renal protective therapies must be compared. As 
ACEI treatment in clinical studies slows rather than arrests the progression of CKD [168, 169, 374, 376], 
there is however a need for further research to identify more effective renal protective therapies. 
Vasopeptidase inhibitors (VPI) are a novel class of drugs comprising single molecules that simultaneously 
inhibit both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). This latter ecto-
enzyme is localized principally in the brush border membrane of renal tubule cells and catabolizes several 
vasodilator molecules including the natriuretic peptides, adrenomedullin and bradykinin [518, 519]. Thus 
VPI treatment is associated with reduced production of the vasoconstrictor, Ang II, and accumulation of 
the above vasodilators. In experimental [520, 521] and clinical studies [518] VPls have been shown to be 
effective antihypertensive agents in both low and high renin states. In addition, VPI treatment was 
associated with greater survival than ACEI treatment alone in an experimental model of cardiac failure 
[522]. In clinical studies of cardiac failure, VPI treatment has been associated with better clinical 
outcomes than ACEI treatment in some [523] but not all studies [524]. 
Although they appear to act at multiple levels to slow CKD progression the renal protective effects of ACEI 
are closely associated with their ability to normalize the elevated glomerular capillary hydraulic pressures 
(PGc) observed in remaining nephrons after loss of more than half of the total renal mass [27]. Since VPls 
alter the levels of multiple vasoactive peptides, it is difficult to predict the effects of VPI treatment on 
glomerular haemodynamics. Short-term studies in experimental models of CKD suggest that VPI 
treatment may afford renal protection in addition to that achievable with ACEI alone [525, 526]. We 
hypotheSized that VPI treatment would afford more effective renal protection than ACEI treatment in the 
5/6 nephrectomy model but that this would be evident only in a protocol in which ACEI treatment did not 
confer complete renal protection. Second, we hypothesized that the improved renal protection with VPI 
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treatment would be associated with greater lowering of Poe than that produced by ACEI. The aims of this 
study were therefore: 
1. To compare the glomerular haemodynamic effects of the VPI, omapatrilat, with that of an ACEI, 
enalapril, in the 5/6 nephrectomy model. 
2. To compare the renal protective effects of omapatrilat vs. enalapril in rats after 5/6 nephrectomy in 
a short-term experiment in which treatment is started before the onset of renal injury. 
3. To compare the renal protective effects of omapatrilat vs. enalapril in rats after 5/6 nephrectomy in 
an experiment in which treatment is started only after the development of renal injury and follow 
up is continued for a prolonged period. 
4.2. Methods 
4.2.1. Short-term treatment protocol 
Twenty seven male Munich-Wistar rats obtained from Simonsen Laboratories (Gilroy, California, USA) 
were subjected to 5/6 nephrectomy as described in the preceding chapters. Rats were housed under 
standard conditions and given unrestricted access to standard rodent chow and water. On day 2 after 
surgery, rats were started on omapatrilat (Bristol-Myers Squibb, Princeton, New Jersey, USA) 150 mg/L 
(OMA; n=6) or enalapril (Sigma Chemical Company, St Louis, Missouri, USA) 100mg/L in drinking water 
(ENA; n=6). Sodium bicarbonate (1.5 mmollL) was added to solubilize omapatrilat and was also added to 
the enaJapril solution. The doses of omapatrilat and enalapril were adjusted to achieve equivalent 
normalization of blood pressure in each group such that final doses were: omapatrilat 133mg/L (8-12 
mglkg/day) and enalapril 120mg/L (7-11 mg/kg/day). Controls received no treatment and were used for 
comparison in both short and long-term treatment protocols (CON; n=15). At 2-week intervals, systolic 
blood pressure (SBP) was measured by the tail-cuff method and daily urinary protein excretion rate (UprV) 
determined by spectrophotometry after precipitation with 3% sulfosalicylic acid on urine collected from rats 
individually housed in metabolic cages for 24 hours. All rats were sacrificed at 12 weeks after surgery. 
The remnant kidney was perfusion-fixed with 10% phosphate buffered formalin delivered through a 
catheter in the abdominal aorta at the measured systolic blood pressure of each rat. 
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4.2.2. Micropuncture studies 
Forty male Munich-Wistar rats underwent 5/6 nephrectomy and at 2-5 days after surgery, were assigned 
to treatment with omapatrilat 25mg/L (n=8) or 150mg/L (n=8), enalapril 25mgIL (n=8) or 150mg/L (n=8), or 
received no therapy (n=8). Micropuncture studies were performed at 4-6 weeks after surgery. Rats were 
anaesthetized with Inactin (100mg/kg body weight, Lp.; Byk Gulden, Konstnaz, Germany) and prepared for 
micropuncture as previously described [27]. A PE-50 tubing catheter was placed in a femoral artery for 
blood sampling and monitoring of arterial blood pressure. The euvolemic state was maintained by infusion 
of bovine serum albumin (4% in Ringer's Lactate; 0.8% of body weight over the first 25 minutes and 
0.6mL/hour thereafter). Solutions of inulin (3%) and para-aminohippurate (PAH) (0.2%) in 0.9% saline 
were infused at 27 jJUmin throUghout the experiment. 
Micropuncture experiments were conducted during two clearance periods of 30-40 minutes. During each 
period an arterial blood sample was obtained for determination of haematocrit as well as plasma inulin, 
PAH and protein concentrations. A timed collection of urine was obtained for determination of urine PAH 
and inulin concentrations to allow calculation of whole kidney plasma flow rate and glomerular filtration 
rate (GFR). Timed collections (1-1.5 minutes) of tubule fluid were obtained from 4 surface proximal 
tubules for determination of single nephron GFR (SNGFR). Time averaged hydraulic pressures were 
measured in surface glomerular capillaries, efferent arterioles and proximal tubules using a continuous 
recording servo-null micropipette transducer system (Instrumentation for Physiology and Medicine, San 
Diego, California, USA). 
Urine volumes were determined gravimetrically. Plasma protein concentration was determined using a 
refractometer. The concentration of inulin in plasma and urine was determined by the macro-anthrone 
method [527] and in tubule fluid specimens, by a micro-immunofluorescence method [528]. PAH 
concentrations in plasma and urine were determined using a colorimetric method [529]. Variables derived 
from the above direct readings were calculated using established formulae [530). 
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4.2.3. Long-term treatment protocol 
Forty one male Munich-Wistar rats were subjected to 5/6 nephrectomy as described above. At 4 weeks 
after renal mass ablation, rats were assigned to two groups matched for SBP and UprV, and started on 
omapatrilat (OMA; n=22) or enalapril (ENA; n=19) in drinking water. Doses were chosen to achieve 
equivalent control of SBP in the treatment groups and after some initial adjustment, 100mg/L (6-9 
mg/kg/day) of omapatrilat and 100mg/L of enalapril was used. SBP and UpN were measured at 2-week 
intervals. At 20 weeks after surgery several rats from each group were sacrificed (20 week set: OMA, 
n=15; ENA, n=11). These rats were identified at the start of treatment at which time they were matched 
for SBP and UpN. The remaining rats were continued on treatment until UpN showed a sustained 
increase to levels above pretreatment values (long-term set: OMA, n=7; ENA, n=8). ENA rats were 
sacrificed at 32 weeks after surgery, when rapidly increasing UpN levels suggested that they would soon 
die due to rapid progression of their renal injury. Among OMA rats, the dose of omapatrilat was increased 
to 120mgIL, 150mg/L and 200m giL at 38, 39 and 44 weeks after surgery, respectively, due to a rising 
trend in SBP and the rats were sacrificed at 50 weeks after surgery. At sacrifice, remnant kidneys were 
perfusion-fixed as described above. 
4.2.4. Morphology 
Renal tissue was embedded in paraffin and processed for light microscopy. The frequency of 
glomerulosclerosis was estimated by examining all glomeruli seen in one or two coronal sections from 
each kidney (mean=208(9) glomeruli) stained by the periodic acid-Schiff method. A glomerulosclerosis 
score (GS) was determined by expressing the number of glomeruli with segmental or global sclerosis as a 
percentage of the total number of glomeruli counted for each rat. Tubulointerstitial injury was assessed at 
medium power on the same sections. Each of 3 aspects of tubulointerstitial injury (tubule proteinaceous 
casts and dilation; interstitial inflammation; interstitial fibrosis) was assigned a score from 0 to 3 according 
to severity (O=no abnormality; 1=mild; 2=moderate; 3=severe), and these scores added to yield an overall 
Tubulointerstitial Score (TIS) from 0 to 9, which was then expressed as a percentage. The histological 
assessment was performed without knowledge of the treatment assignment of individual rats. 
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4.2.5. Statistical Analysis 
Continuous variables are expressed as mean(SEM). Differences among multiple groups were assessed 
using analysis of variance (ANOVA) and a post hoc Scheffe's test. Variables measured repeatedly over 
time were compared among groups using repeated measures ANOVA. A paired t-test was used to 
compare values at different time points in the same subjects. P-values less than 0.05 were considered 
Significant. Statistical analyses were conducted using Statview 4.01 (Abacus Concepts Inc., Berkley, 
California, USA). 
4.3. Results 
4.3.1. Short-term treatment protocol 
Rats from all groups gained weight over 12 weeks, although body weights among CON rats tended to be 
moderately higher than OMA or ENA rats at each time point. Only the difference between CON and OMA 
was statistically significant. There was no difference in body weight between OMA and ENA over time 
(mean difference=15g; P=0.3). CON rats developed sustained hypertension after 5/6 nephrectomy. 
Treatment with either omapatrilat or enalapril prevented this rise in blood pressure and maintained SSP at 
levels generally from 90 to 100 mmHg (Figure 4.1A). There was no significant difference in SBP over time 
in OMA vs. ENA rats. A progressive rise in proteinuria was observed in CON rats after 5/6 nephrectomy 
whereas proteinuria was almost completely prevented by both treatments (Figure 4.1 B). There was no 
difference in uprV between OMA vs. ENA rats over time. Remnant kidney histology revealed substantial 
glomerulosclerosis and tUbulointerstitial injury in CON rats whereas histological injury was virtually absent 
in OMA and ENA rats. There was no difference in GS or TIS in OMA vs. ENA rats (Figure 4.1 C). 
4.3.2. Micropuncture studies 
The results of micropuncture studies are shown in Table 4.1. Body weight was similar among groups. 
Both treatments were associated with small but significant reductions in haematocrit. Mean arterial 
pressures (MAP) displayed similar patterns to those of SBP in the early treatment protocol. Untreated rats 
evidenced severe hypertension whereas both enalapril and omapatrilat treatment resulted in normalization 
of MAP. Although there was a tendency for MAP to be lower at the higher dose of each drug, these 
differences were not statistically significant. As shown in the Table, all other variables measured did not 
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differ between the higher and lower dose of each treatment and data for each treatment were therefore 
pooled for comparison between treatments. Despite lower perfusion pressures, both treatments were 
associated with significant increases in renal plasma flow vs. untreated controls, findings in keeping with 
renal vasodilation. Whole kidney GFR on the other hand, was not different among the groups. As has 
previously been observed, untreated rats evidenced substantial elevations in glomerular capillary hydraulic 
pressure (PGc) when compared to values reported for normal rats [15] . Treatment with either enalapril or 
omapatrilat was associated with reductions in PGC to values similar to those of normal rats . At both dose 
levels PGC tended to be lower in OMA vs. ENA rats and when data from all OMA and ENA rats were 
combined, omapatrilat treatment was associated with significantly lower PGC than enalapril. Glomerular 
transcapillary hydraulic pressure difference (~P) showed similar trends although the difference between 
OMA and ENA was not statistically significant. In keeping with the reductions in ~P, whole kidney filtration 
fraction was significantly lower in both treatment groups. SNGFR and glomerular plasma flow rate were 
substantially higher than previously reported normal values in untreated controls [15] and were similarly 
elevated in all treatment groups. Renal mass ablation was associated with substantial decreases in 
afferent (RA) and efferent (RE) arteriolar resistances in untreated rats compared to previously reported 
normal values [15]. Treatment with omapatrilat or enalapril resulted in significantly greater reductions in 
both RA and RE than 5/6 nephrectomy alone. There were no significant differences in glomerular capillary 
ultrafiltration coefficient, although values tended to be higher in the OMA and ENA groups. 
4.3.3. Long-term treatment protocol 
At the initiation of treatment (4 weeks) body weights were similar among the groups (P=0.98). Body 
weight increased steadily throughout the study in CON rats and in rats from the 20 week set of both 
treatment groups. Among rats followed beyond 20 weeks , body weight stopped increasing after 26 weeks 
and remained stable thereafter. No statistically significant differences in body weight emerged over time 
between the treatment groups in either the 20 week set or long-term sets. 
Following 5/6 nephrectomy, rats in all groups devoeloped hypertension and SBP was similar among groups 
before treatment (P=0.98) (Figure 4.2.). CON rats remained hypertensive until sacrifice. Treatment with 
either omapatrilat or enalapril lowered blood pressures to normal levels and maintained SBP at mean 
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levels that were generally below 120mmHg throughout the study. No statistically significant difference in 
SBP developed over time between OMA and ENA rats either over weeks 6-20 (mean difference=4 mmHg, 
P=0.3) or weeks 22-32 (mean difference=2 mmHg, P=0.7) . 
Rats developed substantial proteinuria over the first 4 weeks after 5/6 nephrectomy and Up,v was similar 
among the groups before treatment (P=0.7) (Figure 4.3.). CON rats continued to show a progressive 
increase in Up,v over the subsequent 8 weeks. Both omapatrilat and enalapril treatment initially reduced 
Up,v to below 20mg/day. However, from 12 weeks there was a progressive rise in UprV among ENA rats 
such that mean values at 20 weeks had reached 0.81 of pretreatment values (P=0.2 for week 20 vs. week 
4 values among ENA rats) . By contrast Up,v increased more slowly among OMA rats such that at 20 
weeks the mean value was only 0.44 of pretreatment values (P<0.0001 for week 20 vs. week 4 values 
among OMA rats). Over weeks 6-20, UprV was significantly higher in ENA vs. OMA rats (P=0.04). 
Beyond 20 weeks, Up,v continued to rise among ENA rats, reaching a mean value 1.8 times that of 
pretreatment levels at 32 weeks (P=0.03 for week 32 vs. week 4 values among ENA rats) . Among OMA 
rats UprV rose more slowly such that 50 week levels were similar (1 .2 times) to pretreatment values (P=0.3 
for week 50 vs. week 4 values). Over weeks 22-32 UprV was significantly higher in ENA vs. OMA rats 
(P=0.03). In the long-term set, 6 of 8 rats in the ENA group and 5 of 7 rats in the OMA group had UprV 
levels greater than pretreatment values at the time of sacrifice. However, the mean time to reach a UprV 
greater than the pretreatment level on two readings was significantly shorter among ENA than OMA rats 
(20 weeks vs. 34 weeks, respectively; P=0.002). 
Histological assessment of remnant kidneys revealed a mean glomerulosclerosis score (GS) of 36.1 % 
among CON rats, which were all sacrificed at 12 weeks post 5/6 nephrectomy (Figure 4.4.). Among OMA 
rats at 20 weeks, GS was significantly lower than this value (GS=13.9%; P=0.001 vs. CON). A similar 
trend was observed in ENA rats at 20 weeks, although the difference was not statistically significant 
(GS=22.1 %; P=0.3 vs. CON). GS tended to be lower in OMA vs. ENA rats at 20 weeks but this difference 
also was not significant (P=0.8). In the long-term set, ENA rats sacrificed at 32 weeks (GS=34±5%) and 
OMA rats sacrificed at 50 weeks (GS=38±8%) had mean GS values very similar to those of untreated 
CON rats at 12 weeks. Tubulointerstitial injury exhibited a similar pattern to that of glomerulosclerosis. At 
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20 weeks the TIS was significantly lower in OMA vs. CON rats and tended to be lower in ENA vs. CON 
rats. In the long-term set, OMA rats at 50 weeks had a mean TIS similar to that of CON rats at 12 weeks. 
The TIS among ENA rats at 32 weeks tended to be lower than that of OMA rats at 50 weeks but this 
difference was not statistically significant (Figure 4.4.). Overall there was a highly significant correlation 
between GS and TIS in individual rats (r=0.82; P<0.0001). 
119 
Table 4.1: Micropuncture data at 4-6 weeks after 5/6 nephrectomy; data=mean(SEM). 
Body Wt Hct MAP RPF GFR FF CA PGC 
9 % mmHg mllmin mllmin gldl mmHg 
CON 279(7) 45(1 ) 143(5) 1.4(0.2) 0.44(0 .05) 0.33(0 .03) 4.8(0 .1 ) 62(3) 
ENA (25mg/l) 300(7) 40(1 )a 97(6)a 2.7(0.4)a 0.62(0.06) 0.26(0.02)a 4.6(0.1 ) 53(3) 
OMA (25 mg/I) 306(6) 40(1 ) 93(3)8 2.7(0.3)a 0.61 (0.07) 0.22(0.00)a 4 .7(0.1) 47(3)a 
ENA (150 mg/I) 284(7) 40(1 la, b 85(2t b 2.6(0.3)b 0.54(0.07) 0.21 (0.01 la, b 4.6(0.1 ) 49(2t b 
OMA (150 mg/I) 283(5) 40(1t' b 85(3)a, b 2.3{0.2)b 0.49(0,03) 0.21 (0.01 la, b 4.5(0 .1 ) 42(1)a, b, C 
PT PE ~P SNGFR QA RA x 10'0 RE X 10'0 Kf 
mmHg mmHg mmHg nllmin nllmin d -5 yne ,s-cm d -5 yne ·s ·cm nll(s·mmHg) 
CON 14(1 ) 25(2) 48(4) 76(8) 237(26) 1.62(0.20) 1.20(0.15) 0.048(0.006) 
ENA (25mg/l) 12(1 ) 19(1 ) 41 (2) 84(6) 334(23) 0.63(0.06)a 0.73(0.09) 0.065(0.009) 
OMA (25 mg/l) 11 (1) 18(1)a 36(3)a 61 (7) 275(28) 0.84(0.10)8 0.79(0 .12) 0.063(0.011 ) 
ENA (150 mg/I) 11 (1) 20(1 )b 38(2)b 56(6) 275(30) 0.69(0.11 t b 0.82(0,11 )b 0.047(0.006) 
OMA (150 mg/I) 11 (O)b 18(2)a, b 31(1)a.b 54(8) 264(40) 0.93(0.17)a, b 0.74(0,10)b 0.068(0.012) 
a P<O.05 VS. CON 
b P<O.05 for combined ENA 
c P<O.05 for combined OMA 
and 1 data or combined OMA and 1 data VS. CON 
and 150mall data VS. combined ENA and 1 data 
Wt Hct h.,m;:,tnl"rit MAP: mean arterial pressure; RPF: renal olasma GFR: 
afferent arteriolar r.;;!nlll;;!rv pressure; tubule 
filtration FF: filtration fr",,..tinn 
pressure; efferent 
arteriolar pressure; tiP: ...,1""":,,, pressure difference; SNGFR: GFR; glomerular plasma flow 
afferent arteriolar r.,.,i.,t",n("",· efferent arteriolar r",.,id",nr",' ultrafiltration coefficient 
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Figure 4.1. Early Treatment Protocol: (A) Systolic blood pressure (SBP) and (8) urinary protein 
excretion rate (UprV) over time among rats subjected to 5/6 nephrectomy and started on omapatrilat 
(OMA-open circles), enalapril (ENA-filled squares) or no treatment (CON-filled triangles) on day 2 
post surgery. SBP and UpN were normalized by both treatments and were significantly lower in 
treated vs. untreated rats (P<O.0001 vs. CON for both systolic blood pressure and proteinuria over 
week 6-12). 
C: Glomerulosclerosis (GS) and Tubulointerstitial Injury Scores (TIS) from kidneys removed at 12 
weeks after 5/6 nephrectomy revealed that omapatrilat (OMA-open bars) and enalapril (ENA-shaded 
bars) effectively prevented the substantial glomerulosclerosis and tubulointerstitial injury observed in 
untreated rats (CON-filled bars) when started on day 2 post surgery (* P<O.005 vs. CON). 
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Figure 4.3. Delayed Treatment Protocol: Urinary protein excretion rate (UprV) over time among rats subjected to 5/6 nephrectomy and started on 
omapatrilat (OMA-open circles), enalapril (ENA-filled squares) or no treatment (CON-filled triangles) at 4 weeks post surgery. Prior to treatment rats 
from all groups developed substantial proteinuria and were closely matched for UprV at 4 weeks post surgery. Treatment with either omapatrilat or 
enalapril resulted in an initial reduction in proteinuria such that UpN was significantly lower among OMA and ENA rats than untreated rats over weeks 
6-12 (P<0.0001). UpN increased after week 10 among ENA rats such that levels at week 20 were no longer significantly lower than pretreatment 
values and at week 32, UprV was significantly higher than pretreatment values. Among OMA rats UpN increased more slowly, such that levels at 
week 20 remained significantly lower than pretreatment values and 50 week levels were similar to pretreatment values. UprV was significantly lower in 
OMA vs. ENA rats over week 6-20 and over weeks 22-32. At week 32, mean UpN among ENA rats was more than double that of OMA rats. 
(* P<0.05 vs. CON over week 6-12; t P<0.05 vs. pretreatment value; t P<0.05 vs. ENA over week 6-20; § P<0.05 vs. ENA over week 22-32) 
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Figure 4.4. Delayed Treatment Protocol: Glomerulosclerosis (GS) and Tubulointerstitial Injury Scores 
(TIS) for rats subjected to 5/6 nephrectomy and started on omapatrilat (OMA-open bars), enalapril (ENA-
stippled bars) or no treatment (CON-filled bars) at 4 weeks post surgery. Both treatments resulted in 
protection from histological injury such that GS and TIS were lower in OMA and ENA rats at week 20 than 
in CON rats at week 12, although only the difference between OMA and CON rats was statistically 
significant. GS among CON rats at week 12, ENA rats at week 32 and OMA rats at week 50 were similar, 
implying that enalapril delayed the progression of glomerular injury by 20 weeks whereas omapatrilat 
delayed it by 38 weeks. TIS showed a similar trend, although ENA rats at week 32 tended to have less 
tubulointerstitial injury. (* P<0.005 vs. CON) 
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4.5. Micropuncture: Means for the plot of glomerular capillary pressure vs. mean 
arterial pressure (MAP) among rats subjected to 5/6 nephrectomy and started on (OMA-open 
circle), enalapril (ENA-filled square) or no treatment (CON-filled triangle) on 2-5 post surgery. Values 
were obtained during micropuncture studies at 4-6 weeks after 5/6 nephrectomy. The broken and solid 
lines lines for vs. MAP among ENA and OMA rats, respe(;tl 
4.4. Discussion 
4.4.1. Shari-term treatment protocol 
We have shown that when treatment was initiated early after 5/6 nephrectomy at doses sufficient to 
normalize blood pressure, both omapatrilat and enalapril almost completely prevented the progressive rise 
in proteinuria and histological renal injury observed in untreated controls over 12 weeks. Since enalapril 
treatment has previously been shown to result in almost complete renal protection in this model [27], we 
did not expect to observe any greater benefit with omapatrilat than enalapril. Other studies comparing VPI 
and ACEI treatment in an early treatment protocol after 5/6 nephrectomy have reported greater renal 
protective effects with the VPI [525, 526]. However, in one of these studies blood pressure was 
substantially different between the treatment groups at the lower dose studied and was not normalized in 
either group, even at a higher dose [525]. In the other, SSP was also significantly higher in ACEI-treated 
than VPI-treated rats [526]. These previous data therefore were unable to distinguish additional renal 
protective effects attributable to greater systemic blood pressure reduction from effects related to unique 
renal actions of VPls. 
4.4.2. Micropuncture Studies 
Previous micropuncture studies in the partial nephrectomy model have shown that elevated glomerular 
capillary pressure is a critical factor in the pathogenesis of progressive renal injury and the renal protective 
effects of low protein diet, ACEI or AT1 RA treatment were closely associated with normalization of PGC [15, 
26-28]. In the present study enalapril and omapatrilat produced similar effects on most of the 
haemodynamic parameters studied. Importantly MAP was lowered to the same extent with both 
treatments. The observed increases in renal plasma flow together with a reduction in filtration fraction 
suggest renal vasodilation and a lowering of PGc. Measurements of single nephron haemodynamics 
confirmed that both afferent and efferent arteriolar resistances were reduced and PGC was significantly 
lowered by both treatments. The PGC values observed in ENA rats were very similar to those reported 
previously in enalapril-treated rats [26-28] . In contrast, omapatrilat treatment was associated with greater 
lowering of PGC than enalapril. As expected, PGC was significantly correlated with MAP when data from all 
rats were pooled (r-O.69; P<O.0001). As shown in Figure 4.5. however, regression lines for PGC vs. MAP 
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in the treatment groups show that at each level of MAP, omapatrilat lowered PGC to a greater extent than 
enalapril. We suggest that this greater lowering of PGC at equivalent levels of MAP represents one of the 
mechanisms whereby omapatrilat produces greater renal protective efficacy. The mechanism whereby 
greater lowering of PGC with omapatrilat was achieved is not revealed by our data since both treatments 
had equivalent effects on afferent and efferent arteriolar resistances. There was, however, a trend 
towards a higher RA in omapatrilat-treated rats that would tend to lower PGc. The precise mechanism 
responsible for this higher value of RA with omapatrilat, whether myogenic or neurohumoral , remains to be 
determined. Two different doses of each drug were studied in order to investigate whether potential 
differences in the haemodynamic effects may be dose-related. However, no significant differences were 
observed between the two doses for each drug studied, suggesting that even at the lower dose, near-
maximal haemodynamic effects were achieved. 
Whereas the additional lowering of PGC achieved with omapatrilat was not associated with discernable 
additional renal protection in the short-term protocol, these findings suggested that additional renal 
protection might be achieved with omapatrilat in longer-term studies. 
4.4.3. Long-term treatment protocol 
As described in Chapter 3 we have observed that when treatment with ACEI or AT1RA is delayed until 
after the onset of renal injury in 5/6 nephrectomized rats , an initial decline in proteinuria is followed by a 
slow but progressive increase. This model of slow progression of CKD during inhibition of the renin-
angiotensin system more closely resembles the findings of clinical trials that have reported slowing rather 
than arrest of CKD progression with ACEI treatment [168, 169,374,376]. We therefore believe that this is 
an appropriate model in which to investigate the possibility that VPI may offer clinically relevant renal 
protective advantages over ACEI alone. Although both treatments initially lowered proteinuria to the same 
extent, we found that omapatrilat maintained significantly lower levels of proteinuria over time than 
enalapril. Moreover, the mean time for rats to reach pretreatment levels of proteinuria was extended by 
an additional 14 weeks in omapatrilat vs. enalapril treated rats (34 weeks vs. 20 weeks). Although this 
study was not designed to assess survival, the fact that ENA rats were sacrificed at 32 weeks due to 
rapidly rising proteinuria whereas OMA rats survived to 50 weeks, suggests that OMA rats would have 
128 
survived longer than ENA rats. The histological findings also attest to more effective renal protection with 
omapatrilat. Among rats sacrificed at 20 weeks after 5/6 nephrectomy, both treatment groups exhibited 
glomerulosclerosis and tubulointerstitial injury scores that tended to be lower than those of untreated 
controls at 12 weeks, implying that both treatments delayed the progression of renal injury. Injury scores 
tended to be lower among OMA rats vs. ENA rats suggesting a possible advantage of omapatrilat over 
enalapril at this relatively early time point. ENA rats sacrificed at 32 weeks had glomerulosclerosis scores 
very similar to those of untreated controls at 12 weeks, indicating that enalapril delayed the progression of 
CKD by 20 weeks. Among OMA rats sacrificed at 50 weeks, GS was also similar to 12 week CON levels , 
implying a 38 week delay in progression to this level. Thus long-term treatment with omapatrilat resulted 
in almost double the delay in CKD progression achieved with enalapril. The dose of enalapril used in this 
study was the same or higher than that used to achieve renal protection in previous studies in this model 
[465, 516], implying that the observed differences between enalapril and omapatrilat treatment are not 
attributable to inadequate dosing of enalapril. Finally, it should be noted that these differences were 
observed between groups of rats in which blood pressures were very closely matched. We are thus able 
to conclude that the additional benefit observed with omapatrilat was due to unique renal actions of VPI 
and not to differences in systemic blood pressure control. The micropuncture studies discussed above 
suggest that one of these differences may be more effective lowering of PGC by omapatrilat. 
Micropuncture studies performed at later times after 5/6 nephrectomy would further test this hypothesis 
but are complicated by the heterogeneity of the glomerular lesions typical of this model, making it doubtful 
that measurements obtained from the few ava ilable surface glomeruli would be representative of the 
remnant kidney as a whole. 
Further studies will be required to elucidate the specific roles of different biochemical mediators, 
particularly the natriuretic peptides and bradykinin, in the enhanced renal protective efficacy observed with 
omapatrilat. The natriuretic peptides are known to mediate some of the haemodynamic changes after 5/6 
nephrectomy [51] but also exert non-haemodynamic effects that may contribute to renal protection [531-
535]. Bradykinin is a potent vasodilator that may mediate some of the antihypertensive effects of ACEI 
[448], but does not appear to contribute Significantly to the renal protective effects of ACEI in rats after 5/6 
nephrectomy [461, 462] or induction of diabetes [463]. Nevertheless in other models, bradykinin may 
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mediate effects that are nnl'",n'tio::llliv beneficial in renal protection [454, renal 
bradykinin levels are likely to be higher with VPI than ACEI treatment because is catabolized by 
both ACE and NEP [536] and NEP is the major route of bradykinin catabolism in the kidney [537]. The 
effects of NEP inhibition on other vasoactive molecules such as endothelin-1 may also be important [538]. 
It is that the additional renal protective efficacy of omapatrilat results from a combination of all of 
the above and other as yet unidentified effects. 
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5. Discussion and Conclusions 
The experiments described above were designed to answer some of the many questions that remain 
regarding mechanisms that contribute to progressive renal injury in CKD. The data presented have added 
important insights, yet many aspects require further elucidation. In this final chapter we place the findings 
of our studies in context and discuss future potential developments in each aspect covered. 
5.1. ACEI versus AT1RA in renal protection 
ACEls and AT1RAs both inhibit the RAS but differences in their mechanism of action make it possible that 
these agents differ in their renal protective efficacy. Early experiments suggested that ACEls and AT1RAs 
afforded similar degrees of renal protection, but the majority may not have been able to detect relatively 
subtle differences as they employed models in which ACEI treatment had already been shown to afford 
almost complete protection from renal injury. In the experiments described in Chapters 2 and 3 we 
examined multiple aspects of renal protection during ACEI or AT1RA treatment to investigate whether 
subtle differences may emerge. Since blood pressure is known to be an important determinant of CKD 
progression, every effort was made to eliminate differences in blood pressure control as a possible 
explanation for any observed differences between the treatments. In all experiments, drug dose was 
titrated to achieve close matching of blood pressure control. 
We were unable to identify any significant differences between ACEI and AT1RA treatment with respect to 
their effect on urinary protein excretion, renal hypertrophy or histological injury. This was true whether 
treatment was started soon after 5/6 nephrectomy (Chapter 2) or delayed until renal injury was established 
(Chapter 3). Even when follow up was continued for considerably longer than is the norm in studies 
employing the 5/6 nephrectomy model, no differences were observed. Minor differences may have 
emerged if follow up had been continued for even longer, but as there was no trend towards a difference 
at 24 weeks, this seems unlikely. 
In both sets of experiments we examined the effect of RAS inhibition on the expression of 
proinflammatory and fibrotic molecules. We selected molecules that are widely recognized as important 
mediators of inflammation or fibrosis. In Chapter 2 we were unable to detect any clear difference in the 
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effect of ACEI vs. AT1RA treatment on the expression of any of the genes studied. In Chapter 3 we noted 
that when RAS inhibitor treatment was started after the onset of renal injury, suppression of 
proinflammatory cytokines was at best incomplete. Nevertheless, the level of expression of these 
molecules at different time points was similar with ACEI and AT1RA treatment. 
These experiments provide the most conclusive evidence to date that ACEls and AT1RAs are equivalent 
with respect to their renal protective effects, at least in the 5/6 nephrectomy model. We examined 
physiological, histological and molecular biological variables in two different study protocols and were 
unable to identify any significant differences between enalapril and candesartan treatment. Clinical 
studies have shown that ACEI treatment results in effective renal protection in type 1 diabetics [168] and in 
patients with non-diabetic CKD [169] whereas AT1RAs are of proven renal protective efficacy in patients 
with type 2 diabetes [170, 171, 382]. Large randomized studies that directly compare the renal protective 
effects of ACEI and AT1RA treatment in human CKD have not yet been published. This is an important 
clinical question because up to 20% of patients are intolerant of ACEI treatment due to a cough [539] and 
would benefit from conversion to an AT1RA. In the absence of further clinical evidence these 
experimental studies do provide at least some support for the option of converting patients intolerant of 
ACEls to AT1RA treatment. 
The pharmacodynamic differences between ACEls and AT1RAs raise the possibility that they may be 
useful as combination therapy. This is question beyond the scope of the present investigation but 
preliminary evidence suggests that combination ACEI and AT1RA therapy may afford more effective renal 
protection than that achieved by either agent alone [389, 540]. 
5.2. Proinflammatory and fibrotic cytokines in CKD progression 
The experiments in Chapters 2 and 3 examined the expression of a group of CAMs (ICAM-1 and VCAM-
1), proinflammatory cytokines (MCP-1, IL-1 ~ and TNF-a) and profibrotic growth factors (TGF-~) in the 5/6 
nephrectomy model. Previous investigations into the potential role of these molecules relied largely on in 
vitro experiments or studied only 1 or 2 factors in vivo. Our goal in studying a group of factors was to 
show that they are upregulated in concert after 5/6 nephrectomy. In this model immunological stimuli for 
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the induction of proinflammatory molecules are absent. Our observations therefore provide strong support 
for the notion that the observed responses of cells in culture to stimuli such as physical stresses, Ang II 
and excessive protein absorption, play a role in establishing a proinflammatory environment in the 
remnant kidney. The data also provide evidence that m~ recruitment in the remnant kidney is an active 
process mediated by the expression of specific genes. The normalization of proinflammatory gene 
expression associated with renal protection during ACEI or AT1 RA treatment demonstrates a close 
association between prevention of gene expression and renal protection but does not prove a causal 
relationship between the two. In Chapter 3, we showed that failure to completely suppress the 
upregulation of MCP-1 and TGF-~ with RAS inhibiting treatments was associated with slowly progressive 
renal injury despite effective control of blood pressure. These observations extend the findings in Chapter 
2 by showing that failure to suppress proinflammatory gene expression at 12 weeks (when renal injury 
was only moderate and blood pressure as well as proteinuria were well controlled) was associated with a 
subsequent progressive rise in proteinuria and more severe renal injury at 24 weeks, despite ongoing 
ACEI or AT1RA treatment. Furthermore, we observed strong correlations between the level of MCP-1 or 
TGF-~ expression and the severity of histological injury. Together these data provide further support for 
the notion that uncontrolled upregulation of proinflammatory molecules and recruitment of macrophages 
contributes to renal injury in the remnant kidney. Studies reporting renal protective effects in the 5/6 
nephrectomy model following treatment with the immunosuppressant mycophenolate [239-242] or the 
PPAR-y agonist troglitazone (which has m~ antiproliferative effects) [247], provide further support for this 
hypothesis. 
We have examined relatively few of the large number of proinflammatory molecules that may be involved 
in CKD progression. In order to examine a larger number of molecules in a single sample, newer 
molecular biology techniques such as RNAase protection assays and oligonucleotide micro-arrays will be 
required. The latter technique in particular allows simultaneous assessment of the expression of several 
thousand genes and will doubtless lead to a more comprehensive picture of the molecular changes 
induced by nephron loss. Such studies will also lead to new challenges because it may be difficult to 
identify which of the many observations are central to renal injury mechanisms. 
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Our data do not allow us to draw conclusions regarding the relative importance of different 
proinflammatory molecules in CKD progression. To address this issue, experiments will be required in 
which specific molecules or genes are selectively inhibited by techniques such as monoclonal antibodies, 
antisense oligonucleotides and gene deletion. These techniques have already been applied in 
experiments investigating the role of TGF-13 in renal fibrosis [274, 508, 541, 542] and will hopefully be 
applied to other molecules. Such experiments may identify specific molecular targets and suggest novel 
therapeutic strategies for attenuating the rate of progression of renal injury. Given the high degree of 
redundancy identified within the inflammatory response it is likely that extensive research will be required 
before safe and effective new treatments are developed. 
5.3. Hypertension and eKD progression 
The data presented in Chapter 3 illustrate the extent to which the level of blood pressure control is a major 
determinant of renal injury, even in the setting of treatment with RAS inhibitors. These observations have 
been confirmed and extended by another study that reported strong correlations (r=0.81, P<0.0001) 
between achieved blood pressure and glomerulosclerosis among rats assigned to different doses of ACEI 
or A T1 RA following 5/6 nephrectomy [348]. This is important because previous clinical studies that have 
examined the renal protective effects of ACEI or AT1RA have employed relatively loose blood pressure 
targets of <140-135/85-90. If the level of blood pressure is indeed important, even greater renal protection 
may have been achieved if lower blood pressure targets had been employed. This issue has 
unfortunately proved difficult to address in clinical studies because of the difficulty in achieving significant 
differences in blood pressure levels between randomized groups [346, 347, 349]. As a result only one 
major clinical study has shown clear benefit associated with a lower blood pressure target. In this study of 
type 1 diabetics receiving ACEI treatment, a lower blood pressure target was associated with lower levels 
of proteinuria but there was no difference in the rate of decline in GFR over 2 years [349]. These practical 
difficulties do not diminish the weight of experimental and clinical evidence suggesting a central role for 
lower blood pressure targets in renal protective strategies. Conclusive proof of benefit will, however, 
require further prospective randomized studies. 
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5.4. Proteinuria and CKD progression 
The data presented in Chapter 3 do not allow us to draw conclusions regarding the potential role of 
proteinuria in the pathogenesis of progressive renal injury. Despite compelling in vitro evidence of the 
proinflammatory effects of exposing tubule cells to plasma proteins, in vivo observations have been 
restricted largely to associations between proteinuria and the severity of renal injury. Since proteinuria has 
long been accepted as a marker of renal injury, further in vivo studies are required in order to strengthen 
the case for a causative role of filtered protein in tubulointerstitial injury. The most useful data would be 
derived from studies in which proteinuria reduction was isolated from other interventions or in studies 
where tubular absorption of filtered protein was selectively inhibited. Such strategies have not yet been 
employed. Currently available interventions for reducing proteinuria (ACEI or AT1RA treatment) also lower 
blood pressure and PGC , making it difficult to identify benefit specifically attributable to reduction of 
proteinuria. Our data do, however, confirm the close association between the amount of proteinuria and 
the severity of renal injury in this model of CKD progression. Similar observations have been made in 
clinical studies and one recent meta-analysis found that each 1 g/day increase in proteinuria was 
associated with a relative risk 5.56 for the combined end-point of doubling of baseline serum creatinine or 
onset of ESRD [339] . These data allow us to conclude that CKD patients with persistent proteinuria 
despite RAS inhibitor therapy are at increased risk for further deterioration in renal function and require 
further intervention to optimize their renal protective treatment. 
5.5. Glomerular capillary hypertension in CKD progression 
Glomerular capillary hypertension was proposed two decades ago as a critical factor in the development 
of the vicious cycle of nephron loss associated with CKD. This hypothesis was based on experiments in 
which normalization of PGC achieved by dietary protein restriction [15] or ACEI treatment [26, 27] was 
associated with dramatic protection of the remnant kidney from subsequent injury. There is to date no 
technique for assessing glomerular haemodynamics in human subjects and it has therefore not been 
possible to examine the relevance of these findings in clinical CKD. Nevertheless, in vitro experiments 
showing the proinflammatory effects of exposing glomerular cells to mechanical stresses such as shear 
stress, cyclical stretching and barostress, do provide further support for the hypothesis by suggesting one 
mechanism whereby glomerular capillary hypertension may contribute to renal injury. Our observations in 
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Chapter 4 provide further support for the notion that increases in PGC ultimately prove detrimental to the 
glomerulus. We found that despite equal effects of ACEI and VPI treatment on systemic blood pressure, 
treatment with a VPI was associated with greater lowering of PGc. In subsequent chronic studies, VPI 
treatment was associated with more effective renal protection than ACEI treatment, suggesting that this 
greater lowering of PGC may have afforded additional renal protection. In order to sUbstantiate this 
hypothesis, micropuncture studies at later time points would be required to show that VPI treatment was 
associated with a lower PGC in the long term. Unfortunately there are generally only 2-4 surface glomeruli 
available for micropuncture in a Munich Wistar rat making it technically difficult at later time points when 
significant glomerulosclerosis is known to be present. Since glomerulosclerosis tends to occur in a patchy 
distribution, it would also be difficult to determine whether or not the measurements obtained were 
representative of remnant kidney glomeruli as a whole. 
5.6. Vasopeptidase inhibitors in renal protection 
The vasopeptidase inhibitors are a relatively novel class of agent with potent haemodynamic effects. We 
have shown in Chapter 4 that treatment with a VPI was associated with more effective long-term renal 
protection than current "gold standard" treatment with an ACEI, despite equivalent control of blood 
pressure. We proposed that greater lowering of PGC is one mechanism whereby VPI treatment may 
confer more effective renal protection. In view of the multiple effects of VPls resulting from the 
simultaneous inhibition of two different enzymes that together effect the metabolism of a multiplicity of 
vasoactive molecules, it must be conceded that there are several other mechanisms that may account for 
our observations. A recent finding that VPI treatment was associated with less effective renal protection 
than ACEI treatment in rats with adriamycin nephrosis, a non-hypertensive model of proteinuric renal 
disease, supports the notion that the potential renal protective benefits of VPls are related to their 
haemodynamic effects [543]. Further studies are required to determine whether differences in the effects 
of VPls on bradykinin or natriuretic peptide catabolism may also be relevant. Regardless of their 
mechanisms of action, these initial studies suggest that the VPls may prove a useful addition to our renal 
protective armamentarium. Clinical studies of CKD have shown at best a halving of the rate of decline in 
GFR with RAS inhibitor therapy and there is therefore a place for more effective renal protective 
interventions. The clinical licensing of some of the VPls has unfortunately been delayed due to safety 
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concerns, over the incidence of It is hoped that these problems will be 
overcome and that clinical trials of the renal protective effects of VPI will follow. 
5.7. Conclusion 
We have employed an integrated approach to study several of mechanisms that contribute to 
progressive renal injury in the 5/6 nephrectomy model of CKD as well as the effects of treatment with 
ACEls, AT1RAs and VPls. These studies investigated physiological, ISiC)IO!lIC;31 and molecular biological 
variables in an to ",r"\\"/1'''' new into mechanisms whereby hypertension, glomerular 
capillary pressure, proteinuria and the renal expression of proinflammatory and profibrotic molecules may 
interact to sustain a vicious cycle of nephron loss that results in end-stage renal failure. In Figure 5.1 we 
present a schema that draws together findings from our studies and those of others to represent a 
comprehensive model ,nf'nrr\nr,,,,tlr\n many of the mechanisms currently thought to be involved. Though 
our understanding of the pathogenesis of progressive renal injury has advanced considerably over the 
past two decades, many require further investigation. It is hoped that the development of new 
molecular biology techniques will allow further elucidation of the mechanisms whereby the observed 
responses to nephron loss occur. This would make possible the development of novel therapeutic 
interventions aimed at CKD in the majority of It may also become possible 
to address the even more int"r""'c:tinli'l possibility of reversing renal injury in CKD. While the outcome of 
such research is awaited, current clinical emphasis should be on applying strategies already proven to 
afford renal protection to all patients and thereby diminish the burden imposed by CKD on individuals and 
health-care systems. 
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